Page last updated: 2024-12-05

praziquantel

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Praziquantel is a synthetic drug used to treat various parasitic infections, including schistosomiasis, tapeworm infections, and liver fluke infections. It is a racemic mixture of two enantiomers, with the (+)-enantiomer being the more active form. Praziquantel is thought to work by increasing the permeability of the parasite's cell membrane, leading to calcium influx and muscle paralysis. This disrupts the parasite's ability to attach to the host's tissues and ultimately leads to its death. Praziquantel is generally well-tolerated, with common side effects including headache, dizziness, and abdominal pain. Its effectiveness and relative safety have made it a crucial component of global efforts to control parasitic infections. Extensive research focuses on developing praziquantel analogues with improved efficacy, reduced side effects, and potential applications beyond its current use in parasitic infections. This ongoing research aims to address the challenges posed by drug resistance and to explore new therapeutic possibilities for praziquantel.'

azinox: Russian drug [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4891
CHEMBL ID976
CHEBI ID91583
CHEBI ID45267
SCHEMBL ID44153
SCHEMBL ID16019896
MeSH IDM0017438

Synonyms (231)

Synonym
AB00052075-15
BRD-A21858158-001-05-2
BRD-A21858158-001-16-9
MLS000038419 ,
DIVK1C_000130
KBIO1_000130
cesol
bay-8440
2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4h-pyrazino[2,1-a]isoquinolin-4-one
brn 0761557
embay 8440
einecs 259-559-6
prasiquantel
ccris 4114
pyquiton
praziquantelum [inn-latin]
2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4h-pyrazino(2,1-a)isoquinolin-4-one
4h-pyrazino(2,1-a)isoquinolin-4-one, 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-
cutter tape tabs
EU-0100909
praziquantel, anthelminic, neurogenic
SPECTRUM_001119
OPREA1_163497
SPECTRUM5_001064
PRESTWICK_402
PRESTWICK2_000260
2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro- 4h-pyrazino[2,1-a]-isoquinolin-4-one
biltricide
cutter
2-(cyclohexanecarbonyl)-3,6,7,11b-tetrahydro-1h-pyrazino[2,1-a]isoquinolin-4-one
droncit
PRESTWICK3_000260
BPBIO1_000088
IDI1_000130
inchi=1/c19h24n2o2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17h,1-3,7-8,10-13h
AB00052075
C07367
praziquantel ,
55268-74-1
DB01058
praziquantel (jan/usp/inn)
D00471
biltricide (tn)
NCGC00089733-04
NCGC00089733-03
MLS000028528
smr000037139
KBIO2_006735
KBIO2_004167
KBIOGR_000963
KBIO3_001699
KBIO2_001599
KBIOSS_001599
PRESTWICK0_000260
SPBIO_002299
SPECTRUM3_000550
PRESTWICK1_000260
SPBIO_001295
NINDS_000130
SPECTRUM2_001288
SPECTRUM4_000482
SPECTRUM1500494
BSPBIO_002199
BSPBIO_000080
LOPAC0_000909
NCGC00089733-05
NCGC00089733-02
MLS001304085
MLS001201812
cysticide
STK030186
NCGC00015818-05
2-(cyclohexylcarbonyl)-1,2,3,6,7-11b-hexahydro-4h-pyrazinoe(2,1a)isoquinolin-4-one
P 4668 ,
HMS2090J19
HMS2092A09
NCGC00015818-11
embay-8440
nsc-757285
praziquantelum
CHEMBL976
HMS500G12
AKOS000541869
HMS1568D22
HMS1920J06
HMS2095D22
HMS3262F20
HMS3259K07
tox21_302927
NCGC00256422-01
dtxsid9021182 ,
dtxcid501182
NCGC00259499-01
tox21_201950
2-(cyclohexanecarbonyl)-1,2,3,6,7,11b-hexahydro-4h-pyrazino[2,1-a]isoquinolin-4-one
A830562
pharmakon1600-01500494
MLS002548849
nsc757285
tox21_110660
CCG-39773
NCGC00015818-06
NCGC00015818-08
NCGC00015818-04
NCGC00015818-12
NCGC00015818-07
unii-6490c9u457
5-24-03-00361 (beilstein handbook reference)
distocide
prazinon
6490c9u457 ,
azinox
nsc 757285
praziquantel [usan:usp:inn:ban:jan]
FT-0630676
NCGC00015818-15
LP00909
S1691
praziquantel [green book]
praziquantel [vandf]
praziquantel [mi]
broadline component praziquantel
praziquantel [usp-rs]
praziquantel [mart.]
praziquantel [usan]
praziquantel [who-dd]
praziquantelum [who-ip latin]
praziquantel [inn]
praziquantel [usp impurity]
praziquantel component of broadline
praziquantel [jan]
praziquantel [orange book]
praziquantel component of profender
praziquantel [ep monograph]
praziquantel (ema epar: veterinary)
praziquantel [usp monograph]
praziquantel [who-ip]
profender component praziquantel
HY-B0244
AB00052075-13
2-cyclohexanecarbonyl-1h,2h,3h,4h,6h,7h,11bh-piperazino[2,1-a]isoquinolin-4-one
NC00468
AKOS016398525
SCHEMBL44153
NCGC00015818-14
tox21_110660_1
cid_4891
bdbm74574
tox21_500909
NCGC00261594-01
SCHEMBL16019896
2-cyclohexylcarbonyl-1,2,3,6,7,11b-hexahydro-4h-pyrazino(2,1-a)isoquinolin-4-one
4h-pyrazino[2,1-a]isoquinolin-4-one, 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-
F0037-0136
2-(cyclohexanecarbonyl)-2,3,6,7-tetrahydro-1h-pyrazino[2,1-a]isoquinolin-4(11bh)-one
MLS006011880
Q-201612
praziquantel, antibiotic for culture media use only
(+/-)-praziquantel
2-cyclohexanecarbonyl-1h,2h,3h,4h,6h,7h,11bh-pyrazino[2,1-a]isoquinolin-4-one
P2125
AB00052075_17
AB00052075_16
OPERA_ID_378
mfcd00058531
AC-8426
sr-01000003100
SR-01000003100-3
praziquantel, united states pharmacopeia (usp) reference standard
2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1h-pyrazino[2,1-a]isoquinolin-4-one
praziquantel, vetranal(tm), analytical standard
CHEBI:91583
HMS3655O19
praziquantel, european pharmacopoeia (ep) reference standard
praziquantel, pharmaceutical secondary standard; certified reference material
praziquantel for system suitability, european pharmacopoeia (ep) reference standard
135526-78-2
SR-01000003100-5
SR-01000003100-7
SBI-0050884.P004
HMS3712D22
SW196645-3
Q424145
praziquantel-(cyclohexyl-d11)
Z1554103331
praziquantel (biltricide)
2-(cyclohexanecarbonyl)-2,3,6,7-tetrahydro-
praziquantel,(s)
1h-pyrazino[2,1-a]isoquinolin-4(11bh)-one
AS-12459
(s)-2-(cyclohexanecarbonyl)-2,3,6,7-tetrahydro-1h-pyrazino[2,1-a]isoquinolin-4(11bh)-one
BCP28525
AMY16524
BCP30228
(s)-praziquantel; praziquantel, (s)-isomer
SDCCGSBI-0050884.P005
NCGC00015818-26
BCP17829
SY052322
SR-01000003100-16
WZB34336
SB49202
praziquantel for system suitability
BP166192
GLXC-26256
EN300-123768
durvet feline tape tabsfor cats
worm and parasites aquarium cure program salt
praziquantel tablets
prazicuantel
praziquantel (usan:usp:inn:ban:jan)
praziquantel (usp-rs)
prazitech
tapeworm dewormer for dogs
worm and parasites aquarium cure program fresh
praziquantel (ep monograph)
praziquantelum (inn-latin)
droncit feline cestocide
droncit canine cestocide
praziquantel (mart.)
droncit 5.68% injectible solution
praziquantel (usp monograph)
dactymor
praziquantel (usp impurity)
tapeworm dewormer for cats
praziquantel injection
p02ba01
droncit canine cestocide tablets, droncit feline cestocide tablets, praziquantel 34 (rx), tapeworm dewormer for cats (otc), tapeworm dewormer for dogs (otc)
prazicleanse
prazi-c tablets (otc), praziquantel tablets (rx)
chebi:45267

Research Excerpts

Overview

Praziquantel (PZQ) is a chiral class-II drug, and it is used as a racemate for the treatment of schistosomiasis. It has been used for more than 30 years due to its efficiency, safety, and mild side effects. Prazquantel is an essential anthelmintic drug recently established to be an activator of a Transient Receptor Potential Melastatin.

ExcerptReferenceRelevance
"Praziquantel (PZQ) is an essential medicine for treating parasitic flatworm infections such as schistosomiasis, which afflicts over 250 million people. "( Mechanism of praziquantel action at a parasitic flatworm ion channel.
Chulkov, EG; Friedrich, L; Maillard, D; Marchant, JS; Park, SK; Rippmann, F; Rohr, CM; Spangenberg, T; Yahya, NA, 2021
)
2.43
"Praziquantel (PZQ) is an anthelmintic chiral pharmaceutical utilized in schistosomiasis treatment, commonly sold as a racemate, whose primary active molecule is the enantiomer L-(-)-PZQ. "( Adsorption of praziquantel enantiomers on chiral cellulose tris 3-chloro, 4-methylphenylcarbamate by frontal analysis: Fisherian and Bayesian parameter estimation and inference.
Cavalcante Dos Santos, R; Cunha, FC; de Mello, MSL; Gomes Barreto, A; Marcellos, CFC; Pereira, N; Tavares, FW, 2022
)
2.52
"Praziquantel (PZQ) is a chiral class-II drug, and it is used as a racemate for the treatment of schistosomiasis. "( Co-Crystalline Solid Solution Affords a High-Soluble and Fast-Absorbing Form of Praziquantel.
Cappuccino, C; Keiser, J; Lusi, M; Muntoni, E; Perissutti, B; Renni, F; Spoletti, E; Voinovich, D, 2023
)
2.58
"Praziquantel (PZQ) is an essential anthelmintic drug recently established to be an activator of a Transient Receptor Potential Melastatin (TRPM"( Metabolism of (R)-Praziquantel versus the Activation of a Parasite Transient Receptor Potential Melastatin Ion Channel.
Ballard, P; Bödding, M; Friedrich, L; Ho Baeurle, TH; Keiser, J; Maillard, D; Marchant, JS; Park, SK; Spangenberg, T, 2023
)
2.69
"Praziquantel is a schistosomicide, which has been used for more than 30 years due to its efficiency, safety, and mild side effects. "( Praziquantel ameliorates CCl
Kong, D; Liu, J; Liu, X; Lu, Z; Qiu, J; Wang, Y; Xie, Y; Zhang, R; Zhou, C, 2019
)
3.4
"Praziquantel is a broad spectrum antihelmintic agent and represents the drug of choice for the treatment of schistosomiasis. "( Orphan Formulations in Pediatric Schistosomiasis Treatment: Development and Characterization of Praziquantel Nanoparticle-Loaded Powders for Reconstitution.
Gonzalez Vidal, NL; Gonzalez, MA; Ramírez Rigo, MV, 2019
)
2.17
"Praziquantel (PZQ) is a highly effective low-cost anthelmintic agent used as the first-choice treatment against schistosomiasis. "( Preparation and characterization of a new solid form of praziquantel, an essential anthelmintic drug. Praziquantel racemic monohydrate.
Kaufman, TS; Maggio, RM; Salazar-Rojas, D, 2020
)
2.25
"Praziquantel is a remarkably effective drug for the treatment of schistosomiasis. "( Praziquantel: An Enigmatic, Yet Effective, Drug.
Timson, DJ, 2020
)
3.44
"Praziquantel is an old drug registered for human use in 1982 and has since been administered en masse for chemotherapy, risking the development of resistance, thus the need for new drugs with different mechanisms of action."( Prediction of antischistosomal small molecules using machine learning in the era of big data.
Agyenkwa-Mawuli, K; Broni, E; Kwofie, SK; Miller Iii, WA; Wilson, MD, 2022
)
1.44
"praziquantel (PZQ). It is an anthelmintic drug of current importance for adults and children as it is the recommended therapy against schistosomiasis."( Multiparticulate system combining taste masking and immediate release properties for the aversive compound praziquantel.
Breitkreutz, J; Münster, M; Schmidt, C; Schoch, C, 2017
)
1.39
"Praziquantel is a feasible bath treatment for barbel infected with D. spathaceum and has potential for oral treatment of broodfish infected with P. laevis."( Efficacy and toxicity of praziquantel in helminth-infected barbel (Barbus barbus L.).
Chupani, L; Machova, J; Piackova, V; Stara, A; Steinbach, C; Velisek, J; Zuskova, E, 2018
)
1.51
"Praziquantel is an effective medicine in the treatment."( [Clinical analysis of 17 cases of paragonimiasis].
De-Sheng, T; Hai-Yong, H; Yi-Xin, L, 2016
)
1.16
"Praziquantel is a treatment of choice not only for humans but also for animal reservoirs."( Reservoir Animals and Their Roles in Transmission of Opisthorchis viverrini.
Tangkawattana, P; Tangkawattana, S, 2018
)
1.2
"Praziquantel (PZQ) is an inexpensive, low toxicity BCS II class anthelmintic drug used for the treatment of neglected tropical diseases. "( Identification of degradation products of praziquantel during the mechanochemical activation.
Passerini, N; Perissutti, B; Šagud, I; Škorić, I; Zanolla, D, 2018
)
2.19
"Praziquantel is an antiparasitic drug used for decades. "( Conformational polymorphic changes in the crystal structure of the chiral antiparasitic drug praziquantel and interactions with calcium carbonate.
Aguzzi, C; Albertini, B; Borrego-Sánchez, A; Carazo, E; Cerezo, P; Hernández-Laguna, A; Passerini, N; Perissutti, B; Sainz-Díaz, CI; Viseras, C, 2018
)
2.14
"Praziquantel is a recommended drug for treatment against all forms of schistosomiasis."( Synthesis of fluorescent derivatives of praziquantel: cell-imaging and interaction with Schistosoma japonicum cercariae.
Fan, X; Li, X; Li, Y; Liu, C; Wu, Y; Xie, Y, 2013
)
1.38
"Praziquantel (PZQ) is an acylated quinoline-pyrazine originally developed for veterinary application but now one of the most used anti-helminthic drugs for treatment of certain trematodes and cestodes in both human and other animals. "( Mutagenic and physiological responses in the juveniles of African catfish, Clarias gariepinus (Burchell 1822) following short term exposure to praziquantel.
Ajima, MN; Echi, PC; Ikwuagwu, OE; Nnaji, MC; Nwamba, HO; Nwani, CD; Oluah, SN, 2014
)
2.05
"Praziquantel (PZQ) is a highly efficacious anthelmintic against many flatworms including schistosomes. "( Evaluation of a method for induction of praziquantel resistance in Schistosoma mansoni.
Abu El Einin, HM; El Nashar, AS; Hishmat, MG; Lotfy, WM, 2015
)
2.13
"Praziquantel (PZQ) is an effective pesticide against monogeneans. "( Comparison of praziquantel pharmacokinetics and tissue distribution in fresh and brackish water cultured grass carp (ctenopharyngodon idellus) after oral administration of single bolus.
Hu, K; Xie, X; Yang, X; Zhao, Y, 2015
)
2.22
"Praziquantel (PZQ) is a pyrazinoisoquinoline anthelmintic that was discovered in 1972 by Bayer Germany. "( Nanostructured Lipid Carriers as a Strategy to Improve the In Vitro Schistosomiasis Activity of Praziquantel.
Allegretti, SM; Chaud, MV; Chorilli, M; de Oliveira, RN; de Souza, AL; Garnero, C; Gremião, MP; Kolenyak-Santos, F; Longhi, MR, 2015
)
2.08
"Praziquantel (PZQ) is a key therapy for treatment of parasitic flatworm infections of humans and livestock, but the mechanism of action of this drug is unresolved. "( Ergot Alkaloids (Re)generate New Leads as Antiparasitics.
Agbedanu, PN; Chan, JD; Day, TA; Dosa, PI; Grab, T; Marchant, JS; Zamanian, M, 2015
)
1.86
"Oral praziquantel is considered to be an effective treatment."( Clinical Features of Pulmonary Sparganosis.
Feng, Y; Gao, BL; Li, M; Li, N; Li, QY; Xiang, Y, 2015
)
0.87
"Praziquantel (PZQ) is an anthelmintic drug used against trematode and cestode parasites of humans and veterinary animals. "( Praziquantel induced oxidative stress and apoptosis-like cell death in Raillietina echinobothrida.
Giri, BR; Roy, B, 2016
)
3.32
"Praziquantel (PZQ) is an antihelminthic drug whose P-glycoprotein (P-gp) substrate specificity has not been conclusively characterized. "( Intracellular accumulation of Praziquantel in T lymphoblastoid cell lines, CEM (parental) and CEMVBL(P-gp-overexpressing).
Edwards, G; Kigen, G, 2016
)
2.17
"Praziquantel is an effective antischistosomal drug especially for adult worms."( Effect of praziquantel prolonged administration on granuloma formation around Schistosoma japonicum eggs in lung of sensitized mice.
Huang, YX; Li, HJ; Liang, YS; Wang, TS; Wang, W; Xu, YL; Yin, XR; Yu, CX, 2011
)
1.49
"Praziquantel is a broad-spectrum antihelminth agent."( In vivo efficacy of praziquantel against Echinoparyphium aconiatum (Trematoda: Echinostomatidae) parasitizing the great pond snails Lymnaea stagnalis (Gastropoda: Lymnaeidae).
Voutilainen, A, 2011
)
1.41
"Praziquantel (PZQ) is an isoquinoline derivative (2-cyclohexylcarbonyl-1, 2, 3, 6, 7, 11b-hexahydro-4H-pyrazino{2,1-a}-isoquinoline-4-one), and is currently the drug of choice for all forms of schistosomiasis. "( Anti-inflammatory/anti-fibrotic effects of the hepatoprotective silymarin and the schistosomicide praziquantel against Schistosoma mansoni-induced liver fibrosis.
Ain-Shoka, AA; Badawy, AA; Ebeid, FA; El-Lakkany, NM; El-Maadawy, WH; Hammam, OA, 2012
)
2.04
"Praziquantel (PZQ) is an effective drug for treatment of neurocysticercosis. "( [Comparative analysis of the influence of food and cimetidine in plasma levels of praziquantel].
Castro, N; González-Esquivel, DF; Jung, H; López, M,
)
1.8
"Praziquantel is an anti-schistosoma drug, its wastewater contains numerous cyanide and other colloid pollutant. "( Treatment of praziquantel wastewater using the integrated process of coagulation and gas membrane absorption.
Li, L; Shen, Z; Xu, Z, 2005
)
2.14
"Praziquantel (PZQ) is a broadly effective anthelminthic drug available for human and veterinary use, being the drug of choice for the treatment of all forms of schistosomiasis. "( Theoretical and experimental study of a praziquantel and beta-cyclodextrin inclusion complex using molecular mechanic calculations and H1-nuclear magnetic resonance.
de Jesus, MB; de Matos Alves Pinto, L; de Paula, E; Fraceto, LF; Jaime, C; Lino, AC; Takahata, Y, 2006
)
2.04
"Praziquantel seems to be an ideal drug against Schistosoma mansoni infection especially for mass treatment as it is given in a single oral dose."( Assessment of efficacy of praziquantel against Schistosoma mansoni infection.
Anwar, WA; el Kholy, AM; Massoud, AA, 1984
)
1.29
"Praziquantel is a newly developed drug effective in the treatment of schistosomiasis. "( Treatment of Schistosoma mekongi with praziquantel: a double-blind study.
Cheever, AW; Hofstetter, M; Nash, TE; Ottesen, EA, 1982
)
1.98
"Praziquantel appears to be an effective, well tolerated and easily administrable schistosomicide and thus a favourable contribution to the control of urinary schistosomiasis."( [Trial of praziquantel in the treatment of urinary schistosomiasis in Senegal].
Bah, IB; Diallo, S; Dieng, Y; Diouf, F; Ndir, O; Victorius, A, 1981
)
1.39
"Praziquantel is an excellent drug for treatment against Opisthorchis viverrini infection. "( Field trial of praziquantel in human opisthorchiasis in Thailand.
Pawabut, P; Supanvanich, K; Supanvanich, S, 1981
)
2.06
"Praziquantel proved to be a safe and effective drug for therapy of Clonorchis/Opisthorchis infections."( High efficacy of praziquantel in the treatment of 22 patients with Clonorchis/Opisthorchis infections.
Dietrich, M; Feldheim, W; Feldmeier, H; Horstmann, RD, 1981
)
1.32
"Praziquantel (PQ) is a commonly used drug to treat schistosomiasis patients."( Praziquantel (antischistosomal drug): is it clastogenic, co-clastogenic or anticlastogenic?
Anwar, WA, 1994
)
2.45
"Praziquantel is a synthetic drug with a remarkable activity against parasites, particularly treamatodes and cestodes. "( Genotoxic activity of praziquantel.
Montero, R; Ostrosky, P, 1997
)
2.05
"Praziquantel (PZQ) is a broadly effective trematocide and cestocide, widely employed in veterinary and human medicine. "( Pharmacokinetics and microsomal oxidation of praziquantel and its effects on the P450 system in three-month-old lambs infested by Fasciola hepatica.
Gervasi, PG; Giorgi, M; Giusiani, M; Longo, V; Mengozzi, G; Salvatori, AP; Soldani, G, 2001
)
2.01
"Praziquantel seems to be a very promising drug against S."( Preliminary trials with praziquantel in human infections due to Schistosoma mansoni.
Chaves, A; Katz, N; Rocha, RS, 1979
)
1.29
"Praziquantel (PZQ) is a racemic compound composed of equal proportions of its optical isomers, levo- and dextro-PZQ. "( A comparison of the antischistosomal effect of levo- and dextro-praziquantel on Schistosoma japonicum and S. mansoni in mice.
Irie, Y; Nara, T; Ohmae, H; Tanaka, M; Utsunomiya, H; Yasuraoka, K, 1989
)
1.96
"Praziquantel (PQT) is a chiral compound with an asymmetric center at the 11 b-position. "( [Stereoselectivity of arrhythmogenic effect of praziquantel in conscious rabbits].
Qian, YS; Quan, YZ, 1989
)
1.98
"Praziquantel (PQT) is a racemic mixture. "( [The liver first pass effects and bile concentrations of (-)-, (+)- and (+/-)-praziquantel in rabbits].
Liu, YH; Qian, MX; Qiu, ZY; Quan, YZ, 1989
)
1.95
"Praziquantel (PQ) is a commonly used drug to treat patients with schistosomiasis. "( Enhancement of benzene clastogenicity by praziquantel in mice.
Anwar, WA; Au, WW; Legator, MS; Ramanujam, VM, 1989
)
1.99
"Praziquantel is a broad spectrum anti-helminthic drug active against a variety of parasitic trematodes and cestodes. "( Effects of anti-schistosomal chemotherapy on immune responses, protection and immunity. III. An effective regimen of praziquantel does not alter immune capabilities of normal mice.
Colley, DG; Tawfik, AF, 1986
)
1.92
"Praziquantel is a most effective and rapid scolicidal agent which may well be of clinical value."( Protoscolicidal effect of praziquantel--in-vitro and electron microscopical studies on Echinococcus granulosus.
Chinnery, JB; Morris, DL; Richards, KS, 1986
)
1.29

Effects

Praziquantel has a high efficacy against Schistosoma, few and transient side effects, simple administration and competitive cost. It is equally suited for both individual and large-scale treatment.

Praziquantel has been in use by helminthiasis and schistosomiasis control programs for about 30 years. R-Prazquantel (R-PZQ) has been shown as the therapeutic form, whereas S-PzQ is less efficacious. The optimal dose for children younger than 4 years is not known.

ExcerptReferenceRelevance
"Praziquantel has an impact on reducing the prevalence and intensity of urogenital schistosomiasis. "( Urogenital schistosomiasis in three different water access in the Senegal river basin: prevalence and monitoring praziquantel efficacy and re-infection levels.
Boissier, J; Diop, B; Doucouré, S; Mathieu-Begné, E; Rey, O; Sène, M; Senghor, B; Sokhna, C; Sow, D, 2022
)
2.37
"Praziquantel has a high efficacy against Schistosoma, few and transient side effects, simple administration and competitive cost, and is equally suited for both individual and large-scale treatment."( Application of praziquantel in schistosomiasis japonica control strategies in China.
Huang, Y; Wu, W, 2013
)
1.46
"Praziquantel not only has broad-spectrum anti-trematode and anti-tapeworm effects, but also has pharmacological effects such as regulating inflammatory response and anti-fibrosis. "( [Progress of researches on the actions of praziquantel against hepatic fibrosis].
Dai, JR; Yuan, X, 2021
)
2.33
"Praziquantel (PZQ) has been extensively used as the drug of choice for the treatment of schistosomiasis on account of its safety and effectiveness against all major forms of schistosomiasis. "( Praziquantel efficacy, urinary and intestinal schistosomiasis reinfection - a systematic review.
Aboagye, IF; Addison, YAA, 2023
)
3.8
"Praziquantel has an impact on reducing the prevalence and intensity of urogenital schistosomiasis. "( Urogenital schistosomiasis in three different water access in the Senegal river basin: prevalence and monitoring praziquantel efficacy and re-infection levels.
Boissier, J; Diop, B; Doucouré, S; Mathieu-Begné, E; Rey, O; Sène, M; Senghor, B; Sokhna, C; Sow, D, 2022
)
2.37
"Praziquantel (PZQ) has been the first line antischistosomal drug for all species of Schistosoma, and the only available drug for schistosomiasis japonica, without any alternative drugs since the 1980s. "( Small change, big difference: A promising praziquantel derivative designated P96 with broad-spectrum antischistosomal activity for chemotherapy of schistosomiasis japonica.
Dong, LL; Huang, P; Sun, DQ; Sun, H; Wang, XY; Xia, CM; Xu, J; Zhang, RZ, 2023
)
2.62
"Praziquantel has been in use by helminthiasis and schistosomiasis control programs for about 30 years. "( Praziquantel and risk of visual disorders: Case series assessment.
Debesai, M; Russom, M, 2020
)
3.44
"Praziquantel (PZQ) has been commonly used to treat diverse parasitic infections for over thirty years. "( Acute pancytopenia due to praziquantel treatment for cerebral cysticercosis: A rare case report.
Deng, H; Fu, Y; Lai, J; Li, Q; Zhang, Y, 2020
)
2.3
"R-Praziquantel (R-PZQ) has been shown as the therapeutic form, whereas S-PZQ is less efficacious and responsible for the bitter taste of the tablet."( In vitro and in vivo human metabolism and pharmacokinetics of S- and R-praziquantel.
Kapungu, NN; Li, X; Masimirembwa, C; Nhachi, C; Thelingwani, RS, 2020
)
1.35
"Praziquantel has been cited as the only drug for treating schistosomiasis. "( Ultrastructural alterations in Schistosoma mansoni juvenile and adult male worms after in vitro incubation with primaquine.
Bayaumy, FE; Kamel, RO, 2017
)
1.9
"Praziquantel has been the drug of choice for schistosomiasis control for more than 40 years, yet surprisingly, the optimal dose for children younger than 4 years is not known. "( Efficacy and safety of praziquantel in preschool-aged and school-aged children infected with Schistosoma mansoni: a randomised controlled, parallel-group, dose-ranging, phase 2 trial.
Coulibaly, JT; Hattendorf, J; Keiser, J; Kovač, J; Panic, G; Silué, KD, 2017
)
2.21
"Praziquantel has remained the drug of choice for schistosomiasis chemotherapy for almost 40 years. "( Antischistosomal agents: state of art and perspectives.
da Silva Filho, AA; de Moraes, J; Lago, EM; Silva, LM; Teixeira, TR; Xavier, RP, 2018
)
1.92
"Praziquantel has proven to be effective against this parasitic disease, though there are increasing concerns regarding tolerance/resistance that calls for new drugs."( In vitro schistosomicidal activity of tamoxifen and its effectiveness in a murine model of schistosomiasis at a single dose.
Allegretti, SM; Corrêa, SAP; Mendes, T; Miguel, DC; Oliveira, RN; Vieira, KM, 2019
)
1.24
"Praziquantel has been the mainstay of schistosomiasis control since 1984 and widely distributed since 2006 through 'preventive chemotherapy' programmes to school-aged children or at-risk populations. "( The little we know about the pharmacokinetics and pharmacodynamics of praziquantel (racemate and R-enantiomer).
Delgado-Romero, P; Keiser, J; Olliaro, P, 2014
)
2.08
"Praziquantel (PZQ) has shown some anti-schistosomal effect, but little information is available about the effect of PZQ-prolonged administration on granuloma formation around schistosome eggs."( Transdermal praziquantel administration attenuates hepatic granulomatosis in mice infected with Schistosoma japonicum.
Bao-an, Y; Jiang-shan, D; Li-zhi, W; Xin-Sheng, Z; Yi, W, 2015
)
1.52
"Praziquantel has been distributed using community resource persons in fixed sites and house-to-house visits; however the uptake is still below target coverage."( Uptake of mass drug administration programme for schistosomiasis control in Koome Islands, Central Uganda.
Bagonza, J; Elliott, AM; Kiracho, EE; Nuwaha, F; Tuhebwe, D; Yeka, A, 2015
)
1.14
"Praziquantel has been used for the treatment of diseases caused by infection with various parasites. "( Effect of praziquantel treatment on the expression of matrix metalloproteinases in relation to tissue resorption during fibrosis in hamsters with acute and chronic Opisthorchis viverrini infection.
Boonmars, T; Hiraku, Y; Pinlaor, P; Pinlaor, S; Prakobwong, S; Wongkham, C, 2009
)
2.2
"Praziquantel, which has been used in the treatment and control of canine and feline tapeworm infections for about 35 years, has not been tested against these parasites for a long period in Turkey. "( [Efficacy of praziquantel injectable solution against feline and canine tapeworms.].
Bilgin, Z; Erçin, S; Oter, K; Tinar, R; Tüzer, E, 2010
)
2.17
"Praziquantel chemotherapy has been the focus of the Schistosomiasis Control Program in Brazil for the past two decades. "( Spatial distribution of Schistosoma mansoni infection before and after chemotherapy with two praziquantel doses in a community of Pernambuco, Brazil.
Barbosa, CS; Carvalho, OS; Domingues, AL; Favre, TC; Felipe, KT; Galvão, AF; Guimarães, RJ; Pereira, AP; Pieri, OS; Zani, LC, 2010
)
2.02
"Praziquantel has been used for the treatment of liver fluke infection, but an oxidative/nitrative stress may occur after a short-term treatment and participate in side effects. "( Curcumin induces a nuclear factor-erythroid 2-related factor 2-driven response against oxidative and nitrative stress after praziquantel treatment in liver fluke-infected hamsters.
Charoensuk, L; Hiraku, Y; Laothong, U; Pinlaor, P; Pinlaor, S; Prakobwong, S; Ruangjirachuporn, W; Yongvanit, P, 2011
)
2.02
"Praziquantel has been used to treat schistosome infections since 1979 and currently is the only chemotherapeutic agent in production for this purpose, raising concerns about the potential for the emergence of drug resistance. "( Schistosoma mansoni population structure and persistence after praziquantel treatment in two villages of Bahia, Brazil.
Barbosa, LM; Blank, WA; Blanton, RE; Carmo, TM; Costa, JM; Reis, EA; Reis, MG; Silva, LK; Test, MR, 2011
)
2.05
"Praziquantel has been used as first-line drug for chemotherapy of schistosomiasis since 1984. "( Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and meta-analysis.
Dong, HF; Guo, Y; Jiang, MS; Liu, R; Zhao, QP, 2011
)
2.19
"Praziquantel has a high efficacy against Schistosoma, few and transient side effects, simple administration and competitive cost, and is equally suited for both individual and large-scale treatment."( Application of praziquantel in schistosomiasis japonica control strategies in China.
Huang, Y; Wu, W, 2013
)
1.46
"Praziquantel has been shown to be highly effective against all known species of Schistosoma infecting humans. "( PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution.
Evangelista, RC; Mainardes, RM, 2005
)
2.06
"Praziquantel has been shown to be highly effective against all known species of Schistosoma infecting humans. "( Development of praziquantel-loaded PLGA nanoparticles and evaluation of intestinal permeation by the everted gut sac model.
Chaud, MV; Evangelista, RC; Gremião, MP; Mainardes, RM,
)
1.93
"Praziquantel recently has been approved in the United States for use against a broad range of trematodes and cestodes. "( Praziquantel: a major advance in anthelminthic therapy.
Guerrant, RL; Pearson, RD, 1983
)
3.15
"Praziquantel has provided new hope."( Praziquantel therapy in neurocysticercosis.
Agrawal, A; Singhal, KC; Srivastava, A; Srivastava, VK, 1993
)
2.45
"Praziquantel has not been considered useful for therapy of subarachnoid cysticercosis. "( [Cysticercosis of the cerebellopontine angle: treatment with single-dose praziquantel].
del Brutto, OH,
)
1.81
"Praziquantel has become the most widely available and effective chemotherapy for schistosomiasis."( Drug treatment of tropical parasitic infections: recent achievements and developments.
Stephenson, I; Wiselka, M, 2000
)
1.03
"Praziquantel has no effect on the histopathology of small intestine or skeletal muscles."( Effect of some drugs on some histopathological and immunological aspects of experimental trichinosis in albino rats.
Abou-Ragab, HA; el-Ridi, AM; Etewa, SE; Ismail, MM; Ramadan, ME; Shehata, MM, 1990
)
1
"Praziquantel therapy has produced a much better prognosis in neurocysticercosis since 1980. "( [CT follow-up of neurocysticercosis treated with praziquantel].
Aulich, A; Hammer, B; Schwartz, A, 1987
)
1.97

Actions

ExcerptReferenceRelevance
"Praziquantel-induced increase in nitrate/nitrite level was significantly reduced by administration of L-NAME 100 mg/kg."( Mediation of the schistosomicidal effect of praziquantel through nitric oxide.
Ammar, EM; Eissa, LA; Said, SA, 2002
)
1.3

Treatment

Praziquantel treatment of infected mice fed with a standard diet (IN-PZQ) resulted in a significant reduction of worm and egg burdens. The treatment significantly reduced systemic OPN levels and liver collagen deposition, indicating that OPN could be a reliable tool for monitoring PZQ efficacy.

ExcerptReferenceRelevance
"Praziquantel treatment of infected mice fed with a standard diet (IN-PZQ) resulted in a significant reduction of worm and egg burdens and a normalization of iron and calcium levels."( Protein undernutrition reduces the efficacy of praziquantel in a murine model of Schistosoma mansoni infection.
Abou-Bacar, A; Boukeng Jatsa, H; Brunet, J; Cannet, C; Gipwe Feussom, N; Greigert, V; Kadji Fassi, JB; Kamgang, R; Kamtchouing, P; Kenfack, CM; Membe Femoe, U; Pfaff, AW; Tchuem Tchuenté, LA; Tienga Nkondo, E, 2022
)
1.7
"Praziquantel (PZQ) is the treatment of choice."( Human urogenital schistosomiasis in West and Sub-Saharan Africa migrants in Sardinia, Italy: A retrospective monocentric study.
Babudieri, S; De Vito, A; Fiore, V; Geremia, N; Lai, V; Madeddu, G; Princic, E; Rappelli, P, 2022
)
1.44
"Praziquantel (PZQ) treatment presents low efficacy and adverse effects in parasites juvenile stages."( Synthesis, in vitro schistosomicidal activity and ultrastructural alterations caused by thiosemicarbazones and thiazolidinones against juvenile and adult Schistosoma mansoni worms (Sambon, 1907).
Alves de Lima, MDC; Alves, LC; Bezerra de Mélo, ME; Brayner, FA; de Almeida Júnior, ASA; de Oliveira, JF; do Nascimento, AV; Feitosa, APS; Júnior, NCP; Leite, NMS; Tavares da Rocha, RE, 2022
)
1.44
"Praziquantel was the treatment of choice (70.1% for 3 days and 29.9% in a single-day dose), and 77 (51.7%) were lost to follow-up."( Delay in schistosomiasis diagnosis and treatment: a multicenter cohort study in Italy.
Bartoloni, A; Caligaris, S; Canetti, D; Castelli, F; Cenderello, G; Comelli, A; Di Biagio, A; Gaiera, G; Magro, P; Marchese, V; Nicolini, LA; Riccardi, N; Spinicci, M; Zammarchi, L, 2020
)
1.28
"Praziquantel treatment significantly reduced systemic OPN levels and liver collagen deposition, indicating that OPN could be a reliable tool for monitoring PZQ efficacy and fibrosis regression in murine schistosomiasis."( Praziquantel pharmacotherapy reduces systemic osteopontin levels and liver collagen content in murine schistosomiasis mansoni.
Pereira, FEL; Pereira, TA; Souza, MM; Trindade Santos, E; Vaz de Melo Trindade, G, 2021
)
2.79
"Praziquantel (PZQ) treatment for Schistosoma japonicum infection in pregnant women has been demonstrated to be safe and effective."( Effect of maternal praziquantel treatment for Schistosoma japonicum infection on the offspring susceptibility and immunologic response to infection at age six, a cohort study.
Acosta, LP; Baltazar, P; Barry, CV; Colt, S; Friedman, JF; Jarilla, B; Jiz, MA; Kurtis, JD; Olveda, RM; Tallo, V; Wu, HW, 2021
)
1.67
"Praziquantel treatment damages the outermost surface of the parasite, the tegument, liberating surface antigens from dying worms that invoke a robust immune response which in some subjects results in immunologic resistance to reinfection."( Immunomics-Guided Antigen Discovery for Praziquantel-Induced Vaccination in Urogenital Human Schistosomiasis.
Becker, L; Felgner, PL; Greco, B; Jasinskas, A; Loukas, A; Mduluza, T; Mutapi, F; Nakajima, R; Oeuvray, C; Pearson, MS; Sotillo, J; Tedla, BA, 2021
)
1.61
"Praziquantel treatment decreased adult-worm burden, but had a larger negative impact on the mean daily number of miracidia, a proxy for fecundity, across all three parasite isolates."( Praziquantel decreases fecundity in Schistosoma mansoni adult worms that survive treatment: evidence from a laboratory life-history trade-offs selection study.
Faust, CL; Lamberton, PHL; Webster, JP, 2017
)
2.62
"Praziquantel-based mass treatment is the main approach to controlling schistosomiasis mansoni in endemic areas. "( Perceptions about interventions to control schistosomiasis among the Lake Victoria island communities of Koome, Uganda.
Elliott, AM; Sanya, RE; Seeley, J; Tumwesige, E, 2017
)
1.9
"The praziquantel treatment can achieve a good prognosis."( [Clinical features of 14 cases of cerebral schistosomiasis in Jiangxi Province].
Hui-Qun, X; Yun, X; Zhi-Hong, G, 2017
)
0.94
"Praziquantel oral treatment had a curative effect and little adverse reaction."( [Clinical analysis of 12 cases of paragonimiasis].
Bo, L; Ying-Hong, S, 2017
)
1.18
"Praziquantel treatment was not linked to a major shift in the gut taxonomic profiles, thus reinforcing the good safety profile of the drug by ruling out off-targets effects on the gut microbes.16S rRNA gene of the Fusobacteriales order was significantly more abundant in cured individuals, both at baseline and 24 hours post-treatment."( Investigations on the interplays between Schistosoma mansoni, praziquantel and the gut microbiome.
Coulibaly, JT; Daubenberger, C; Frey, JE; Gueuning, M; Keiser, J; Panic, G; Schneeberger, PHH, 2018
)
1.44
"Praziquantel is a treatment of choice not only for humans but also for animal reservoirs."( Reservoir Animals and Their Roles in Transmission of Opisthorchis viverrini.
Tangkawattana, P; Tangkawattana, S, 2018
)
1.2
"Praziquantel treatment can significantly alleviate the lesions of the liver and the spleen and decrease the ICOS expression by Tfh cells in the peripheral blood and spleen."( [T Follicular Helper Cells and Related Molecules in Schistosoma japonicum Infected Mice after Praziquantel Treatment].
Cao, JP; Hu, Y; Jiang, YY; Liu, H; Shen, YJ; Wang, YJ; Xu, YX; Zhang, YM; Zheng, L, 2016
)
2.1
"Praziquantel treatment (40 mg/kg) resulted in 96.4% cure rate and 99.4% egg reduction rate."( Schistosoma mansoni infection among preschool age children attending Erer Health Center, Ethiopia and the response rate to praziquantel.
Abay, SM; Esmael, A; Kebede, T; Kemal, M; Tadesse, G, 2019
)
1.44
"Praziquantel treatment did not significantly alter the trajectory of the concentration of any of the cytokines examined."( Maternal, placental and cord blood cytokines and the risk of adverse birth outcomes among pregnant women infected with Schistosoma japonicum in the Philippines.
Abioye, AI; Acosta, LP; Baltazar, P; Ernerudh, J; Friedman, JF; Joshi, A; Kurtis, JD; McDonald, EA; Olveda, RM; Park, S; Pond-Tor, S; Sharma, S; Tallo, V; Wu, H, 2019
)
1.24
"Praziquantel treatment of S."( Effect of maternal Schistosoma mansoni infection and praziquantel treatment during pregnancy on Schistosoma mansoni infection and immune responsiveness among offspring at age five years.
Cose, S; Dunne, DW; Elliott, AM; Jones, FM; Mawa, PA; Naniima, P; Tweyongyere, R; Webb, EL, 2013
)
1.36
"Praziquantel treatment kills adult worms, boosting antigen exposure and protective antibody levels."( Predicted impact of mass drug administration on the development of protective immunity against Schistosoma haematobium.
Mduluza, T; Midzi, N; Mitchell, KM; Mutapi, F; Savill, NJ; Woolhouse, ME, 2014
)
1.12
"The praziquantel treatment is selected firstly when the diagnosis was established."( [Diagnosis and treatment of cerebral schistosomiasis: a report of 166 cases].
Huang, X; Jin, WX; Wu, M; Xie, K; Zhu, F, 2014
)
0.88
"Praziquantel is the treatment of choice and has been considered for preventive chemotherapy."( Clonorchiasis.
Keiser, J; Qian, MB; Utzinger, J; Zhou, XN, 2016
)
1.16
"Praziquantel (PZQ) is the treatment of choice against various trematode and cestode infections. "( Development and validation of an enantioselective LC-MS/MS method for the analysis of the anthelmintic drug praziquantel and its main metabolite in human plasma, blood and dried blood spots.
Duthaler, U; Huwyler, J; Keiser, J; Kovač, J; Leonidova, A; Meister, I, 2016
)
2.09
"Praziquantel (PZQ) is the treatment of choice for infections with the liver fluke Opisthorchis viverrini, a major health problem in Southeast Asia. "( Pharmacokinetic Study of Praziquantel Enantiomers and Its Main Metabolite R-trans-4-OH-PZQ in Plasma, Blood and Dried Blood Spots in Opisthorchis viverrini-Infected Patients.
Duthaler, U; Huwyler, J; Keiser, J; Kovac, J; Meister, I; Odermatt, P; Sayasone, S; Vanobberghen, F, 2016
)
2.18
"Praziquantel treatment not only cures infection but also frees the host from the powerful immunomodulatory action of the parasites."( Human schistosomiasis in the post mass drug administration era.
Fenwick, A; Maizels, R; Mutapi, F; Woolhouse, M, 2017
)
1.18
"Praziquantel treatment is significantly associated with the reversal of S."( Ultrasonographic evaluation of urinary tract morbidity in school-aged and preschool-aged children infected with Schistosoma haematobium and its evolution after praziquantel treatment: A randomized controlled trial.
Barda, B; Coulibaly, JT; Hatz, C; Keiser, J, 2017
)
1.37
"Praziquantel treatment led to 'cure' in 90.9% and 70.5% of children as measured by the egg detection and CCA methods, respectively."( Use of circulating cathodic antigen strips for the diagnosis of urinary schistosomiasis.
Butterworth, AE; Deelder, AM; Mduluza, T; Midzi, N; Munyati, S; van Dam, GJ, 2009
)
1.07
"Praziquantel treatment of schistosomiasis boosts antischistosome responses, with type 2 helper T cell bias that may contribute to immunologically mediated killing and to protection against reinfection. "( Effect of praziquantel treatment during pregnancy on cytokine responses to schistosome antigens: results of a randomized, placebo-controlled trial.
Dunne, DW; Duong, T; Elliott, AM; Katunguka-Rwakishaya, E; Mawa, PA; Ndibazza, J; Ngom-Wegi, S; Tweyongyere, R; Vennervald, BJ, 2008
)
2.19
"Praziquantel treatment during pregnancy caused significant boosts in interferon-gamma (IFN-gamma), interleukin (IL)-2, IL-4, IL-5, IL-13, and IL-10 responses to schistosome worm antigen and in IFN-gamma, IL-5, and IL-13 responses to schistosome egg antigen, but these boosts were not as substantial as those seen for women treated after delivery."( Effect of praziquantel treatment during pregnancy on cytokine responses to schistosome antigens: results of a randomized, placebo-controlled trial.
Dunne, DW; Duong, T; Elliott, AM; Katunguka-Rwakishaya, E; Mawa, PA; Ndibazza, J; Ngom-Wegi, S; Tweyongyere, R; Vennervald, BJ, 2008
)
1.47
"Praziquantel treatment was characterised by a significantly lower erythrocyte count, haemoglobin level, packed cell volume and total protein at both dose levels after 24 h compared with the controls, but these parameters were similar to the control values at 96 h."( The effect of praziquantel applied per os on selected haematological and biochemical indices in common carp (Cyprinus carpio L.).
Kroupová, H; Piacková, V; Pijácek, M; Sudová, E; Svobodová, Z, 2009
)
1.43
"Praziquantel treatment of schistosomiasis during pregnancy was only recommended in 2002; hence the effects of treatment during pregnancy are not fully known. "( Effect of praziquantel treatment of Schistosoma mansoni during pregnancy on intensity of infection and antibody responses to schistosome antigens: results of a randomised, placebo-controlled trial.
Dunne, DW; Duong, T; Elliott, AM; Emojong, NO; Jones, FM; Katunguka-Rwakishaya, E; Mawa, PA; Mpairwe, H; Tweyongyere, R; Vennervald, BJ, 2009
)
2.2
"Praziquantel treatment during pregnancy boosted anti-worm IgG isotypes and to a lesser extent IgE, but these boosts were less pronounced than in women whose treatment was delayed until after delivery."( Effect of praziquantel treatment of Schistosoma mansoni during pregnancy on intensity of infection and antibody responses to schistosome antigens: results of a randomised, placebo-controlled trial.
Dunne, DW; Duong, T; Elliott, AM; Emojong, NO; Jones, FM; Katunguka-Rwakishaya, E; Mawa, PA; Mpairwe, H; Tweyongyere, R; Vennervald, BJ, 2009
)
1.48
"Praziquantel treatment in Opisthorchis viverrini-infected patients reduces the hepatobiliary fibrosis due to tissue resorption, however, some fibroses are irreversible."( Effect of praziquantel treatment on the expression of matrix metalloproteinases in relation to tissue resorption during fibrosis in hamsters with acute and chronic Opisthorchis viverrini infection.
Boonmars, T; Hiraku, Y; Pinlaor, P; Pinlaor, S; Prakobwong, S; Wongkham, C, 2009
)
1.48
"Praziquantel treatment did not decrease the infection intensity of STHs."( Reduction in hookworm infection after praziquantel treatment among children and young adults in Leyte, the Philippines.
Acosta, LP; Aggarwal, N; Coutinho, HM; Friedman, JF; Jiz, MA; Kurtis, JD; Leenstra, T; McGarvey, ST; Olveda, RM; Shaw, JG; Wu, HW, 2010
)
1.35
"Praziquantel treatment during pregnancy boosts maternal immune responses to schistosome antigens and reduces worm burden."( Effect of praziquantel treatment of Schistosoma mansoni during pregnancy on immune responses to schistosome antigens among the offspring: results of a randomised, placebo-controlled trial.
Cose, S; Dunne, DW; Elliott, AM; Jones, FM; Kihembo, M; Mawa, PA; Tweyongyere, R; Vennervald, BJ; Webb, EL, 2011
)
1.49
"Praziquantel treatment during pregnancy showed no effect on cytokine responses or antibodies levels to SWA or SEA either in cord blood or at age one year, except for IgG1 to SWA, which was elevated in infants of treated mothers, reflecting maternal levels."( Effect of praziquantel treatment of Schistosoma mansoni during pregnancy on immune responses to schistosome antigens among the offspring: results of a randomised, placebo-controlled trial.
Cose, S; Dunne, DW; Elliott, AM; Jones, FM; Kihembo, M; Mawa, PA; Tweyongyere, R; Vennervald, BJ; Webb, EL, 2011
)
1.49
"Praziquantel treatment was initiated promptly, avoiding significant morbidity."( Schistosomiasis: an unusual finding of the cervix.
Blagg, NA; Chen, W; Flynn, EA; Shreefter, MJ, 2012
)
1.1
"Praziquantel treatment needs may be over- or underestimated depending on the level of spatial aggregation. "( Determining treatment needs at different spatial scales using geostatistical model-based risk estimates of schistosomiasis.
Schur, N; Utzinger, J; Vounatsou, P, 2012
)
1.82
" Praziquantel treatment markedly alters polarization of schistosome-specific cytokine responses, and these changes, particularly in response to egg-stage parasites, may promote resistance to reinfection."( Integrated analysis of innate, Th1, Th2, Th17, and regulatory cytokines identifies changes in immune polarisation following treatment of human schistosomiasis.
Appleby, LJ; Bourke, CD; Mduluza, T; Midzi, N; Mitchell, KM; Mutapi, F; Nausch, N; Rujeni, N, 2013
)
1.3
"Thus praziquantel mass treatment can be spaced to a much longer period, reducing the expense of treatment, delivery and distribution."( Effects of single-dose praziquantel on morbidity and mortality resulting from intestinal schistosomiasis.
Baraka, OZ; el-Tom, IA; Homieda, MM; Kheir, MM; Mukhtar, MM,
)
0.9
"Praziquantel was the only treatment used."( Imported schistosomiasis in Europe: sentinel surveillance data from TropNetEurop.
Beran, J; Bisoffi, Z; Bronner, U; Clerinx, J; Corachán, M; da Cunha, S; Fleischer, K; Fry, G; Gjørup, I; Grobusch, MP; Harms, G; Hatz, C; Hellgren, U; Jelinek, T; Kapaun, A; Knobloch, J; Matteelli, A; Mühlberger, N; Myrvang, B; Nielsen, LN; Puente, S; Schmid, ML; Schulze, M,
)
0.85
"Praziquantel treatment was highly efficacious at three weeks after treatment when judged by egg reduction rate (95.3%) and cure rate of heavy infections (94.1%). "( Patterns of Schistosoma haematobium infection, impact of praziquantel treatment and re-infection after treatment in a cohort of schoolchildren from rural KwaZulu-Natal/South Africa.
Appleton, CC; Becker, W; Kvalsvig, JD; Magnussen, P; Olsen, A; Saathoff, E, 2004
)
2.01
"Praziquantel treatment induced damage to the surface membrane as measured by the use of a variety of fluorescent compounds."( Responses of the surface membrane and excretory system of Schistosoma mansoni to damage and to treatment with praziquantel and other biomolecules.
Coelho, PM; Kusel, JR; Oliveira, FA; Ribeiro, F, 2006
)
1.27
"Praziquantel treatment for Schistosoma mansoni infection enhances Th2 responsiveness against parasite Ags, but also increases the variance in Ab isotype levels. "( Carriage of DRB1*13 is associated with increased posttreatment IgE levels against Schistosoma mansoni antigens and lower long-term reinfection levels.
Booth, M; Carpenter, D; Dunne, DW; Jones, FM; Joseph, S; Kabatereine, NB; Kariuki, HC; Mwatha, JK; Ouma, JH; Shaw, MA; Vennervald, BJ, 2006
)
1.78
"Praziquantel is the drug treatment of choice."( Human schistosomiasis.
Clerinx, J; Gryseels, B; Kestens, L; Polman, K, 2006
)
1.06
"In praziquantel treated group the level of testosterone was lowered 10, 20 & 30 days post treatment, progesterone and 17 beta-estradiol fell 30 days post treatment after primary rise."( Effect of praziquantel on sex hormone levels in murine schistosomiasis mansoni.
Abdalla, KF; Abdel-Aziz, SM; Afifi, LM; el Fakahany, AF; el-Hamshary, AS, 1994
)
1.2
"Praziquantel treatment alone appeared to reduce the number of cysts, but did not decrease the viability of the remaining parasites."( Effective, single-dose treatment or porcine cysticercosis with oxfendazole.
Bernal, T; Falcon, N; Garcia, HH; Gavidia, CM; Gilman, RH; Gonzales, AE; Lopez-Urbina, MT; Romero, M; Tsang, VC, 1996
)
1.02
"Praziquantel treatment reduced worm burdens by 80-90% in both strains."( A biological and immunological comparison of Chinese and Philippine Schistosoma japonicum.
Duke, M; Hope, M; McManus, DP, 1996
)
1.02
"Praziquantel-treated children had more nausea, abdominal pain, and headache but these side effects were statistically more common in children with schistosomiasis, suggesting a strong influence of dying parasites."( Double-blind placebo-controlled study of concurrent administration of albendazole and praziquantel in schoolchildren with schistosomiasis and geohelminths.
Aligui, G; Gachihi, G; Hewlett, J; Horton, RJ; King, C; Koech, D; Kombe, Y; Liu, CY; McGarvey, S; Odhiambo, O; Olds, GR; Olveda, R; Ouma, J; Parraga, I; Peters, P; Ramirez, B; Reeve, P; Whalen, C; Wu, G, 1999
)
1.25
"Praziquantel for tapeworm treatment should not be given at doses lower than 10 mg/kg."( Mass treatment against human taeniasis for the control of cysticercosis: a population-based intervention study.
Ambrosio, J; Avila, G; Flisser, A; Medina-Santillán, R; Sarti, E; Schantz, PM,
)
0.85
"The praziquantel plus placebo-treated group attained a cure rate of 73%, artesunate plus placebo a rate of 27%, the combination of artesunate and praziquantel a rate of 81%, and placebo alone a rate of 20%."( Artesunate and praziquantel for the treatment of Schistosoma haematobium infections: a double-blind, randomized, placebo-controlled study.
Binder, RK; Borrmann, S; Faucher, JF; Kremsner, PG; Lell, B; Matsiegui, PB; Neubauer, R; Szlezák, N, 2001
)
1.14
"The praziquantel treatment improved the scores of all three tests among children who got high scores in the first tests."( Effects of Schistosoma haematobium infection on mental test scores of Kenyan school children.
Aoki, Y; Kiliku, FM; Kimura, E; Migwi, DK; Moji, K; Muhoho, ND; Mutua, WR; Uga, S, 1992
)
0.76
"In praziquantel-treated mice, the reduction in the per cent resistance was accompanied by a diminution in the size of hepatic granulomata and its in vivo correlate the delayed foot pad swelling."( Effect of specific chemotherapy on the immune response and resistance to reinfection in experimental Schistosomiasis mansoni.
Azab, ME; Botros, SS; el-Garem, AA; el-Nahal, HM; Hassan, SI; Shaker, ZA, 1990
)
0.79
"Praziquantel is useful for treatment of tenia infections and ivermectin is useful for strongyloides and trichostrongyloides."( [New anthelmintic drugs].
Apt, W, 1990
)
1
"Praziquantel treatment of the rats was shown to be highly effective in killing the worms and to lead them to degenerate, as early as in 3 days post-treatment."( [Effect of praziquantel treatment on pulmonary lesions of rats infected with Paragonimus iloktsuenensis].
Chai, JY; Han, YC; Hong, ST; Kim, SY; Lee, SH; Lee, YS; Sohn, WM, 1989
)
1.39
"In praziquantel-treated mice (500 mg/kg for 2 days orally), the reduction in the percent resistance (45.5%) was accompanied by a significant diminution in the size of granuloma, delayed foot pad swelling and granuloma proportionate T-helper cells number."( Levamisole restored the compromised state of immunity after specific chemotherapy in experimental schistosomiasis mansoni.
Azab, ME; Botros, SS; el-Garem, A; el-Nahal, HM; Hassan, SI; Shaker, ZA, 1989
)
0.79
"Praziquantel treatment of S."( Effect of praziquantel on Schistosoma mansoni eggs: leucine aminopeptidase (LAP) activity and anti-LAP antibodies.
Dresden, MH; Matsuda, H; Xu, YZ, 1988
)
1.4
"Treatment with praziquantel and epsiprantel were unsuccessful in eliminating the organism but was apparently successful in flea prevention."( Elimination of probable praziquantel-resistant Dipylidium caninum with nitroscanate in a mixed-breed dog: a case report.
Acevedo, A; Bowman, DD; Liotta, JL; Loftus, JP; Wu, T; Zhu, M, 2022
)
1.37
"Treatment with praziquantel at a higher dosage may be required."( Case report: Infection with Dicrocoelium dendriticum in a Japanese Chin dog.
Gori, F; Oehm, AW; Schnyder, M, 2023
)
1.25
"Treatment with praziquantel resulted in a significantly reduced prevalence of S."( Evaluation of serum-based real-time PCR to detect Schistosoma mansoni infection before and after treatment.
Fuss, A; Mazigo, HD; Mueller, A, 2020
)
0.9
"Mass treatment with praziquantel, safe water supplies and use of toilets were deemed the most acceptable interventions by the participants."( Perceptions about interventions to control schistosomiasis among the Lake Victoria island communities of Koome, Uganda.
Elliott, AM; Sanya, RE; Seeley, J; Tumwesige, E, 2017
)
0.77
"Mass treatment with praziquantel applied once to endemic communities led to an important and long-lasting sustained reduction of S."( Long-term effect of mass chemotherapy, transmission and risk factors for Schistosoma mansoni infection in very low endemic communities of Venezuela.
Ballén, D; Hofstede, SN; Incani, RN; Tami, A; van Liere, GA, 2014
)
0.72
"Treatment with Praziquantel is simple and effective."( [A man in his thirties with icterus and itching].
Brekke, H; Holmberg, M; Huppertz-Hauss, G; Skudal, H, 2014
)
0.74
"Treatment with praziquantel improved his chest radiographic findings and a decrease of serum total IgE, as well as the values of immunoserological examination for P."( A rare case of paragonimiasis miyazakii with lung involvement diagnosed 7 years after infection: A case report and literature review.
Hanaka, M; Hanaka, T; Ishimoto, H; Kanazawa, T; Kawanami, T; Kawanami, Y; Mukae, H; Nishida, C; Yamasaki, K; Yatera, K, 2015
)
0.76
"Treatment with praziquantel did not have a significant effect on birthweight (2·85 kg in both groups, β=-0·002 [95% CI -0·088 to 0·083]; p=0·962)."( Efficacy and safety of praziquantel for the treatment of human schistosomiasis during pregnancy: a phase 2, randomised, double-blind, placebo-controlled trial.
Acosta, LP; Ayaso, EB; Baltazar, PI; Estanislao, GG; Friedman, JF; Ida, A; Kurtis, JD; Lesiguez, JL; McDonald, EA; Monterde, DB; Olveda, RM; Tallo, V; Watson, N; Wu, HW, 2016
)
1.08
"Treatment with praziquantel was carried out on a case-by-case basis, and included oral, parenteral, and nebulized administration."( Detection and Management of Air Sac Trematodes (Szidatitrema Species) in Captive Multispecies Avian Exhibits.
Craig, TM; Delaski, KM; Dronen, NO; Gamble, KC; Nelson, S; Pond, J, 2015
)
0.76
"Treatment with praziquantel (PZQ) has become virtually the sole basis of schistosomiasis control in sub-Saharan Africa and elsewhere, and the drug is reviewed here in the context of the increasing rate that it is being used for this purpose. "( Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs.
Botros, S; Cioli, D; Coles, G; Doenhoff, MJ; Engels, D; Hagan, P; Mbaye, A; Pica-Mattoccia, L; Southgate, V; Tchuem Tchuenté, LA, 2009
)
2.15
"G1b: treated with Praziquantel (PZQ) in a dose of 500 mg/kg for two consecutive days."( Parasitological and histo-pathological studies on schistosomiasis mansoni infected mice and treated with praziquatel and/or oltipraz.
Morsy, GH, 2009
)
0.68
"Treatment with praziquantel followed by metronidazole and tinidazole reduced abnormalities in the liver and eosinophilia."( A case of probable mixed-infection with Clonorchis sinensis and Fasciola sp.: CT and parasitological findings.
Choi, WH; Chu, JP; Kim, JJ; Kim, TY; Lee, YS; Oh, IH; Song, HO; Yun, JH, 2010
)
0.7
"Treatment with praziquantel the drug of choice in Uganda used in schistosomiasis control programme has reduced development of severe schistosomiasis."( Epidemiology, of bilharzias (schistosomiasis) in Uganda from 1902 until 2005.
Ekkehard, D; Emmanuel, IO, 2008
)
0.69
"Treatment of praziquantel 143 mg/(kg x d) x 3 d (tid) resulted in a worm reduction of 96.9%, if the treatment course reduced to 2 d, the rate was 63.2%."( [Treatment of rats infected with Clonorchis sinensis using clinical administration regimens of tribendimidine, praziquantel and artesunate].
Qiang, HQ; Xiao, SH; Xu, LL; Xue, J; Zhang, YN, 2010
)
0.93
"Treatment with praziquantel was given."( Urinary schistosomiasis in children in the United Kingdom.
Qazi, A; Stahlschmidt, J; Subramaniam, R, 2012
)
0.72
"Treatment by praziquantel remains justified together with health education, improving living standard and hopes placed in the future vaccination campaigns associated with medical treatment in endemic areas."( [Portal hypertension and schistosomiasis: "an originally killing entity"].
Klotz, F, 2003
)
0.67
"Treatment with praziquantel associated with corticosteroids was successful in all cases. "( Treatment of schistosomal myeloradiculopathy with praziquantel and corticosteroids and evaluation by magnetic resonance imaging: a longitudinal study.
Antunes, CM; Lambertucci, JR; Maciel, PE; Ribas, JG; Silva, LC; Souza-Pereira, SR, 2004
)
0.93
"Treatment with praziquantel (10 mg/kg BW) proved to be efficient."( [Holiday dreams with a downside: uncommon tapeworm infection in an infant].
Prosl, H, 2005
)
0.67
"The treatment with praziquantel for the 30 patients, with urine positive to S."( Clinical and laboratorial evaluation of urinary schistosomiasis in Brazilians after staying in Mozambique.
Conceição, MJ; da Silva, IM; Noh, J; Rey, L; Tsang, V,
)
0.45
"Mass treatment with praziquantel and albendazole led to a significant decrease in the intensity of Schistosoma mansoni - 70% (95% confidence interval (CI): 66-73%) after one year and 82% (95% CI: 80-85%) after two years of treatment. "( Impact of a national helminth control programme on infection and morbidity in Ugandan schoolchildren.
Brooker, S; Fenwick, A; Fleming, FM; Kabatereine, NB; Kazibwe, F; Koukounari, A; Stothard, JR; Tukahebwa, EM; Webster, JP; Zhang, Y, 2007
)
0.66
"Treatment with praziquantel induced a significant decline in both ECP and EPX, but only a non-significant reduction in faecal MPO."( Assessment of Schistosoma mansoni induced intestinal inflammation by means of eosinophil cationic protein, eosinophil protein X and myeloperoxidase before and after treatment with praziquantel.
Dunne, DW; Kabatereine, NB; Reimert, CM; Tukahebwa, EM; Vennervald, BJ, 2008
)
0.88
"Treatment with praziquantel resulted in a remarkable decrease of the titers with cercaria antigen and in only a gradual decrease with egg, tegument and gut antigen."( Variations of titers of immunofluorescent antibody against cercaria, adult and egg antigens developed in rabbits infected with Schistosoma japonicum before and after treatment with praziquantel.
Beisler, GK; Matsuda, H; Nakao, M; Tanaka, H, 1984
)
0.8
"Treatment with Praziquantel was uneffective."( [Pure spinal cysticercosis. Note on the cerebrospinal fluid].
Baulac, M; Carydakis, C; Laplane, D; Philippon, J; Schuller, E, 1984
)
0.61
"Treatment with praziquantel was given at 35 mg/day for 10 days, dexamethasone and carbamazepine were also given to reduce side effects."( Subcutaneous and cerebral cysticercosis treated with praziquantel.
Conde, J; Cross, JH; Quimosing, EM, 1984
)
0.86
"Treatment with praziquantel at the beginning of the lumen phase of Hymenolepis nana in mice showed conclusively that: (i) the mouse given eggs of H. "( Stage-specific immunogens of Hymenolepis nana in mice.
Ito, A, 1984
)
0.62
"Treatment with praziquantel 50 mg/kg body weight daily for 14 days resulted in clinical and radiological improvement in the first patient, although she obviously still harbored a number of viable non-calcified parasites."( Cerebral cysticercosis: treatment with praziquantel. Report of two cases.
Hess, K; Markwalder, K; Valavanis, A; Witassek, F, 1984
)
0.88
"By treatment with praziquantel there was an essential improvement of seizure frequency and headaches."( [Cerebral cysticercosis. A report on the treatment with praziquantel].
Maier-Metz, F; Meyer-Wahl, JG, 1984
)
0.84
"Treatment with praziquantel and bitheonol was associated with clinical cure."( Paragonimus mexicanus pericarditis: report of two cases and review of the literature.
Arguedas, A; Arrieta, G; Lanzas, R; Saborio, P, 1995
)
0.63
"Treatment with praziquantel caused an increase in the content of malonic dialdehyde only in the erythrocytic membrane."( [The effect of chloxyl and praziquantel treatment on the lipid phase of the erythrocyte membrane and on the antioxidant system in opisthorchiasis patients].
Nalobin, SA; Nalobin, VA; Zhmurov, VA,
)
0.77
"Mice treated with praziquantel alone showed no significant change compared to control groups."( Histopathological evidences for the antifibrogenic effect of colchicine in schistosomiasis mansoni in mice.
el-Monayerhy, MS; Fahmy, IA; Montasser, MF; Rashad, MS; Sabry, NM; Younis, TA, 1994
)
0.61
"Treatment with praziquantel resulted in egg clearance and resolution of gastrointestinal symptoms."( Locally acquired Brachylaima sp. (Digenea: Brachylaimidae) intestinal fluke infection in two South Australian infants.
Butcher, AR; Cameron, AS; Cribb, TH; Forsyth, JR; Kirk, MD; Knight, B; Norton, RE; Talbot, GA, 1996
)
0.63
"Treatment with praziquantel is effective and prevents the serious sequelae of chronic infection."( Acute clonorchiasis.
Cheng, AF; Ip, M; Leung, N, 1995
)
0.63
"Treatment with praziquantel eliminated this trend except in a few subjects with splenomegaly alone (probably due to malaria) or with schistosomal hepatosplenic disease."( Schistosomiasis mansoni in Kenya: relationship between infection and anaemia in schoolchildren at the community level.
Butterworth, AE; Gachare, JW; Kariuki, HC; Mbugua, G; Omondi, BG; Ouma, JH; Sturrock, RF; Thiongo, FW,
)
0.47
"Treatment with praziquantel led to complete clinical and radiographic recovery."( [Paragonimiasis: a rare little known disease].
Fèbvre, M; Frottier, J; Guiard-Schmid, JB; Lacombe, K; Meynard, JL; Meyohas, MC; Osman, D, 1998
)
0.64
"Treatment with praziquantel decreased the infection rate to 5.3% at 6 weeks later."( Epidemiology of clonorchiasis in Ninh Binh Province, Vietnam.
Cong, LD; Hao, HT; Inaba, H; Kino, H; Sano, M; Son, DT; Toan, ND; Van Chau, L; Van De, N, 1998
)
0.64
"Treatment with praziquantel associated with cimetidine to increase the drug bioavailability and prednisone to reduce the inflammatory reaction gives good results."( Parenchymatous cerebral neurocysticercosis in a quadriplegic patient.
Al-Khodairy, AT; Annoni, JM; Uebelhart, D, 1999
)
0.64
"Treatment with praziquantel reduces the prevalence and intensity of Schistosoma mansoni infection. "( Evidence for a long-term effect of a single dose of praziquantel on Schistosoma mansoni-induced hepatosplenic lesions in northern Uganda.
Doehring, E; Frenzel, K; Grigull, L; Loroni-Lakwo, T; Ndugwa, CM; Odongo-Aginya, E; Schweigmann, U; Spannbrucker, N; Vester, U, 1999
)
0.91
"Treatment with praziquantel in combination with artemether resulted in a significantly greater reduction of worm burden than was found for the groups treated with praziquantel or artemether alone, using the same dosages and schedules."( Effect of praziquantel together with artemether on Schistosoma japonicum parasites of different ages in rabbits.
Huifang, G; Jinying, M; Jiqing, Y; Peiying, J; Shuhua, X; Tanner, M, 2000
)
1.05
"Treatment with praziquantel was given at 40 mg/kg of body weight in a single dose."( [Efficacity of praziquantel in school-aged children in a hyperendemic zone for Schistoma haematobium (Niger, 1999)].
Chippaux, JP; de Chabalier, F; Garba, A; Sidiki, A; Tohon, Z, 2001
)
1
"Treatment with praziquantel of individuals from the area residing temporarily in an urban region with no transmission, and re-treatment after 3 weeks of non-cured individuals within the area resulted in normal cure rates (78-88%)."( Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence.
De Vlas, SJ; Diop, M; Engels, D; Faye, D; Gryseels, B; Guissé, F; Ly, A; Mbaye, A; Polman, K; Stelma, FF; Tchuem-Tchuenté, LA; Van Lieshout, L, 2001
)
0.96
"Treatment with praziquantel for 3 days resulted in disappearance of the abnormal chest radiographic findings, and a reduced blood eosinophil level, IgE level and ELISA titre for Paragonimus miyazakii."( [A case of Paragonimus miyazakii with migrating infiltrates: use of ELISA in diagnosis and treatment].
Katagiri, S; Kondo, M; Nagai, A; Ohnuki, T; Tamaoki, J, 2002
)
0.65
"Treatment with praziquantel was found to reduce the number of worms (97%), with complete absence of immature ova and increase in the number of dead ova."( Effect of combined chemotherapy and anti-inflammatory drugs on murine schistosomiasis.
Mahmoud, MR; Nosseir, MM; Zoheiry, MM, 2002
)
0.65
"Treatment with praziquantel resulted in the regression of only some of the cysts."( [Selective sensitivity of cysts to praziquantel and albendazole in a case of cerebral cysticercosis].
Belec, L; Cohen, L; Pierrot-Deseilligny, C; Sanson, M; Signoret, JL, 1992
)
0.9
"Treatment with Praziquantel resulted in substantial restoration of the production of 14CO2 from [14C]tryptophan."( Tryptophan metabolism and vitamin B6 nutritional status in patients with schistosomiasis mansoni and in infected mice.
Bender, DA; Njagi, EN; Okelo, GB, 1992
)
0.62
"Treatment with praziquantel or albendazole has hastened the disappearance of the cysts on computed tomography and improved clinical symptoms."( Neurocysticercosis: neurologic, pathogenic, diagnostic and therapeutic aspects.
Davis, LE; Kornfeld, M, 1991
)
0.62
"Treatment with praziquantel was given to all infected children."( Ultrasound scanning for detecting morbidity due to Schistosoma haematobium and its resolution following treatment with different doses of praziquantel.
de Savigny, D; Degrémont, A; Hatz, C; Koella, JC; MacPherson, CN; Mayombana, C; Tanner, M,
)
0.67
"Upon treatment with praziquantel (100 mg/kg body wt), this level was significantly less within 1 week."( Schistosoma mansoni: detection of circulating antigens in murine schistosomiasis by antigen-capture sandwich ELISA using a monoclonal antibody.
Barsoum, IS; Colley, DG; Kamal, KA, 1990
)
0.59
"Treatment with Praziquantel was thoroughly effective in clearing the persistent Schistosoma haematobium infection."( Schistosomiasis in an American medical investigator.
Beland, JE; Heyneman, D; Higashi, GI; Kloos, H; Young, D, 1986
)
0.61
"Treatment with Praziquantel reduced the patient's intellectual deterioration, but hydrocephalus developed."( Severe dementia associated with neurocysticercosis.
Ardila, A; Penagos, B; Rosselli, A; Rosselli, M, 1988
)
0.61
"Treatment with praziquantel always stopped cercarial emission; this cessation lasted for a few days with the lowest concentration and for up to 25 d with the highest."( Effect of praziquantel on larval stages of Schistosoma japonicum.
Combes, C; Yi, XM, 1987
)
1.02
"Treatment with praziquantel for neurocysticercosis frequently induces adverse reactions due to acute destruction of parasites; these reactions are suppressed by dexamethasone therapy. "( Plasma levels of praziquantel decrease when dexamethasone is given simultaneously.
Jung, H; Sotelo, J; Vazquez, ML, 1987
)
0.97
"Mice treated with praziquantel showed a prompt decrease in S."( Reversal of hepatic fibrosis after praziquantel therapy of murine schistosomiasis.
Dunn, MA; Girgis, NI; Ishak, EA; Khayyal, MT; Mansour, MM; Morcos, SH; Saleh, S, 1985
)
0.87
"Treatment by praziquantel (Biltricide) was followed by an increase of antibodies rate, but it was not possible to appreciate the effectiveness of this therapy."( [2 cases of cysticercosis observed in Cameroon].
Doucet, J; Herzog, U; Le Fichoux, Y; Marty, P; Marty-Jaussan, I,
)
0.48
"Treatment with Praziquantel under corticosteroid therapy was successful with almost complete disappearance of radiologic abnormalities on the computerised tomographic examination performed 7 months after the end of treatment."( [Cerebral cysticercosis. Apropos of a case treated with praziquantel].
Bruguier, A; Diebler, C; Leger, J; Ponsot, G; Texier, P,
)
0.72
"Treatment with praziquantel was associated with rapid symptomatic improvement, and after treatment no parasitic eggs were recovered from patients' stools."( Outbreak of parasitic gastroenteritis among travelers returning from Africa.
Navin, TR; Poland, GA; Sarosi, GA, 1985
)
0.61

Toxicity

Study examines adverse events experienced following co-administration of albendazole and praziquantel to school-age children in a rural area in Kwale County, Kenya. Adverse events were of mild and moderate intensity and were more frequent in the prazquantel group than in the tribendi.

ExcerptReferenceRelevance
" Surveillance for praziquantel adverse reactions for all these groups was done."( Side effects of praziquantel in bilharzial children on a field level.
el-Hawey, AM; el-Rakieby, A; Massoud, AM; Nassar, MO; Rozeik, MS, 1990
)
0.96
" A recombinant hepatitis B vaccine was safe and immunogenic when given to patients with schistosomiasis mansoni."( Safety and immunogenicity of a recombinant hepatitis B vaccine in patients infected with Schistosoma mansoni.
Bassily, S; el-Ghorab, N; el-Masry, NA; Hyams, KC, 1990
)
0.28
" These results suggest that praziquantel is a relatively safe drug with respect to liver function."( Praziquantel did not exhibit hepatotoxicity in a study with isolated hepatocytes.
Botros, S; Ebeid, F; Farghali, H; Metwally, A,
)
1.87
" These studies have shown that monthly topical administration of selamectin is safe and highly effective in the treatment of naturally acquired ascarid and hookworm infections in cats."( Efficacy and safety of selamectin against gastrointestinal nematodes in cats presented as veterinary patients.
Benchaoui, HA; Boy, MG; Clemence, RG; Jernigan, AD; Rowan, TG; Six, RH; Smith, DG; Sture, GH; Thomas, CA; Watson, P, 2000
)
0.31
"2 micromol/L UCB for 10 min prior to the incubation with toxic concentrations of TFP (0."( Effect of bilirubin on toxicity induced by trifluoperazine, dibucaine and praziquantel to erythrocytes.
Brites, D; Brito, MA; Malheiros, SV; Meirelles, NC, 2001
)
0.54
"The present study using a murine model heavily infected with Schistosoma japonicum aimed to elucidate the pathogenesis of adverse effects of praziquantel treatment of schistosome-infected subjects."( Adverse effects of praziquantel treatment of Schistosoma japonicum infection: involvement of host anaphylactic reactions induced by parasite antigen release.
Matsumoto, J, 2002
)
0.84
"As previously shown, the development of adverse effects in praziquantel treatment of Schistosoma japonicum infection involves host anaphylactic reactions associated with a rapid elevation of the level of plasma histamine."( Mast-cell-dependent histamine release after praziquantel treatment of Schistosoma japonicum infection: implications for chemotherapy-related adverse effects.
Matsuda, H; Matsumoto, J, 2002
)
0.82
" Information about human and veterinary medical uses and adverse reactions is evaluated."( Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics.
Dayan, AD, 2003
)
0.61
" Neither adverse effects on mares nor abortions occurred."( Evaluation of the safety of ivermectin-praziquantel administered orally to pregnant mares.
Alves-Branco, F; Mercier, P; Sapper, Mde F; White, CR, 2003
)
0.59
"Administration of the ivermectin-praziquantel paste appears to be safe in pregnant mares and their foals."( Evaluation of the safety of ivermectin-praziquantel administered orally to pregnant mares.
Alves-Branco, F; Mercier, P; Sapper, Mde F; White, CR, 2003
)
0.87
" This retrospective study suggested that PZQ therapy is safe during pregnancy."( Is praziquantel therapy safe during pregnancy?
Adam, I; Elwasila, el T; Homeida, M, 2004
)
0.94
" No adverse reactions were observed in the European study, and only mild ones of short duration in a few cats from both treatment groups of the North American study."( Field evaluation of the efficacy and safety of emodepside/praziquantel spot-on solution against naturally acquired nematode and cestode infections in domestic cats.
Altreuther, G; Buch, J; Charles, SD; Davis, WL; Krieger, KJ; Radeloff, I, 2005
)
0.57
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" On the day of treatment, each treated animal was examined for adverse reactions to the paste 10min after treatment and then hourly for 4h."( Clinical trials of efficacy of praziquantel horse paste 9% against tapeworms and its safety in horses.
Barutzki, D; Heine, J; Slacek, B; Slocombe, JO, 2007
)
0.63
"Our data suggest that co-administration of ivermectin, albendazole and praziquantel is safe in areas where lymphatic filariasis, soil-transmitted helminthiasis and schistosomiasis are co-endemic and where several rounds of treatment with one or two drugs have been implemented in the past."( Triple co-administration of ivermectin, albendazole and praziquantel in zanzibar: a safety study.
Biswas, G; Bradley, MH; Chitsulo, L; Engels, D; Gabrielli, AF; Haji, HJ; Mohammed, KA; Molyneux, DH; Mubila, L; Savioli, L, 2008
)
0.83
" No suspected adverse drug reactions were observed in the study."( Field evaluation of the efficacy and safety of emodepside plus praziquantel tablets (Profender tablets for dogs) against naturally acquired nematode and cestode infections in dogs.
Altreuther, G; Krieger, KJ; LeSueur, C; Radeloff, I; Schimmel, A, 2009
)
0.59
" No treated animals showed adverse events."( Efficacy and safety of emodepside 2.1%/praziquantel 8.6% spot-on formulation in the treatment of feline aelurostrongylosis.
Bartolini, R; Di Cesare, A; Heine, J; Iorio, R; Lohr, B; Milillo, P; Pampurini, F; Schaper, R; Traversa, D, 2009
)
0.62
"To understand the adverse and curative effects of film coated praziquantel for treatment of schistosomiasis japonica."( [Efficacy and adverse effects of film coated praziquantel for treatment of schistosomiasis japonica].
Guo, JG; Wu, XH; Xu, J; Yang, GB; Yang, WP; Zeng, XJ; Zheng, J; Zhou, XN, 2009
)
0.85
" 460 targets with no relative symptoms were followed up for adverse effect of drugs in one month and efficacy evaluation of praziquantel was carried out in 104 parasitological positives 3 months post-treatment."( [Efficacy and adverse effects of film coated praziquantel for treatment of schistosomiasis japonica].
Guo, JG; Wu, XH; Xu, J; Yang, GB; Yang, WP; Zeng, XJ; Zheng, J; Zhou, XN, 2009
)
0.82
" The total side effect rates of film coated praziquantel group and control group in 1-2 hours post-treatment were 20."( [Efficacy and adverse effects of film coated praziquantel for treatment of schistosomiasis japonica].
Guo, JG; Wu, XH; Xu, J; Yang, GB; Yang, WP; Zeng, XJ; Zheng, J; Zhou, XN, 2009
)
0.87
"The smell and adverse effects of film coated tablets of praziquantel were decreased significantly and its efficacy for treatment of schistosomiasis japonica was equal to the control tablets."( [Efficacy and adverse effects of film coated praziquantel for treatment of schistosomiasis japonica].
Guo, JG; Wu, XH; Xu, J; Yang, GB; Yang, WP; Zeng, XJ; Zheng, J; Zhou, XN, 2009
)
0.86
" Abdominal pain was the most frequent adverse event, with a higher incidence among children treated with mefloquine (89%), mefloquine-artesunate (83%), and artesunate (60%) than among children treated with praziquantel (46%)."( Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, and praziquantel against Schistosoma haematobium: randomized, exploratory open-label trial.
Adoubryn, KD; Hatz, C; Keiser, J; N'Goran, EK; N'Guessan, NA; Silué, KD; Utzinger, J; Vounatsou, P, 2010
)
0.78
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" Most adverse events were mild or moderate and affected all treatment groups; serious adverse events--vertigo, nausea, vomiting, and anxiety--were reported only by patients taking mefloquine or mefloquine-artesunate."( Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, tribendimidine, and praziquantel in patients with Opisthorchis viverrini: a randomised, exploratory, open-label, phase 2 trial.
Akkhavong, K; Hatz, C; Keiser, J; Odermatt, P; Sayasone, S; Soukhathammavong, P; Vonghachack, Y; Vounatsou, P, 2011
)
0.59
" No serious adverse events were reported or observed after treatment."( The acceptability and safety of praziquantel alone and in combination with mebendazole in the treatment of Schistosoma mansoni and soil-transmitted helminthiasis in children aged 1-4 years in Uganda.
Kabatereine, NB; Namwanje, H; Olsen, A, 2011
)
0.65
" Children were closely monitored by a paediatrician for any adverse reactions for 7 days."( A randomised controlled clinical trial on the safety of co-administration of albendazole, ivermectin and praziquantel in infected schoolchildren in Uganda.
Kabatereine, N; Namwanje, H; Olsen, A, 2011
)
0.58
" INTERPRETATION/SIGNIFICANCE: PZQ treatment is as safe and efficacious in children aged 1-5 years as it is in older children aged 6-10 years in whom PZQ is the drug of choice for control of schistosome infections."( Schistosoma haematobium treatment in 1-5 year old children: safety and efficacy of the antihelminthic drug praziquantel.
Appleby, L; Bourke, C; Mduluza, T; Midzi, N; Mitchell, K; Mutapi, F; Nausch, N; Rujeni, N, 2011
)
0.58
" 666 patients (78%) reported 1327 adverse events (AE) 4 h post-dosing."( A multicentre randomized controlled trial of the efficacy and safety of single-dose praziquantel at 40 mg/kg vs. 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil.
Alves, F; Amarillo, ML; Belizario, VJ; Chitsulo, L; Diaw, M; Domingues, AC; Favre, TC; Kaatano, GM; Lapujade, O; Lwambo, NJ; Olliaro, PL; Ouldabdallahi, M; Pieri, OS; Vaillant, MT, 2011
)
0.59
"No suspected adverse drug reactions were observed in any of the 403 dogs enrolled in the three studies including 234 dogs treated with emodepside/toltrazuril suspension."( Field evaluations of the efficacy and safety of Emodepside plus toltrazuril (Procox® oral suspension for dogs) against naturally acquired nematode and Isospora spp. infections in dogs.
Adler, K; Altreuther, G; Gasda, N; Hellmann, K; Hutchens, D; Krieger, KJ; Schimmel, A; Thurieau, H, 2011
)
0.37
" Adverse events were monitored within 4h after dosing by the survey team and 24h after treatment using a questionnaire."( Efficacy and safety of two closely spaced doses of praziquantel against Schistosoma haematobium and S. mansoni and re-infection patterns in school-aged children in Niger.
Barkiré, N; Djibo, A; Fenwick, A; Garba, A; Gouvras, AN; Labbo, R; Lamine, MS; Sebangou, H; Sofo, B; Utzinger, J; Webster, JP, 2013
)
0.64
" Separately, a previously tested side-effect questionnaire was employed before and 24 hours after PZQ treatment to assess incidence and amelioration of symptoms in young children and their mothers."( Performance and safety of praziquantel for treatment of intestinal schistosomiasis in infants and preschool children.
Arinaitwe, M; Atuhaire, A; Betson, M; Bickle, Q; Kabatereine, NB; Navaratnam, AM; Sousa-Figueiredo, JC; Stothard, JR, 2012
)
0.68
" Adverse effects were common (40."( [Intestinal parasites in children in Biankouma, Ivory Coast (mountaineous western region): efficacy and safety of praziquantel and albendazole].
Adoubryn, KD; Aka, NA; Assoumou, A; Bintto, F; Kouadio-Yapo, CG; Ouhon, J,
)
0.34
" Clinical symptoms were documented at baseline, and adverse events were recorded and graded 3 and 24 hours after each dose."( Efficacy and safety of tribendimidine against Clonorchis sinensis.
Jiang, ZH; Keiser, J; Li, W; Liang, H; Qian, MB; Tan, YG; Utzinger, J; Yang, YC; Yap, P; Zhou, H; Zhou, XN, 2013
)
0.39
" Patients treated with praziquantel experienced significantly more adverse events than did tribendimidine recipients (P < ."( Efficacy and safety of tribendimidine against Clonorchis sinensis.
Jiang, ZH; Keiser, J; Li, W; Liang, H; Qian, MB; Tan, YG; Utzinger, J; Yang, YC; Yap, P; Zhou, H; Zhou, XN, 2013
)
0.7
" sinensis infection and resulted in fewer adverse events compared to praziquantel."( Efficacy and safety of tribendimidine against Clonorchis sinensis.
Jiang, ZH; Keiser, J; Li, W; Liang, H; Qian, MB; Tan, YG; Utzinger, J; Yang, YC; Yap, P; Zhou, H; Zhou, XN, 2013
)
0.62
" Adverse events were assessed and graded 4 and 24 hours posttreatment by interviewing mothers/guardians."( Efficacy and safety of praziquantel in preschool-aged children in an area co-endemic for Schistosoma mansoni and S. haematobium.
Coulibaly, JT; Keiser, J; Knopp, S; N'gbesso, YK; N'Goran, EK; Utzinger, J, 2012
)
0.69
" Treatment was generally well tolerated, but moderately severe adverse events (i."( Efficacy and safety of praziquantel in preschool-aged children in an area co-endemic for Schistosoma mansoni and S. haematobium.
Coulibaly, JT; Keiser, J; Knopp, S; N'gbesso, YK; N'Goran, EK; Utzinger, J, 2012
)
0.69
" Children remained under medical supervision for 4h and adverse events were recorded."( Safety and efficacy of praziquantel syrup (Epiquantel®) against Schistosoma haematobium and Schistosoma mansoni in preschool-aged children in Niger.
Alfari, A; Aouami, MA; Djibo, A; Fenwick, A; Garba, A; Lamine, MS; Phillips, AE; Tahirou, A; Utzinger, J, 2013
)
0.7
" For the majority of the patients, the drug was well tolerated and no serious adverse events were noted; however, clinical signs in the form of abdominal pain associated or not with diarrhea and vomiting were noted."( [Comparison of the efficacy and safety of praziquantel administered in single dose of 40 versus 60 mg/kg for treating urinary schistosomiasis in Mauritania].
Chitsulo, L; Konaté, L; Mamadou, D; Ouldabdallahi, M; Ouldbezeid, M; Ousmane, B, 2013
)
0.65
" From the obtained results, PZQ-loaded SLN could be a new drug delivery system for the schistosomiasis treatment especially in marginalized communities, improving the therapeutic efficacy and reducing the toxic effects of PZQ."( In vitro evaluation of permeation, toxicity and effect of praziquantel-loaded solid lipid nanoparticles against Schistosoma mansoni as a strategy to improve efficacy of the schistosomiasis treatment.
Allegretti, SM; Andreani, T; Chaud, MV; de Oliveira, RN; de Souza, AL; dos Santos, FK; Gremião, MP; Kiill, CP; Silva, AM; Souto, EB, 2014
)
0.65
" The present study examines adverse events (AEs) experienced following co-administration of albendazole and praziquantel to school-age children in a rural area in Kwale County, Kenya."( A school-based cross-sectional survey of adverse events following co-administration of albendazole and praziquantel for preventive chemotherapy against urogenital schistosomiasis and soil-transmitted helminthiasis in Kwale County, Kenya.
Bendera, FS; Bockarie, MJ; Mwanje, MT; Ng'ang'a, PM; Njenga, SM, 2014
)
0.83
" The current study adds to the evidence base that dual administration of albendazole and praziquantel in school-based mass drug administration is safe with only mild adverse events noted."( A school-based cross-sectional survey of adverse events following co-administration of albendazole and praziquantel for preventive chemotherapy against urogenital schistosomiasis and soil-transmitted helminthiasis in Kwale County, Kenya.
Bendera, FS; Bockarie, MJ; Mwanje, MT; Ng'ang'a, PM; Njenga, SM, 2014
)
0.84
" In this work, we analyze the adverse effects seen in 57 patients diagnosed with hydatidosis who were treated with praziquantel plus albendazole combined therapy between 2006 and 2010."( Safety of the combined use of praziquantel and albendazole in the treatment of human hydatid disease.
Alvela-Suárez, L; Belhassen-Garcia, M; Cordero-Sánchez, M; Novo-Veleiro, I; Pardo-Lledías, J; Pérez del Villar, L; Romero-Alegría, A; Valverde-Merino, MP; Velasco-Tirado, V, 2014
)
0.9
" No treatment related adverse experiences were observed throughout the study."( Efficacy against nematode and cestode infections and safety of a novel topical fipronil, (S)-methoprene, eprinomectin and praziquantel combination product in domestic cats under field conditions in Europe.
Capári, B; Chester, ST; Duscher, G; Keidane, D; Kirkova, Z; Kley, K; Knaus, M; Petkevičius, S; Rapti, D; Rehbein, S; Rosentel, J; Tielemans, E; Visser, M; Wagner, A; Wagner, T; Winter, R, 2014
)
0.61
" Milbemax® was shown to be safe in treated dogs."( Field clinical study evaluating the efficacy and safety of an oral formulation containing milbemycin oxime/praziquantel (Milbemax®, Novartis Animal Health) in the chemoprevention of the zoonotic canine infection by Dirofilaria repens.
Aquilino, V; Avolio, S; Bartolini, R; Braun, G; Di Cesare, A; Di Giulio, E; Drake, J; La Torre, F; Meloni, S; Pandolfi, F; Paoletti, B; Traversa, D, 2014
)
0.62
"The results of this study confirm that the monthly use of Milbemax® in dogs is effective and safe for the prevention of subcutaneous dirofilariosis in endemic areas."( Field clinical study evaluating the efficacy and safety of an oral formulation containing milbemycin oxime/praziquantel (Milbemax®, Novartis Animal Health) in the chemoprevention of the zoonotic canine infection by Dirofilaria repens.
Aquilino, V; Avolio, S; Bartolini, R; Braun, G; Di Cesare, A; Di Giulio, E; Drake, J; La Torre, F; Meloni, S; Pandolfi, F; Paoletti, B; Traversa, D, 2014
)
0.62
" Cure rates and egg reduction rates were assessed, and adverse events were monitored after treatments."( Efficacy and safety of praziquantel, tribendimidine and mebendazole in patients with co-infection of Clonorchis sinensis and other helminths.
Duan, JH; Jiang, B; Liu, YC; Xiao, SH; Xu, LL; Zhang, HB; Zhang, LP; Zhou, XN; Zhu, SQ; Zhuang, SF, 2014
)
0.71
" Most adverse events were mild and transient."( Efficacy and safety of praziquantel, tribendimidine and mebendazole in patients with co-infection of Clonorchis sinensis and other helminths.
Duan, JH; Jiang, B; Liu, YC; Xiao, SH; Xu, LL; Zhang, HB; Zhang, LP; Zhou, XN; Zhu, SQ; Zhuang, SF, 2014
)
0.71
" sinensis as praziquantel with less adverse events, and achieved significantly higher cure rate in the treatment for hookworm than those of praziquantel and mebendazole."( Efficacy and safety of praziquantel, tribendimidine and mebendazole in patients with co-infection of Clonorchis sinensis and other helminths.
Duan, JH; Jiang, B; Liu, YC; Xiao, SH; Xu, LL; Zhang, HB; Zhang, LP; Zhou, XN; Zhu, SQ; Zhuang, SF, 2014
)
1.08
" It is concluded that Seresto(®) is chemically compatible with solvents used in major spot-on formulations on the market and is dermally and systemically safe for adult dogs and cats when used concomitantly with Advocate(®) and Profender(®) spot-on formulations."( Chemical Compatibility and Safety of Imidacloprid/Flumethrin Collar (Seresto®) Concomitantly Used with Imidacloprid/Moxidectin (Advocate®, Advantage® Multi) and Emodepside/Praziquantel (Profender®) Spot-on Formulations.
Crafford, D; Deuster, K; Fourie, J; Krüdewagen, EM; Remer, C; Schunack, B; Stanneck, D; Wolken, S, 2015
)
0.61
" There was no significant difference between any of the haematological or biochemical indices in YTK treated with PZQ and controls, indicating that PZQ is safe for use at 100 mg PZQ kg(-1) BW day(-1) in YTK and that exposure to high doses or prolonged duration does not have negative effects on the YTK haematological or biochemical parameters we measured."( Praziquantel treatment for yellowtail kingfish (Seriola lalandi): dose and duration safety study.
Bubner, EJ; D'Antignana, T; Deveney, MR; Forwood, JM; Landos, M, 2016
)
1.88
" Safety data were collected including immediate reactogenicity, post-dosing toxicology ascertained 24 h after study drug administration, and maternal and newborn serious adverse events."( Efficacy and safety of praziquantel for the treatment of human schistosomiasis during pregnancy: a phase 2, randomised, double-blind, placebo-controlled trial.
Acosta, LP; Ayaso, EB; Baltazar, PI; Estanislao, GG; Friedman, JF; Ida, A; Kurtis, JD; Lesiguez, JL; McDonald, EA; Monterde, DB; Olveda, RM; Tallo, V; Watson, N; Wu, HW, 2016
)
0.74
" No treatment-related adverse experiences were observed throughout the study."( Efficacy against nematode infections and safety of afoxolaner plus milbemycin oxime chewable tablets in domestic dogs under field conditions in Europe.
Breiltgens, T; Brianti, E; Capári, B; Dantas-Torres, F; Dollhofer, D; Gau, M; Jeannin, P; Joachim, A; Kaulfuß, KH; Kirkova, Z; Kley, K; Knaus, M; Lebon, W; Lechner, J; Mallouk, Y; Mihalca, AD; Mirabito, R; Petkevičius, S; Rapti, D; Rehbein, S; Sedeilhan, M; Shukullari, E; Visser, M, 2017
)
0.46
" Safety was reported as frequencies of adverse events."( Efficacy and safety of praziquantel 40 mg/kg in preschool-aged and school-aged children: a meta-analysis.
Olliaro, P; Zwang, J, 2017
)
0.77
" Praziquantel was reportedly safe at all ages, with only mild reported adverse events which cleared rapidly after treatment."( Efficacy and safety of praziquantel 40 mg/kg in preschool-aged and school-aged children: a meta-analysis.
Olliaro, P; Zwang, J, 2017
)
1.68
" Adverse events were recorded at baseline, 3 hours, and 24 hours posttreatment."( Efficacy and Safety of Praziquantel Against Light Infections of Opisthorchis viverrini: A Randomized Parallel Single-Blind Dose-Ranging Trial.
Andrews, JR; Bogoch, II; Hattendorf, J; Keiser, J; Meister, I; Odermatt, P; Phongluxa, K; Sayasone, S; Senggnam, K; Vonghachack, Y; Xayavong, S, 2017
)
0.77
" Adverse events were mild but higher in the standard treatment group (3 × 25 mg/kg) than in the single-dose treatment arms."( Efficacy and Safety of Praziquantel Against Light Infections of Opisthorchis viverrini: A Randomized Parallel Single-Blind Dose-Ranging Trial.
Andrews, JR; Bogoch, II; Hattendorf, J; Keiser, J; Meister, I; Odermatt, P; Phongluxa, K; Sayasone, S; Senggnam, K; Vonghachack, Y; Xayavong, S, 2017
)
0.77
" viverrini infections, while presenting fewer adverse events."( Efficacy and Safety of Praziquantel Against Light Infections of Opisthorchis viverrini: A Randomized Parallel Single-Blind Dose-Ranging Trial.
Andrews, JR; Bogoch, II; Hattendorf, J; Keiser, J; Meister, I; Odermatt, P; Phongluxa, K; Sayasone, S; Senggnam, K; Vonghachack, Y; Xayavong, S, 2017
)
0.77
" For both age groups, the number of adverse events was similar among the three praziquantel treatment groups, with fewer adverse events observed in the placebo groups."( Efficacy and safety of praziquantel in preschool-aged and school-aged children infected with Schistosoma mansoni: a randomised controlled, parallel-group, dose-ranging, phase 2 trial.
Coulibaly, JT; Hattendorf, J; Keiser, J; Kovač, J; Panic, G; Silué, KD, 2017
)
0.99
" Physicians assessing adverse events and laboratory personnel were masked to treatment allocation, but the investigators administering treatment and the participants could have recognised the treatment group based on differences in the number, appearance, and odour of the tablets."( Efficacy and safety of tribendimidine versus praziquantel against Opisthorchis viverrini in Laos: an open-label, randomised, non-inferiority, phase 2 trial.
Hattendorf, J; Keiser, J; Meister, I; Odermatt, P; Phongluxa, K; Sayasone, S; Senggnam, K; Vonghachack, Y; Xayavong, S, 2018
)
0.74
" Adverse events were of mild and moderate intensity and were more frequent in the praziquantel group than in the tribendimidine group (odds ratio 4·5, 95% CI 3·2-6·3; p<0·0001)."( Efficacy and safety of tribendimidine versus praziquantel against Opisthorchis viverrini in Laos: an open-label, randomised, non-inferiority, phase 2 trial.
Hattendorf, J; Keiser, J; Meister, I; Odermatt, P; Phongluxa, K; Sayasone, S; Senggnam, K; Vonghachack, Y; Xayavong, S, 2018
)
0.97
" However, tribendimidine has a similar egg reduction rate to praziquantel and leads to fewer adverse events and thus might complement praziquantel in O viverrini control programmes, particularly in settings co-endemic for hookworm."( Efficacy and safety of tribendimidine versus praziquantel against Opisthorchis viverrini in Laos: an open-label, randomised, non-inferiority, phase 2 trial.
Hattendorf, J; Keiser, J; Meister, I; Odermatt, P; Phongluxa, K; Sayasone, S; Senggnam, K; Vonghachack, Y; Xayavong, S, 2018
)
0.98
" Adverse events were mild and transient."( Efficacy and safety of ascending doses of praziquantel against Schistosoma haematobium infection in preschool-aged and school-aged children: a single-blind randomised controlled trial.
Barda, B; Coulibaly, JT; Hattendorf, J; Keiser, J; Kovač, J; N'Gbesso, YK; Panic, G; Yapi, RB, 2018
)
0.75
" Adverse events were assessed 24 hours post-treatment through questionnaires administered to the parents or guardians."( Safety, efficacy and acceptability of praziquantel in the treatment of Schistosoma haematobium in pre-school children of Kwale County, Kenya.
Kihara, JH; Kimani, BW; Mbugua, AK; Ng'ang'a, M; Njomo, DW, 2018
)
0.75
"The study revealed that crushed PZQ is safe and effective in the treatment of urogenital schistosomiasis in this age group."( Safety, efficacy and acceptability of praziquantel in the treatment of Schistosoma haematobium in pre-school children of Kwale County, Kenya.
Kihara, JH; Kimani, BW; Mbugua, AK; Ng'ang'a, M; Njomo, DW, 2018
)
0.75
"Concurrent topical administration of a fluralaner plus moxidectin and a praziquantel product did not result in adverse findings."( Safety of topical administration of fluralaner plus moxidectin concurrently with praziquantel in cats.
Fisara, P; Roepke, RKA; Walther, FM, 2018
)
0.94
" However, there are no published data regarding adverse events associated with these medications."( Schistosomiasis and soil-transmitted helminthiasis preventive chemotherapy: Adverse events in children from 2 to 15 years in Bengo province, Angola.
Barros, H; Brito, M; Fançony, C; Lemos, M; Moura, S; Nery, SV; Pedro, JM; Sousa, CP, 2020
)
0.56
"Treatment of urinary Schistosoma hematobium infections with a repeated high monthly dose of 60 mg/kg of praziquantel for 3 months is safe and effective."( Three monthly doses of 60 mg/kg praziquantel for Schistosoma haematobium infection is a safe and effective treatment regimen.
Adjei-Kusi, P; Baffour-Awuah, S; Darko, SN; Hanson, H; Owusu-Dabo, E; Twumasi-Ankrah, S; Yar, D, 2020
)
1.06
" Safety was summarized using reported adverse events (AEs)."( Efficacy and safety of single-dose 40 mg/kg oral praziquantel in the treatment of schistosomiasis in preschool-age versus school-age children: An individual participant data meta-analysis.
Coulibaly, JT; Garba, A; Halleux, C; Keiser, J; King, CH; Mutapi, F; N'Goran, EK; Olliaro, PL; Raso, G; Scherrer, AU; Sousa-Figueiredo, JC; Stete, K; Utzinger, J; Vaillant, MT, 2020
)
0.81
"There is no indication that single-dose 40 mg/kg oral praziquantel would be less efficacious and less safe in preschool-age children compared to school-age children, with the caveat that only few randomized comparisons exist between the two age groups."( Efficacy and safety of single-dose 40 mg/kg oral praziquantel in the treatment of schistosomiasis in preschool-age versus school-age children: An individual participant data meta-analysis.
Coulibaly, JT; Garba, A; Halleux, C; Keiser, J; King, CH; Mutapi, F; N'Goran, EK; Olliaro, PL; Raso, G; Scherrer, AU; Sousa-Figueiredo, JC; Stete, K; Utzinger, J; Vaillant, MT, 2020
)
1.06
" Adverse events were assessed within four hours of drugs intake."( Efficacy and safety of praziquantel and dihydroartemisinin piperaquine combination for treatment and control of intestinal schistosomiasis: A randomized, non-inferiority clinical trial.
Aklillu, E; Kamuhabwa, A; Kinung'hi, S; Minzi, O; Mnkugwe, RH, 2020
)
0.87
"4%) of the study participants experienced mild and transient treatment-associated adverse events, post-treatment abdominal pain (27."( Efficacy and safety of praziquantel and dihydroartemisinin piperaquine combination for treatment and control of intestinal schistosomiasis: A randomized, non-inferiority clinical trial.
Aklillu, E; Kamuhabwa, A; Kinung'hi, S; Minzi, O; Mnkugwe, RH, 2020
)
0.87
" The combinations of the anthelmintic drug with antioxidants RSV and SkQ1 ameliorate host oxidative stress and mitigate adverse effects of PZQ on hepatic parenchyma."( Antioxidants resveratrol and SkQ1 attenuate praziquantel adverse effects on the liver in Opisthorchis felineus infected hamsters.
Cheng, G; Kolosova, NG; Mordvinov, VA; Pakharukova, MY; Rakhmetova, AS; Zaparina, O, 2021
)
0.88
"This study was to determine the relationship between a praziquantel-related adverse event with the health community perception to chemopreventive of Schistosomiasis in Dodolo village, Napu Valley, Central Sulawesi."( Does the presence of praziquantel-related adverse events affect the health community's perception toward the mass chemopreventive program in the highest prevalence area of Schistosomiasis in Indonesia? Study in Dodolo village, Napu Valley, Central Sulawes
Afriana, F; Daris, R; Hidayat, SH; Putri, ASD; Vera Diana, T, 2021
)
1.19
"The incidence of praziquantel-related adverse events was 92% (73), with the highest frequency were nausea (69%), vomit (57%), and headache (47%)."( Does the presence of praziquantel-related adverse events affect the health community's perception toward the mass chemopreventive program in the highest prevalence area of Schistosomiasis in Indonesia? Study in Dodolo village, Napu Valley, Central Sulawes
Afriana, F; Daris, R; Hidayat, SH; Putri, ASD; Vera Diana, T, 2021
)
1.28
"The Dodolo community had a supportive health perception for the success of the Schistosomiasis elimination program, despite the high frequency of adverse events after praziquantel consumption."( Does the presence of praziquantel-related adverse events affect the health community's perception toward the mass chemopreventive program in the highest prevalence area of Schistosomiasis in Indonesia? Study in Dodolo village, Napu Valley, Central Sulawes
Afriana, F; Daris, R; Hidayat, SH; Putri, ASD; Vera Diana, T, 2021
)
1.14
"The aim of this active safety surveillance study was to identify the incidence, type, severity, and risk factors for adverse events (AEs) following mass administration of praziquantel and albendazole."( Safety of Praziquantel and Albendazole Coadministration for the Control and Elimination of Schistosomiasis and Soil-Transmitted Helminths Among Children in Rwanda: An Active Surveillance Study.
Aklillu, E; Barry, A; Bergman, U; Bienvenu, E; Kabatende, J; Mugisha, M; Ntirenganya, L, 2022
)
1.32
"Praziquantel and albendazole MDA is safe and well-tolerated; however, one in five children experience transient mild to moderate, and in few cases severe, AEs."( Safety of Praziquantel and Albendazole Coadministration for the Control and Elimination of Schistosomiasis and Soil-Transmitted Helminths Among Children in Rwanda: An Active Surveillance Study.
Aklillu, E; Barry, A; Bergman, U; Bienvenu, E; Kabatende, J; Mugisha, M; Ntirenganya, L, 2022
)
2.57
" Conclusion: Praziquantel is effective and safe in the treatment of patients with neurocysticercosis."( Efficacy and safety of praziquantel in the treatment of neurocysticercosis in Vietnam.
Loi, CB; Phuc, TQ; Thang, TD; Thanh, DT; Thieu, NQ; Tho, TH; Tran-Anh, L, 2022
)
1.4
"0001) was a predictor of MDA-associated adverse events, but no significant association with genotypes were found."( Effect of pharmacogenetic variations on praziquantel plasma concentration and safety outcomes among school children in Rwanda.
Aklillu, E; Barry, A; Bienvenu, E; Kabatende, J; Mnkugwe, RH; Mugisha, M; Ntirenganya, L; Telele, NF, 2023
)
1.18
" The most common drug-related treatment-emergent adverse events were abdominal pain (41 [14%] of 288 participants), diarrhoea (27 [9%]), vomiting (16 [6%]), and somnolence (21 [7%])."( Efficacy, safety, and palatability of arpraziquantel (L-praziquantel) orodispersible tablets in children aged 3 months to 6 years infected with Schistosoma in Côte d'Ivoire and Kenya: an open-label, partly randomised, phase 3 trial.
Aka, NAD; Assandé Aka, R; Badenhorst, H; Bagchus, WM; Bezuidenhout, D; Bödding, M; Dälken, B; Haj-Ali Saflo, O; Huber, E; Kourany-Lefoll, E; N'Goran, EK; Odiere, MR; Ogutu, B; Ouattara, M; Rawago, F; Tappert, A; Yin, X, 2023
)
1.18
" Adverse events were infrequent and mild to moderate during both treatment cycles."( Efficacy and safety of antiparasitic therapy for neurocysticercosis in rural Tanzania: a prospective cohort study.
Bottieau, E; Carabin, H; Dorny, P; Fleury, A; Gabriël, S; Jackson, E; Magnussen, P; Makasi, C; Mwape, KE; Ngowi, BJ; Prazeres da Costa, C; Prodjinotho, UF; Ruether, C; Schmidt, V; Stelzle, D; Trevisan, C; Van Damme, I; Winkler, AS; Zulu, G, 2023
)
0.91
" Safety assessment was performed by collecting adverse events from all children for six subsequent days following administration of the study drugs."( Feasibility and safety of integrating mass drug administration for helminth control with seasonal malaria chemoprevention among Senegalese children: a randomized controlled, observer-blind trial.
Afolabi, MO; Agbla, SC; Camara, B; Diop, B; Diouf, A; Diouf, MP; Fall, EHB; Gaye, NA; Greenwood, B; Gueye, B; Kane, NM; Lo, AC; Loum, MA; Manga, IA; Mbaye, IM; Ndiaye, JLA; Niang, D; Sall, FB; Seck, A; Sene, D; Sow, D, 2023
)
0.91
"Integration of MDA for helminths with SMC drugs was safe and feasible among Senegalese children."( Feasibility and safety of integrating mass drug administration for helminth control with seasonal malaria chemoprevention among Senegalese children: a randomized controlled, observer-blind trial.
Afolabi, MO; Agbla, SC; Camara, B; Diop, B; Diouf, A; Diouf, MP; Fall, EHB; Gaye, NA; Greenwood, B; Gueye, B; Kane, NM; Lo, AC; Loum, MA; Manga, IA; Mbaye, IM; Ndiaye, JLA; Niang, D; Sall, FB; Seck, A; Sene, D; Sow, D, 2023
)
0.91

Pharmacokinetics

No significant pharmacokinetic interaction between the albendazole and praziquantel was demonstrated. The developed method had a successful application to comparative pharmacokinetics study of racemate prazquantel and R-enantiomer.

ExcerptReferenceRelevance
" Statistical comparisons indicated that there were no significant differences in the pharmacokinetic parameters estimated in the two groups of animals."( Effect of experimentally-induced hepatic cirrhosis on the pharmacokinetics of orally administered praziquantel in the rat.
Kokwaro, GO; Taylor, G,
)
0.35
" The pharmacokinetic parameters did not differ significantly between patients with simple active schistosomiasis (group 1) and those with hepatosplenomegaly with liver involvement but without ascites and jaundice (group 2)."( Clinical and pharmacokinetic study of praziquantel in Egyptian schistosomiasis patients with and without liver cell failure.
Abdel-Bary, MA; Abdel-Fatah, SA; el Guiniady, MA; el Touny, MA; Metwally, A, 1994
)
0.56
" The PB-pretreated rats showed a 6-fold decrease in AUC, a 5-fold decrease in Cmax and an 8-fold increase in CLtot compared to the saline treated controls."( Effects of phenobarbital and 3-methylcholanthrene pretreatment on the pharmacokinetics of praziquantel in rats.
Hasler, JA; Masimirembwa, CM; Naik, YS,
)
0.35
" To study its pharmacokinetic characteristics, levels of praziquantel in plasma were determined for eight healthy volunteers after the administration of three oral doses of 25 mg/kg of body weight given at 2-h intervals, alone and with the simultaneous administration of cimetidine."( Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single-day therapeutic regimen.
Castro, N; Corona, T; Jung, H; Medina, R; Sotelo, J, 1997
)
0.85
" Peak concentration in serum is reached after 1 to 2 hours and the elimination half-life is between 1 and 3 hours."( Pharmacokinetic optimisation of the treatment of neurocysticercosis.
Jung, H; Sotelo, J, 1998
)
0.3
" In view of several differences in both its pharmacokinetic profile in different animal species and in the cytochrome P450-dependent system between ruminant and nonruminant species, the present study was undertaken to determine the pharmacokinetics of this drug, its effects on the P450 system and the involvement of cytochrome P450 in its metabolism in 3-month-old lambs infested by Fasciola hepatica."( Pharmacokinetics and microsomal oxidation of praziquantel and its effects on the P450 system in three-month-old lambs infested by Fasciola hepatica.
Gervasi, PG; Giorgi, M; Giusiani, M; Longo, V; Mengozzi, G; Salvatori, AP; Soldani, G, 2001
)
0.57
"Grapefruit juice changes the pharmacokinetic parameters of a variety of drugs metabolized primarily by cytochrome P450 3A."( Effects of liquid and freeze-dried grapefruit juice on the pharmacokinetics of praziquantel and its metabolite 4'-hydroxy praziquantel in beagle dogs.
Giorgi, M; Giusiani, M; Mengozzi, G; Meucci, V; Soldani, G; Vaccaro, E, 2003
)
0.55
" Pharmacokinetic studies in dogs confirmed that SRP was absorbed more slowly than PZQ."( Sustained-release praziquantel tablet: pharmacokinetics and the treatment of clonorchiasis in beagle dogs.
Choi, MH; Chung, BS; Hong, ST; Kho, WG; Lee, M; Lee, SH; Lee, SJ; Li, S; Seo, M, 2003
)
0.65
" No significant pharmacokinetic interaction between the albendazole and praziquantel was demonstrated."( Pharmacokinetic investigation of albendazole and praziquantel in Thai children infected with Giardia intestinalis.
Chanthavanich, P; Kabkaew, K; Lapphra, K; Limkittikul, K; Na-Bangchang, K; Pengsaa, K; Pojjaroen-Anant, C; Sirivichayakul, C; Subchareon, A; Wisetsing, P, 2004
)
0.81
"The pharmacokinetic interactions and tolerability of albendazole, praziquantel and ivermectin combinations were assessed in 23 healthy Thai volunteers (12 males and 11 females)."( Assessments of pharmacokinetic drug interactions and tolerability of albendazole, praziquantel and ivermectin combinations.
Hanpitakpong, W; Kietinun, S; Lazdins, J; Na-Bangchang, C; Na-Bangchang, K; Pawa, KK, 2006
)
0.8
" However, no data are available on the potential pharmacokinetic drug interaction between ketoconazole and praziquantel in humans."( Pharmacokinetic interaction between ketoconazole and praziquantel in healthy volunteers.
Mahatthanatrakul, W; Ratsamemonthon, K; Ridtitid, W; Wongnawa, M, 2007
)
0.8
"To investigate the potential pharmacokinetic interaction of ketoconazole with praziquantel in healthy adult Thai male volunteers."( Pharmacokinetic interaction between ketoconazole and praziquantel in healthy volunteers.
Mahatthanatrakul, W; Ratsamemonthon, K; Ridtitid, W; Wongnawa, M, 2007
)
0.82
" A non-compartmental model was applied for pharmacokinetic parameter analysis of praziquantel."( Pharmacokinetic interaction between ketoconazole and praziquantel in healthy volunteers.
Mahatthanatrakul, W; Ratsamemonthon, K; Ridtitid, W; Wongnawa, M, 2007
)
0.82
" The pharmacokinetic study consists of two parts."( Pharmacokinetics of a new ivermectin/praziquantel oil suspension after intramuscular administration in pigs.
Chen, L; Guo, Z; He, J; Hu, X; Tang, S; Wang, G; Xiao, X; Zhao, T, 2012
)
0.65
"Four studies were conducted to determine the pharmacokinetic characteristics and in vitro metabolism of eprinomectin, a semi-synthetic avermectin, in cats."( Pharmacokinetics and metabolism of eprinomectin in cats when administered in a novel topical combination of fipronil, (S)-methoprene, eprinomectin and praziquantel.
Kellermann, M; Knaus, M; Kvaternick, V; Rehbein, S; Rosentel, J, 2014
)
0.6
" For this reason, the main aim of the present study was to evaluate the pharmacokinetic (PK) profile of PZQ-NP, through HPLC-MS/MS assays."( Preclinical pharmacokinetic evaluation of praziquantel loaded in poly (methyl methacrylate) nanoparticle using a HPLC-MS/MS.
Calil-Elias, S; Fonseca, LB; Guilarducci-Ferraz, CV; Malhado, M; Nele, M; Pereira, HM; Pinto, DP; Pinto, JC; Santos, JG; Silva, AC; Silveira, GP; Viçosa, AL, 2016
)
0.7
"We investigated the pharmacokinetic characteristics of praziquantel (PZQ) in rice field eels Monopterus albus."( Pharmacokinetics and residue depletion of praziquantel in rice field eels Monopterus albus.
Ai, X; Dong, J; Xu, N; Yang, Y, 2016
)
0.95
" The results showed that all of the IVM pharmacokinetic parameters of Tivm+pzq were similar to those of the reference."( Pharmacokinetics of a new ivermectin/praziquantel suspension after intramuscular administration in sheep.
Chen, L; Hao, L; Qian, M; Tang, S; Xiao, X, 2016
)
0.71
" However, pharmacokinetic (PK) studies investigating the disposition of PZQ enantiomers (R- and S-PZQ) and its main metabolite, R-trans-4-OH-PZQ, in diseased patients are lacking."( Pharmacokinetic Study of Praziquantel Enantiomers and Its Main Metabolite R-trans-4-OH-PZQ in Plasma, Blood and Dried Blood Spots in Opisthorchis viverrini-Infected Patients.
Duthaler, U; Huwyler, J; Keiser, J; Kovac, J; Meister, I; Odermatt, P; Sayasone, S; Vanobberghen, F, 2016
)
0.74
" We conducted the first PZQ pharmacokinetic (PK) and pharmacodynamic (PD) study in young children comparing dosing."( Population Pharmacokinetics and Pharmacodynamics of Praziquantel in Ugandan Children with Intestinal Schistosomiasis: Higher Dosages Are Required for Maximal Efficacy.
Atuhaire, A; Bustinduy, AL; Corstjens, PL; de Sousa-Figueiredo, JC; Hope, WW; Kabatereine, NB; Roberts, SA; Scott, JT; Stanton, MC; Stothard, JR; Van Dam, GJ; Ward, S; Waterhouse, D, 2016
)
0.68
" To address these problems, we conducted the first pharmacokinetic and pharmacodynamic study of young children within an area of Uganda where Schistosoma mansoni is hyperendemic."( Population Pharmacokinetics and Pharmacodynamics of Praziquantel in Ugandan Children with Intestinal Schistosomiasis: Higher Dosages Are Required for Maximal Efficacy.
Atuhaire, A; Bustinduy, AL; Corstjens, PL; de Sousa-Figueiredo, JC; Hope, WW; Kabatereine, NB; Roberts, SA; Scott, JT; Stanton, MC; Stothard, JR; Van Dam, GJ; Ward, S; Waterhouse, D, 2016
)
0.68
" However, compared with the market available PZQ tablet after oral administration (150 mg/kg), our injections revealed longer plasma elimination half-life (26."( Pharmacokinetics of new high-concentration and long-acting praziquantel oily suspensions after intramuscular administration in cattle.
Hao, L; Qian, M; Tang, S; Wei, L, 2017
)
0.7
" Then, the developed method had a successful application to comparative pharmacokinetic study of racemate praziquantel and R-enantiomer."( A quantification method for determination of racemate praziquantel and R-enantiomer in rat plasma for comparison of their pharmacokinetics.
Ji, J; Nie, L; Sun, D; Wang, H; Zhang, D, 2017
)
0.92
" Non-compartmental pharmacokinetic analysis was performed using PKsolver."( Evaluation of the pharmacokinetic-pharmacodynamic relationship of praziquantel in the Schistosoma mansoni mouse model.
Abla, N; Haas, H; Keiser, J; Reimers, N; Spangenberg, T; Vargas, M, 2017
)
0.69
"L-praziquantel (PZQ) pharmacokinetic data were analyzed from two relative bioavailability Phase 1 studies in adult, healthy subjects with two new oral dispersion tablet (ODT) formulations of L-PZQ administered under various combinations of co-administration with food, water, and/or crushing."( Extrapolation of praziquantel pharmacokinetics to a pediatric population: a cautionary tale.
Abla, N; Bagchus, W; Bonate, PL; Burt, H; Keiser, J; Kovac, J; Lüpfert, C; Passier, P; Wang, T, 2018
)
1.54
" A non-compartmental approach was used for pharmacokinetic analysis."( The effect of ketoconazole on praziquantel pharmacokinetics and the role of CYP3A4 in the formation of X-OH-praziquantel and not 4-OH-praziquantel.
Cavallin, E; Isin, E; Li, XQ; Masimirembwa, C; Nhachi, C; Nleya, L; Thelingwani, R, 2019
)
0.8
" The development of an optimal pediatric formulation and dose selection would benefit from a population pharmacokinetic (popPK) model."( R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with Schistosoma mansoni and S. haematobium and Lao adults infected with Opisthorchis viverrini.
Coulibaly, J; Falcoz, C; Guzy, S; Keiser, J; Kovač, J; Lin, YW; Meister, I; Sayasone, S; Wesche, D, 2022
)
1.44

Compound-Compound Interactions

The aim of the present study was to investigate the potential anti-fibrotic effect of human Wharton's jelly-derived mesenchymal stem cells (WJMSCs) combined with praziquantel (PZQ) in S. Schistosoma japonicum. The purpose of the study is to explore the efficacy of mefloquine administered orally at single, multiple doses.

ExcerptReferenceRelevance
" A single treatment with this drug combination gave 100% reductions in Toxocara canis and Taenia hydatigena in experimentally induced infections in dogs."( Efficacy of a drug combination of praziquantel, pyrantel embonate, and febantel against helminth infections in dogs.
Gemmell, MA; Lloyd, S, 1992
)
0.56
"In this work, praziquantel (EMBAY 8440, CAS 55268-74-1), an oral antihelminthic drug effective against the three species of schistosomes pathogenic to man, was tested alone and in combination with cimetidine (CAS 51481-61-9), aH2-receptor antagonist having a known potentiative power when combined with other drugs."( Treatment of experimental schistosomiasis mansoni with praziquantel alone and combined with cimetidine.
Bennet, JL; Botros, SS; Ebeid, FA; Metwally, AA, 1994
)
0.9
" Juvenile rockfish were divided into 7 groups, and orally administered praziquantel alone (50, 100 and 200 mg kg(-1) body wt, BW) or in combination with cimetidine at a dose of 200 mg kg(-1) BW for each praziquantel dose."( Treatment of Microcotyle sebastis infestation in cultured rockfish Sebastes schlegeli by oral administration of praziquantel in combination with cimetidine.
Cho, JB; Kim, KH; Kwon, SR; Lee, EH, 2001
)
0.75
"The purpose of the study is to explore the efficacy of mefloquine administered orally at single, multiple doses, or in combination with artesuante, artemether, or praziquantel in mouse--Schistosoma japonicum model."( Effect of mefloquine administered orally at single, multiple, or combined with artemether, artesunate, or praziquantel in treatment of mice infected with Schistosoma japonicum.
Jiao, PY; Mei, JY; Xiao, SH, 2011
)
0.78
" In addition, although mebendazole has been extensively used together with praziquantel against infections with schistosomiasis and soil-transmitted helminthiasis (STH) in school-aged children, no specific acceptability or safety studies have been published on this drug combination in younger children."( The acceptability and safety of praziquantel alone and in combination with mebendazole in the treatment of Schistosoma mansoni and soil-transmitted helminthiasis in children aged 1-4 years in Uganda.
Kabatereine, NB; Namwanje, H; Olsen, A, 2011
)
0.88
"A randomized clinical trial was conducted to determine the safety of praziquantel alone and in combination with mebendazole in the treatment of Schistosoma mansoni and STH in children aged 1 to 4 years."( The acceptability and safety of praziquantel alone and in combination with mebendazole in the treatment of Schistosoma mansoni and soil-transmitted helminthiasis in children aged 1-4 years in Uganda.
Kabatereine, NB; Namwanje, H; Olsen, A, 2011
)
0.89
"To study the therapeutical effect and mechanisms of resveratrol and its combination with praziquantel on the liver fibrosis due to Schistosoma japonicum infection."( [Therapeutic effect of resveratrol as well as resveratrol combined with praziquantel on the liver fibrosis due to Schistosoma japonicum infection in mice].
Chen, Y; Xiao, Z, 2013
)
0.84
"To investigate the clinical therapeutic effect of biological information infrared liver therapeutic apparatus (BILT) combined with praziquantel in the treatment of patients with chronic schistosomiasis."( [Therapeutic effect of BILT combined with praziquantel in treatment of chronic schistosomiasis].
Hong-Bo, W; Li-le, L; Na, Z; Ni-Na, P; Ru-Yi, L; Yan, M; Yu, H, 2017
)
0.92
" A total of 142 chronic schistosomiasis patients were divided into an experimental group (BILT combined with praziquantel) with 64 cases and a control group (routine treatment with praziquantel alone) with 78 cases on the basis of the age, gender, disease duration and liver function as paired condition."( [Therapeutic effect of BILT combined with praziquantel in treatment of chronic schistosomiasis].
Hong-Bo, W; Li-le, L; Na, Z; Ni-Na, P; Ru-Yi, L; Yan, M; Yu, H, 2017
)
0.93
"BILT combined with praziquantel can significantly alleviate the short-term clinical symptoms, restore liver function and also alleviate hepatic fibrosis of the patients with chronic schistosomiasis."( [Therapeutic effect of BILT combined with praziquantel in treatment of chronic schistosomiasis].
Hong-Bo, W; Li-le, L; Na, Z; Ni-Na, P; Ru-Yi, L; Yan, M; Yu, H, 2017
)
1.05
" This study aimed to evaluate the role of Met as anti-schistosomal and anti-fibrotic agents alone or in combination with PZQ treatment."( An adjuvant effect of Metformin as an anti-fibrotic agent when administered with the anti-schistosomal Praziquantel in Schistosoma mansoni infected mice.
El-Naggar, SA; El-Said, KS; Harras, SF; Salama, WM, 2021
)
0.84
"This study aimed to evaluate the efficacy of gamma-aminobutyric acid (GABA) alone or combined with praziquantel (PZQ) against Schistosoma (S) mansoni infection in a murine model."( Schistosomicidal and hepatoprotective activity of gamma-aminobutyric acid (GABA) alone or combined with praziquantel against Schistosoma mansoni infection in murine model.
Fahmy, AM; Hegab, A; Tm, D; William, S, 2022
)
1.15
" Significant improvement in hepatic oxidative stress levels, serum albumin and total protein in response to GABA treatment alone or combined with PZQ."( Schistosomicidal and hepatoprotective activity of gamma-aminobutyric acid (GABA) alone or combined with praziquantel against Schistosoma mansoni infection in murine model.
Fahmy, AM; Hegab, A; Tm, D; William, S, 2022
)
0.94
" leaves (MOL) alone or in combination with praziquantel (PZQ) drug targeting-infected mice with Schistosoma mansoni-induced liver and spleen damage."( Parasitological and histopathological studies to the effect of aqueous extract of Moringa oleifera Lam. leaves combined with praziquantel therapy in modulating the liver and spleen damage induced by Schistosoma mansoni to male mice.
Elrayess, RA; Gad El-Hak, HN; Ghobashy, MA; Saad El-Din, MI, 2023
)
1.38

Bioavailability

Praziquantel (PZQ) pharmacokinetic data were analyzed from two relative bioavailability Phase 1 studies in adult, healthy subjects with two new oral dispersion tablet (ODT) formulations. The effect of cytochrome P-450 inhibitors on the metabolism of praziquants was investigated in rats.

ExcerptReferenceRelevance
" Since praziquantel, the drug used to treat neurocysticercosis, undergoes extensive liver first-pass metabolism, we carried out a prospective study to verify whether there was a decrease in oral bioavailability induced by carbamazepine and phenytoin."( Phenytoin and carbamazepine decreased oral bioavailability of praziquantel.
Bittencourt, PR; Diekmann, HW; Fernandes, AG; Gracia, CM; Jung, W; Martins, R, 1992
)
0.98
" Mebendazol and flubendazol are poorly absorbed and are effective for ascaris, oxyuriasis and trycocephalus both in adults and children."( [New anthelmintic drugs].
Apt, W, 1990
)
0.28
"In order to find ways to increase the usually very low bioavailability of praziquantel, the effect of cytochrome P-450 inhibitors on the metabolism of praziquantel was investigated in rats."( Inhibitory effects of cimetidine ketoconazole and miconazole on the metabolism of praziquantel.
Diekmann, HW; Overbosch, D; Schneidereit, M, 1989
)
0.73
" The comparative bioavailability of four of the internationally available brands of praziquantel tablets were then studied in eight healthy volunteers using a crossover design."( Comparative bioavailability of praziquantel tablets.
Kaojarern, S; Nathakarnkikool, S; Suvanakoot, U, 1989
)
0.79
" Both the peak plasma concentration of praziquantel and the bioavailability (measured as the area under the plasma concentration time curve) were significantly greater in the two groups of patients with liver disease (P less than ."( Praziquantel pharmacokinetics and side effects in Schistosoma japonicum-infected patients with liver disease.
Fernando, MT; Laughlin, LW; Padre, L; Ranoa, CP; Ritter, W; Watt, G; White, NJ, 1988
)
1.99
"The effects of cimetidine, bicarbonate and glucose on the bioavailability of the two brands of praziquantel (CAS 55268-74-1) available in Egypt were studied in normal healthy volunteers."( Effect of cimetidine, bicarbonate and glucose on the bioavailability of different formulations of praziquantel.
Bennett, JL; Botros, S; Ebeid, F; Metwally, A, 1995
)
0.73
" Statistical analysis of the pharmacokinetic parameters of brand 1 vs brand 2 (in a dose of 20 or 40 mg kg-1) revealed no significant difference in elimination (ke), absorption rate constant (ka), elimination half life (t1/2e), area under the time-concentration curve (Auc), serum maximum concentration (Cpmax) and time to maximum concentration (Tmax)."( Impact of drug dosage and brand on bioavailability and efficacy of praziquantel.
Bennett, J; Botros, S; Ebeid, F; el attar, Gel D; Metwally, A, 1995
)
0.53
" These findings also suggest that the bioavailability of praziquantel could be altered to a significant extent in humans taking drugs that are phenobarbital type inducers."( Effects of phenobarbital and 3-methylcholanthrene pretreatment on the pharmacokinetics of praziquantel in rats.
Hasler, JA; Masimirembwa, CM; Naik, YS,
)
0.6
" CHQ decreased the bioavailability of PZQ and reduced its maximum serum concentrations to a significant extent in rats and in humans."( The effect of chloroquine on the pharmacokinetics and metabolism of praziquantel in rats and in humans.
Hasler, JA; Masimirembwa, CM; Naik, YS, 1994
)
0.52
" Bioavailability of the drug is markedly reduced when given jointly with antiepileptics or corticosteroids, specially carbamazepine, phenytoin or dexamethasone."( Pharmacokinetic optimisation of the treatment of neurocysticercosis.
Jung, H; Sotelo, J, 1998
)
0.3
" In spite of its poor solubility, PZQ is well absorbed across the gastrointestinal tract, but large doses are required to achieve adequate concentrations at the target sites."( Improvement of the in vitro dissolution of praziquantel by complexation with alpha-, beta- and gamma-cyclodextrins.
Becket, G; Schep, LJ; Tan, MY, 1999
)
0.57
" Treatment with praziquantel associated with cimetidine to increase the drug bioavailability and prednisone to reduce the inflammatory reaction gives good results."( Parenchymatous cerebral neurocysticercosis in a quadriplegic patient.
Al-Khodairy, AT; Annoni, JM; Uebelhart, D, 1999
)
0.65
" These features indicate that agents or drugs which are able to modulate P450 3A-dependent catalysis may interfere with the metabolism, bioavailability and therapeutic effects of PZQ."( Pharmacokinetics and microsomal oxidation of praziquantel and its effects on the P450 system in three-month-old lambs infested by Fasciola hepatica.
Gervasi, PG; Giorgi, M; Giusiani, M; Longo, V; Mengozzi, G; Salvatori, AP; Soldani, G, 2001
)
0.57
" This effect may be due to the low bioavailability of PZQ that has a low hydrosolubility and fast metabolism."( Improvement of antischistosomal activity of praziquantel by incorporation into phosphatidylcholine-containing liposomes.
Costa, PI; Gremião, MP; Mourão, SC; Salgado, HR, 2005
)
0.59
" Compared with intravenous administration, PZQ bioavailability (area under curve, AUC0-24h) was slightly improved when the drug was administered with food in both kingfish plasma (56."( Bioavailability and pharmacokinetics of a praziquantel bolus in kingfish Seriola lalandi.
Tingle, MD; Tubbs, LA, 2006
)
0.6
"The level of drug-metabolizing enzymes (cytochrome P450 [CYP450] and cytochrome b5 [cyt b5]) and the bioavailability of praziquantel (PZQ) were investigated in batches of mice infected with Schistosoma mansoni displaying either a decreased susceptibility to PZQ ("EE2" and "BANL"-isolates), or a normal susceptibility to the drug ("CD" isolate)."( Drug-metabolizing enzymes and praziquantel bioavailability in mice harboring Schistosoma mansoni isolates of different drug susceptibilities.
Botros, SS; Ebeid, FA; El-Din, SH; El-Lakkany, NM; Sabra, AN, 2006
)
0.83
"The aim of this study was to assess the feasibility of solid lipid nanoparticles (SLN) to enhance the oral bioavailability of praziquantel (PZQ)."( Enhancement the oral bioavailability of praziquantel by incorporation into solid lipid nanoparticles.
Chang, Y; Geng, Y; Li, H; Yang, L; You, J; Zhang, Y, 2009
)
0.83
"The purpose of this study was to formulate praziquantel (PZQ)-loaded hydrogenated castor oil (HCO) solid lipid nanoparticles (SLN) to enhance the bioavailability and prolong the systemic circulation of the drug."( Formulation, characterization and pharmacokinetics of praziquantel-loaded hydrogenated castor oil solid lipid nanoparticles.
Dong, Z; Pan, B; Wang, F; Wang, M; Wang, X; Xie, S; Zhou, W; Zhu, L, 2010
)
0.87
" SLN increased the bioavailability of PZQ by 14."( Formulation, characterization and pharmacokinetics of praziquantel-loaded hydrogenated castor oil solid lipid nanoparticles.
Dong, Z; Pan, B; Wang, F; Wang, M; Wang, X; Xie, S; Zhou, W; Zhu, L, 2010
)
0.61
"This study investigates the efficacy, bioavailability and drug metabolizing enzymes mainly involved in the metabolism of the commercial brands of praziquantel (PZQ) in Egypt in comparison with the original pure powder."( Comparative efficacy and bioavailability of different praziquantel brands.
Botros, S; El-Lakkany, N; Ibrahim, M; Sabra, AN; Seif el-Din, SH, 2011
)
0.82
" This work correlates the physical properties and the dissolution behavior of PZQ-polyvinylpyrrolidone (PVP) solid dispersion (SD) at the ratios of 1:1 and 3:7 with its oral bioavailability and its in vivo efficacy against Schistosoma mansoni (S."( Bioavailability and in vivo efficacy of a praziquantel-polyvinylpyrrolidone solid dispersion in Schistosoma mansoni-infected mice.
El-Lakkany, N; Heikal, L; Seif El-Din, SH, 2012
)
0.64
"PZQ, especially when administered 45 days following infection, compared with the positive-control group (untreated) and the groups that received free PZQ, can be explained by greater bioavailability in the host organism; the preferred target of lip."( Liposomal-praziquantel: efficacy against Schistosoma mansoni in a preclinical assay.
Allegretti, SM; de Souza, AL; Frezza, TF; Gremião, MP; Magalhães, LA; Zanotti-Magalhães, EM, 2013
)
0.79
"Praziquantel remains the drug of choice for schistosomiasis, but it has the low bioavailability and single dosage form."( [Progress of research on preparation and application of praziquantel].
Liu, YF; Ma, Z; Ning, A; Wu, DZ; Zhu, WF, 2013
)
2.08
" All fish consuming medicated feeds had a significant reduction in flukes relative to control fish; however, efficacy data and blood serum analysis suggested that diets containing PZQ microcapsules had lower bioavailability than those containing PZQ powder."( Praziquantel form, dietary application method and dietary inclusion level affect palatability and efficacy against monogenean parasites in yellowtail kingfish.
Michael, RJ; Partridge, GJ; Thuillier, L, 2014
)
1.85
" This study focused on improving the biological characteristics of the already-existing antischistosomal praziquantel (PZQ) by incorporating it into montmorillonite (MMT) clay as a delivery carrier to overcome its known bioavailability drawbacks."( Praziquantel in a clay nanoformulation shows more bioavailability and higher efficacy against murine Schistosoma mansoni infection.
Botros, SS; El-Feky, GS; El-Lakkany, NM; Mohamed, WS; Nasr, HE; Seif El-Din, SH, 2015
)
2.07
" However, this treatment presents limitations such as low and/or erratic bioavailability that can contribute to cases of tolerance."( Effectiveness of hyperbaric oxygen for experimental treatment of schistosomiasis mansoni using praziquantel-free and encapsulated into liposomes: assay in adult worms and oviposition.
Allegretti, SM; de Oliveira, CN; de Souza, AL; Dolder, MA; Frezza, TF; Giorgio, S; Gremião, MP; Joazeiro, PP; Prado, CC, 2015
)
0.64
" Although widely used, PZQ exhibits low and erratic bioavailability because of its poor water solubility."( Nanostructured Lipid Carriers as a Strategy to Improve the In Vitro Schistosomiasis Activity of Praziquantel.
Allegretti, SM; Chaud, MV; Chorilli, M; de Oliveira, RN; de Souza, AL; Garnero, C; Gremião, MP; Kolenyak-Santos, F; Longhi, MR, 2015
)
0.64
" The oral bioavailability (F) was 20."( Pharmacokinetics and residue depletion of praziquantel in rice field eels Monopterus albus.
Ai, X; Dong, J; Xu, N; Yang, Y, 2016
)
0.7
" In addition, the relative bioavailability of our formulated suspensions was improved up to 441."( Pharmacokinetics of new high-concentration and long-acting praziquantel oily suspensions after intramuscular administration in cattle.
Hao, L; Qian, M; Tang, S; Wei, L, 2017
)
0.7
"PZQ-NE-dispersed chitosan/glycerol 2-phosphate disodium/HPMC (NE/CS/β-GP/HMPC) hydrogel was successfully prepared to improve bioavailability of PZQ."( Design and optimization of thermosensitive nanoemulsion hydrogel for sustained-release of praziquantel.
Cong, Z; Li, J; Peng, X; Shi, Y; Wang, Y; Wei, B, 2017
)
0.68
" Pharmacokinetic parameters indicated that NE/CS/β-GP/HMPC hydrogel can significantly slow down drug elimination, prolong mean residence time and improve bioavailability of PZQ."( Design and optimization of thermosensitive nanoemulsion hydrogel for sustained-release of praziquantel.
Cong, Z; Li, J; Peng, X; Shi, Y; Wang, Y; Wei, B, 2017
)
0.68
" Solid dispersions (SDs) in water-soluble polymers have been reported to increase solubility and bioavailability of poorly water-soluble drugs like PZQ, generally due to the amorphous form stabilization."( Structural Elucidation of Poloxamer 237 and Poloxamer 237/Praziquantel Solid Dispersions: Impact of Poly(Vinylpyrrolidone) over Drug Recrystallization and Dissolution.
Diogo, HP; Leonardi, D; Nunes, TG; Orlandi, S; Priotti, J; Salomon, CJ, 2018
)
0.73
" In earlier papers a mechanochemical activation has been used to induce physical transformations on the drug which would ameliorate its solubility and hence its bioavailability and a systematic study of the effects of varying temperature, frequency and time of milling on drug melting enthalpy and drug recovery was given."( Identification of degradation products of praziquantel during the mechanochemical activation.
Passerini, N; Perissutti, B; Šagud, I; Škorić, I; Zanolla, D, 2018
)
0.75
"Lipid nanocapsules (LNCs) have shown potential to increase the bioavailability and efficacy of orally administered drugs."( Praziquantel-lipid nanocapsules: an oral nanotherapeutic with potential
Amara, RO; Eissa, MM; El-Azzouni, MZ; El-Khordagui, LK; El-Moslemany, RM; Ramadan, AA, 2018
)
1.92
" According to the pharmacokinetic data, the use of the composition increased the bioavailability of praziquantel 3 times."( Physicochemical Properties and Anti-Opisthorchosis Effect of Mechanochemically Synthesized Solid Compositions of Praziquantel with Glycyrrhizic Acid Disodium Salt.
Avgustinovich, DF; Chistyachenko, YS; Dushkin, AV; Khvostov, MV; Lyakhov, NZ; Meteleva, ES; Mordvinov, VA; Polyakov, NE; Suntsova, LP; Tolstikova, TG; Tsyganov, MA; Vishnivetskaya, GB, 2018
)
0.91
"L-praziquantel (PZQ) pharmacokinetic data were analyzed from two relative bioavailability Phase 1 studies in adult, healthy subjects with two new oral dispersion tablet (ODT) formulations of L-PZQ administered under various combinations of co-administration with food, water, and/or crushing."( Extrapolation of praziquantel pharmacokinetics to a pediatric population: a cautionary tale.
Abla, N; Bagchus, W; Bonate, PL; Burt, H; Keiser, J; Kovac, J; Lüpfert, C; Passier, P; Wang, T, 2018
)
1.54
"Praziquantel (PZQ), an antihelmintic agent commonly administered to humans and cattle, has low aqueous solubility, which compromises its bioavailability and efficacy."( Praziquantel systems with improved dissolution rate obtained by high pressure homogenization.
Gonzalez Vidal, NL; Gonzalez, MA; Ramírez Rigo, MV, 2018
)
3.37
" Unfortunately, it exhibits low oral bioavailability which can compromise its efficacy."( Niosomes for enhanced activity of praziquantel against Schistosoma mansoni: in vivo and in vitro evaluation.
Abd Elazeem, MA; Aboul Asaad, IA; El Maghraby, GM; El-Kowrany, SI; El-Nouby, KA; Zoghroban, HS, 2019
)
0.79
"In an effort to overcome the palatability issues currently constraining the effective delivery of praziquantel (PZQ) via feed to treat monogenean parasites in yellowtail kingfish, this study compared the bioavailability and palatability of PZQ in hydrogenated castor oil (HCO) solid lipid nanoparticles (SLN) against pure PZQ in this species."( Bioavailability and palatability of praziquantel incorporated into solid-lipid nanoparticles fed to yellowtail kingfish Seriola lalandi.
Lymbery, AJ; Partridge, GJ; Pilmer, L; Prestidge, CA; Rao, S; Woolley, LD, 2019
)
1.01
"The relative bioavailability of praziquantel was increased by concomitant KTZ administration."( The effect of ketoconazole on praziquantel pharmacokinetics and the role of CYP3A4 in the formation of X-OH-praziquantel and not 4-OH-praziquantel.
Cavallin, E; Isin, E; Li, XQ; Masimirembwa, C; Nhachi, C; Nleya, L; Thelingwani, R, 2019
)
1.09
" This study clarifies the mechanism of increasing the drug's bioavailability in the presence of glycyrrhizin."( Glycyrrhizin-Assisted Transport of Praziquantel Anthelmintic Drug through the Lipid Membrane: An Experiment and MD Simulation.
Dushkin, AV; Kim, AV; Lyakhov, NZ; Medvedev, NN; Meteleva, ES; Polyakov, NE; Selyutina, OY; Shelepova, EA, 2019
)
0.79
" This work aimed to improve the therapeutic outcome of the only available antischistosomal drug worldwide, praziquantel (PZQ), by incorporating it into a novel carrier, "solid lipid nanoparticles (SLNs)", to enhance its solubility, bioavailability and efficacy."( A novel praziquantel solid lipid nanoparticle formulation shows enhanced bioavailability and antischistosomal efficacy against murine S. mansoni infection.
Al-Shorbagy, MY; Botros, S; El-Feky, GS; El-Lakkany, NM; Radwan, A; Saleh, S; William, S, 2019
)
1.16
"SLN-PZQ demonstrated enhanced PZQ bioavailability and antischistosomal efficacy with a safe profile despite the prolonged residence in the systemic circulation."( A novel praziquantel solid lipid nanoparticle formulation shows enhanced bioavailability and antischistosomal efficacy against murine S. mansoni infection.
Al-Shorbagy, MY; Botros, S; El-Feky, GS; El-Lakkany, NM; Radwan, A; Saleh, S; William, S, 2019
)
0.95
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" However, its low aqueous solubility and strong bitter taste highly affect the bioavailability and compliance in pediatric patients."( Orphan Formulations in Pediatric Schistosomiasis Treatment: Development and Characterization of Praziquantel Nanoparticle-Loaded Powders for Reconstitution.
Gonzalez Vidal, NL; Gonzalez, MA; Ramírez Rigo, MV, 2019
)
0.73
" Inversely parallel functions of age described the apparent oral bioavailability (BA) and clearance maturation in children and ageing in adults."( R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with Schistosoma mansoni and S. haematobium and Lao adults infected with Opisthorchis viverrini.
Coulibaly, J; Falcoz, C; Guzy, S; Keiser, J; Kovač, J; Lin, YW; Meister, I; Sayasone, S; Wesche, D, 2022
)
1.44
" Finally, the in vitro solubility of cocrystals without crystal solvents and in vivo bioavailability of PRA-FA were evaluated to further understand the influence on the physicochemical properties of API for the introduction of CCF."( Cocrystals of Praziquantel with Phenolic Acids: Discovery, Characterization, and Evaluation.
An, Q; Du, G; Ji, W; Liu, Q; Lu, Y; Song, J; Xing, C; Yang, D; Yang, S; Zhang, L, 2022
)
1.08

Dosage Studied

Praziquantel (PZQ) is an anthelmintic drug used in developing countries for the treatment of schis. The therapeutic effect of a subcurative dosage of PZQ on Schistosoma mansoni infected mice and resistance to challenged worm infection after treatment were assessed.

ExcerptRelevanceReference
"Side effects increased in frequency as dosage increased."( Preliminary trials with praziquantel in human infections due to Schistosoma mansoni.
Chaves, A; Katz, N; Rocha, RS, 1979
)
0.57
" Thus the divided dosage gave a superior therapeutic result."( Preliminary clinical trials with praziquantel in Schistosoma japonicum infections in the Philippines.
Blas, BL; Boehme, K; Hayashi, M; Noseñas, JS; Ortega, OM; Portillo, GP; Santos, AT, 1979
)
0.54
" These results suggested that a combination solid dosage form was feasible."( Physiochemical interactions of praziquantel, oxamniquine and tablet excipients.
Ahmed, SM; Prankerd, RJ, 1992
)
0.57
"Seventy patients with clonorchis sinensis infection were divided randomly into two groups and treated with levo-praziquantel and praziquantel in the same dosage of 12."( [A comparative trial of levo-praziquantel and praziquantel in the treatment of human Clonorchis sinensis infection].
Liu, YH; Wang, XG; Yan, XH, 1992
)
0.79
" The different dosage regimens of praziquantel did not result in a significantly different reversibility of periportal fibrosis or a decrease in egg excretion."( Ultrasonographical investigation of periportal fibrosis in children with Schistosoma mansoni infection: reversibility of morbidity twenty-three months after treatment with praziquantel.
Abdel-Rahim, IM; Doehring-Schwerdtfeger, E; Ehrich, JH; Elsheikh, M; Franke, D; Kaiser, C; Kardorff, R; Mohamed-Ali, Q; Richter, J; Schlake, J, 1992
)
0.76
"), each time approximately 5 weeks after dosing with 60-80 OV metacercariae at weeks 0, 8, 16, 24 and 32."( Repeated exposure to Opisthorchis viverrini and treatment with the antihelminthic Praziquantel lacks carcinogenic potential.
Ito, N; Moore, MA; Ruchirawat, S; Thamavit, W, 1992
)
0.51
" Praziquantel was orally administered at a daily dosage of 50 mg/kg."( Neurocysticercosis treated with praziquantel. Long-term follow-up of a case.
Chiaramonte, I; Mancuso, P; Tropea, R,
)
1.33
" Praziquantel was given orally at a dosage of 45 mg/kg/day in 3 divided doses at 4-5 hour interval for 15 days."( The treatment of neurocysticercosis with praziquantel.
Bunnag, D; Riganti, M; Vanijanonta, S, 1991
)
1.46
" In this study, 40 patients with Taenia saginata and 15 with Hymenolepis nana were treated by one single oral dose of Praziquantel, at the dosage of 10 mg/kg/day and 20 mg/kg/day respectively."( Successful treatment of Taenia saginata and Hymenolepis nana by single oral dose of praziquantel.
Bouree, P, 1991
)
0.71
"The CSF and plasma concentrations of praziquantel (PZQ) were determined with high pressure liquid chromatography in 37 patients with cysticercosis of the central nervous system during a dosing regimen of PZQ 20 mg/kg p o q 8h for 3 days."( [Determination of praziquantel levels in cerebrospinal fluid and plasma in patients with cysticercosis of the central nervous system treated with praziquantel].
Jia, JY, 1991
)
0.89
" Within several days posttreatment, destrobilated worms can regenerate to a size that is readily apparent in the gut contents, allowing the effective dosage to be determined with much greater confidence."( Anthelmintic-induced destrobilation and its influence on calculated drug efficacy in Hymenolepis diminuta infections in rats.
Arai, HP; Dixon, BR, 1991
)
0.28
" Infected rabbits were administered one oral treatment of PZQ at a dosage of 100 mg/kg at 6, 12, or 24 weeks after infection."( Serologic and ultrasonographic parameters of praziquantel treatment of hepatic fibrosis in Schistosoma japonicum infection.
Irie, Y; Nara, T; Ohmae, H; Taguchi, H; Tanaka, M; Utsunomiya, H; Yasuraoka, K, 1991
)
0.54
" The dosage of L-PQZ was 20 mg/kg, and that of PZQ was 40 mg/kg."( Comparative efficacy of levo-praziquantel and praziquantel in treatment of schistosomiasis japonica at a single dose.
Chen, M; Lian, WN; Liu, ZD; Wang, CZ; Wei, CC; Wu, MH; Xu, ZY; Yang, QJ; Yuan, HC; Zhang, ZJ, 1991
)
0.57
" Control mice and mice infected with Schistosoma mansoni were dosed with PZQ and their urines were examined for the presence of metabolites using a triple-quadrupole mass spectrometer (tandem mass spectrometer)."( Metabolism studies of the antischistosomal drug praziquantel using tandem mass spectrometry: qualitative identification of 17 hydroxylated metabolites from mouse urine.
Abramson, FP; Ali, MH; Cohn, VH; Fetterolf, DD, 1990
)
0.53
" The reduction in adult worm recovery after dosing with 50 mg/kg oxamniquine was 89."( Effects of praziquantel and oxamniquine on a Saudi Arabian strain of Schistosoma mansoni in mice.
Banaja, AA; Ghandour, AM; Shalaby, IM, 1990
)
0.67
"Forty-six school children with japonicum schistosomiasis living in a village at Napu Valley, Indonesia were treated with praziquantel at a dosage of 70 mg/kg in two divided doses in a day."( The effect of praziquantel treatment on liver and spleen size of children with schistosomiasis in Napu Valley, central Sulawesi.
Campbell, J; Hadidjaja, P; Ismid, IS; Putrali, J; Sudomo, M; Syamsuddin, N, 1990
)
0.85
" Dosing intervals in hydatid control programmes utilizing mass dog-purging to estimate re-infection rates should therefore take this factor into consideration."( Hydatid disease in the Turkana District of Kenya, VII: analysis of the infection pressure between definitive and intermediate hosts of Echinococcus granulosus, 1979-1988.
Gathuma, JM; Macpherson, CN; Wachira, TM, 1990
)
0.28
"Sheep (n = 14) with coenuriosis were treated with praziquantel in single or divided doses at total dosage rates of 50 to 500 mg kg-1 live mass."( Treatment of cerebral coenuriosis in sheep with praziquantel.
Tustin, RC; Verster, A, 1990
)
0.79
" Treatment using praziquantel a single dosage of 10 mg/kg body weight expelled the worm including the scolex."( Observations on self-induced Taenia saginata infection.
Tesfa-Yohannes, TM, 1990
)
0.62
" In one protocol five weeks after being infected with 48-52 cercariae, mice were orally dosed with PZQ 300 mg/kg, and killed 82 days later to isolate eggs from the liver."( Failure to induce resistance of Schistosoma japonicum to praziquantel.
Xu, XJ; Yu, SH; Yue, WJ, 1990
)
0.52
"To assess the efficacy of low dose praziquantel regimens in comparison with standard 40 mg/kg dosing in the treatment of urinary schistosomiasis, a random allocation dose-finding trial was performed in children and adults from a Schistosoma haematobium endemic region in Coast Province, Kenya."( Dose-finding study for praziquantel therapy of Schistosoma haematobium in Coast Province, Kenya.
Arap Siongok, TK; De Stigter, KV; King, CH; Koech, D; Mahmoud, AA; Ouma, JH; Peters, PA; Wiper, DW, 1989
)
0.86
" Percent reduction in worm burden in mice treated with levo-PZQ was significantly higher than in those with PZQ at a dosage of 2 x 50 mg/kg (67."( A comparison of the antischistosomal effect of levo- and dextro-praziquantel on Schistosoma japonicum and S. mansoni in mice.
Irie, Y; Nara, T; Ohmae, H; Tanaka, M; Utsunomiya, H; Yasuraoka, K, 1989
)
0.52
"45 patients with Opisthorchis felineus infection, 8 in the acute and 37 in the chronic stage of the disease of moderate severity or mild course were treated with praziquantel dosed 25-60 mg per kilo for one-day course."( [Clinical assessment of immunoglobulin E in the blood and the level of circulating immune complexes in parasitic diseases. 3. Opisthorchiasis].
Bronshteĭn, AM; Gervazieva, VB; Legon'kov, IuA; Ovsiannikova, IG; Ozeretskovskaia, NN,
)
0.33
" Praziquantel was administered in a dosage of 10 mg per kg of body weight, in single doses, and the effectiveness of the drug was documented in 100% of cases, with a follow-up of more than 7 weeks."( [Our experience in the treatment of Taenia saginata (Goenze, 1762) with praziquantel].
Díaz Hernández, A; Díaz Jidy, M; Pérez Avila, J; Ruiz Pérez, A,
)
1.27
" In our study, 30 patients with Taenia saginata and 10 with Hymenolepis nana has been treated by one single dose of praziquantel, a wide-spectrum anti-helminthic drug, at the dosage of 10 mg/kg/day and 20 mg/kg/day respectively."( [Efficacy of a single dose of praziquantel as treatment for Taenia saginata and Hymenolepis nana].
Bourée, P, 1988
)
0.77
" Praziquantel was administrated at daily dosage of 50 mg per kilogram of body weight, by oral route, distributed in three doses during 15 days."( Brain cysticercosis treated with praziquantel. Report of six cases.
Abad, JM; Bollar, A; Fernańdez, J; García-Allut, A; Gelabert, M; Mostaza, A, 1988
)
1.47
"Praziquantel administered at a dosage of 10 mg/kg of body weight/day for 14 days eliminated a fluke infection in a red-billed toucan."( Treatment of flukes in a toucan.
Giddings, RF, 1988
)
1.72
" The latter were defined as those treated for 18 months after a daily dosage of 3 X 25 mg/kg BW/day of praziquantel."( Evaluation of enzyme-linked immunosorbent assay for immunodiagnosis of clonorchiasis.
Chen, CY; Chen, SN; Hsieh, WC; Shih, HH, 1987
)
0.49
" The recommended dosage of 10 mg of febantel and 1 mg of praziquantel/kg cleared greater than or equal to 98% of the 3 helminth species."( Anthelmintic efficacy of febantel combined with praziquantel against Ancylostoma tubaeforme, Toxocara cati, and Taenia taeniaeformis in cats.
Arther, RG; Cox, DD, 1986
)
0.77
" Two dosage regimes were compared, a single dose of 40 mg/kg bodyweight, and a divided dose 2 X 20 mg/kg given 4-6 h apart."( Treatment with praziquantel of schoolchildren with concurrent Schistosoma mansoni and S. haematobium infections in Gezira, Sudan.
Daffalla, AA; Dixon, HG; el Igail, AB; el Tayeb, M; Fenwick, A; Kardaman, MW, 1985
)
0.62
" The eighth patient, who had failed to respond to prior treatment with bithionol, could not tolerate the daily dosage of 75 mg/kg because of nausea."( Paragonimiasis: diagnosis and the use of praziquantel in treatment.
Carberry, WL; Dunning, SB; Johnson, RJ; Jong, EC; Minshew, BH,
)
0.4
" Previous treatment with the drug at the dosage recommended for cestode removal (5 mg/kg, SC) for 2 days was only partially effective."( Paragonimiasis in a dog: treatment with praziquantel.
Kirkpatrick, CE; Shelly, EA, 1985
)
0.54
" Treated dogs were dosed once daily for 3 days."( Anthelmintic efficacy of febantel combined with praziquantel in dogs.
McCurdy, HD; Sharp, ML, 1985
)
0.52
" The total daily dosage was distributed into three equal parts of 1/3 each, with a 4 hours' interval between intakes, except in the last 5 cases, who on the 21st."( Praziquantel in the cerebrospinal fluid in neurocysticercosis.
de Rezende, GL; Diekmann, HW; Groll, E; Livramento, JA; Machado, LR; Nóbrega, JP; Spina-França, A, 1985
)
1.71
" mansoni, or both, were treated with praziquantel (Biltricide; Bayer-Miles) at a dosage of 40 mg/kg body weight."( Effectiveness of praziquantel against the South African strains of Schistosoma haematobium and S. mansoni.
Mosese, G; Osman, Y; Schutte, CH; Van Deventer, JM, 1983
)
0.88
" Up to now safe and successful treatment of over 25,000 patients has been documented in Africa, Asia and South America with single dose or single day dosage schemes against all five schistosome species pathogenic to man."( The profile of the trematodicidal compound praziquantel.
Wegner, DH, 1984
)
0.53
" 53 cases were treated, 33 receiving a dosage of 3 X 25 mg/kg bwt on a single day and 20 receiving the same dosage on two days; the former achieved 99."( Clonorchis sinensis: experimental and clinical studies with praziquantel in Korea.
Soh, CT, 1984
)
0.51
" This study revealed nearly 100% egg reduction in either dosage but the cure rate of the one-day dosage initially was 96% at 2 months follow-up, then 91% at 6 months and 81% at one year."( Clonorchis sinensis: epidemiology in Taiwan and clinical experience with praziquantel.
Chen, CY; Hsieh, WC, 1984
)
0.5
" Thus, the same parasitological cure could be achieved by oltipraz as well as by praziquantel, but with a lower dosage of oltipraz."( Comparative trial of oltipraz versus praziquantel in the treatment of urinary schistosomiasis in the Gabon.
Baltes, R; Burchard, GD; Dietrich, M; Kern, P, 1984
)
0.77
" Mild side effects increased in frequency as dosage increased, abdominal disturbance, vomiting and fever."( Assessment of efficacy of praziquantel against Schistosoma mansoni infection.
Anwar, WA; el Kholy, AM; Massoud, AA, 1984
)
0.57
" Side effects were mild and transient and were more frequent in higher dosage groups."( Opisthorchis viverrini: clinical experience with praziquantel in Hospital for Tropical Diseases.
Bunnag, D; Charoenlarp, P; Harinasuta, T; LooAreesuwan, S; Migasena, S; Pungpark, S; Riganti, M; Suntharasamai, P; Vanijanonta, S; Viravan, C, 1984
)
0.52
" In our clinical trials, complete cure was obtained in 10 patients given praziquantel at a dosage of 3 X 25 mg/kg body weight for 3 consecutive days and with a dosage of 3 X 25 mg/kg for 2 consecutive days, 18 (85."( Paragonimiasis: experimental and clinical experience with praziquantel in Korea.
Rim, HJ, 1984
)
0.74
" The dosage of 30 mg/kg three times a day with 5-h intervals resulted in 91."( Large scale treatment of Clonorchis sinensis infections with praziquantel under field conditions.
Lee, SH, 1984
)
0.51
" The authors recommend a single dose of praziquantel in a dosage of 15 mg/kg of body weight for the treatment of parasitosis."( Field trial on the treatment of fasciolopsiasis with praziquantel.
Bunnag, D; Harinasuta, T; Radomyos, P, 1983
)
0.78
" In the investigational phase III already under way we hope to fill those gaps and also to find the optimum dosage for large scale use under field conditions."( Trial designs for multicentre clinical studies of investigational phases I B to III with praziquantel.
Wegner, DH, 1981
)
0.48
" There were not significant differences between the three dosage groups, and the drug had no adverse haematological or biochemical effects."( Clinical experience with praziquantel in the treatment of Nigerian patients infected with S. haematobium.
Bamgboye, EA; Bammeke, AO; Kofie, BA; Oyediran, AB, 1981
)
0.57
" Two sheep were treated with praziquantel at 100 mg/kg live mass per day for 5 days, 2 sheep at the same dosage for 2 days and one animal at 50 mg/kg per day for 5 days."( Treatment of the larval stage of Taenia multiceps with praziquantel.
Tustin, RC; Verster, A, 1982
)
0.8
" japonicum were treated orally with different dosage regimens of 2-cyclohexylcarbonyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-on e(praziquantel, EMBAY 8440, Biltricide) and were autopsied and perfused 3--4 months after treatment."( The effect of praziquantel on Schistosoma haematobium, S. japonicum and S. mansoni in primates.
James, C; Nelson, GS; Sturrock, RF; Webbe, G, 1981
)
0.82
"Efficacy of an injectable formulation of praziquantel (given IM at a dosage of 5 mg/kg of body weight) against immature Echinococcus multilocularis was studied in 18 experimentally infected dogs and 22 experimentally infected cats."( Efficacy of praziquantel against immature Echinococcus multilocularis in dogs and cats.
Andersen, FL; Cox, DD; Crellin, JR, 1981
)
0.91
" These patients received Praziquantel in a dosage of 20 mg/kg bwt."( Praziquantel in clonorchiasis and opisthorchiasis.
Lang, W; Löscher, T; Nothdurft, HD; Prüfer, L; von Sonnenburg, F, 1981
)
2.01
"Dogs infected with Echinococcus granulosus were treated with praziquantel by three routes and at different dosage rates."( The effect of route of administration on the efficacy of praziquantel against Echinococcus granulosus infections in dogs.
Gemmell, MA; Johnstone, PD; Oudemans, G, 1980
)
0.75
" In infected rabbits treated repeatedly with the above-mentioned dosage of Art at 2-wk intervals (i."( [Pathological changes in the livers of rabbits infected with schistosome cercariae and treated with artemether or praziquantel in the early stage of infection].
Xiao, S; Yang, Y; Zhang, C, 1995
)
0.5
" A third study, simulating current field practice, consisted of dosing the patient four hours apart and analyzing for praziquantel in serial blood samples drawn at specified time intervals after the first and second dose."( Concentration time course of praziquantel in Filipinos with mild Schistosoma japonicum infection.
Barcelon, E; Catto, BA; Ofendo-Reyes, R; Valencia, CI; Webster, LT, 1994
)
0.79
" Larger proportion of grade I cysts were found in the group treated with albendazole at high dosage (33."( [Pathological studies on alveolar hydatid in gerbils treated with albendazole and praziquantel].
Guo, F; Li, Y; Liu, B; Sheng, Y; Zhang, J; Zheng, Q, 1994
)
0.51
"We evaluated the quantitation of two schistosome circulating antigens in serum and urine as a tool for the assessment of the efficacy of praziquantel dosage regimens (40 versus 60 mg/kgbw)."( Monitoring the efficacy of different doses of praziquantel by quantification of circulating antigens in serum and urine of schistosomiasis patients.
Bassily, S; de Jonge, N; Deelder, AM; el-Masry, N; Krijger, FW; Mansour, MM; van Lieshout, L, 1994
)
0.75
" mansoni focus in northern Senegal, following treatment with a standard dosage of 40 mg/kg."( Therapeutic evaluation of two different dose regimens of praziquantel in a recent Schistosoma mansoni focus in Northern Senegal.
Deelder, AM; Gryseels, B; Guisse, F; Mbaye, A; Ndir, O; Niang, M; Polman, K; Stelma, FF; Talla, I, 1997
)
0.54
" The authors report the results obtained in 10 patients with cystic neurocysticercosis of the fourth ventricle who were treated with albendazole at a dosage of 15 mg/kg/day for 2 weeks."( Albendazole and praziquantel treatment in neurocysticercosis of the fourth ventricle.
Correa, D; García, L; García-Torres, E; Madrazo, I; Proaño, JV, 1997
)
0.64
"kg-1 on d 21 after infection, followed by the repeated dosing once every 1 or 2 wk for 2-4 times."( Microscopic observations on livers of rabbits and dogs infected with Schistosoma japonicum cercariae and early treatment with artemether or praziquantel.
Xiao, SH; Yang, YQ; You, JQ; Zhang, CW, 1996
)
0.5
" The patient was treated with praziquantel for 3 days at a daily dosage of 75 mg/kg."( [A case of paragonimiasis westermani].
Hachiya, T; Honda, T; Kaneki, T; Kobayashi, T; Kubo, K; Okubo, Y; Sekiguchi, M; Tanaka, N; Yamamoto, H, 1998
)
0.59
" Treatment with praziquantel at a dosage of 40 mg per kilogram of body weight was given in October 1991 and October 1992 to 460 individuals (group A)."( Evidence for a long-term effect of a single dose of praziquantel on Schistosoma mansoni-induced hepatosplenic lesions in northern Uganda.
Doehring, E; Frenzel, K; Grigull, L; Loroni-Lakwo, T; Ndugwa, CM; Odongo-Aginya, E; Schweigmann, U; Spannbrucker, N; Vester, U, 1999
)
0.9
"Surprisingly low cure rates were repeatedly observed after treatment with a standard dosage of praziquantel in a recently established Schistosoma mansoni focus in northern Senegal."( The contribution of host-related factors to low cure rates of praziquantel for the treatment of Schistosoma mansoni in Senegal.
Deelder, A; Diakhate, M; Falcao Ferreira, ST; Gryseels, B; Guissé, F; Polman, K; Sow, S; Stelma, FF; van Dam, GJ; van Lieshout, L, 1999
)
0.76
"Data on age, height and mid upper-arm circumference (MUAC) from nearly 6000 schoolchildren in Ghana, Tanzania and Malawi (not MUAC) were used to examine their power to predict bodyweight and thus the dosage of praziquantel required to treat schistosomiasis."( Alternatives to bodyweight for estimating the dose of praziquantel needed to treat schistosomiasis.
Adjei, S; Bobrow, E; Bundy, D; de Graft-Johnson, J; Hall, A; Kihamia, C; Mwanri, L; Nokes, C; Wen, ST,
)
0.57
" When the dosage was increased to 600 mg/kg, after 4 h lesions on the tegument similar to those induced by Pra or L-Pra were seen, but less severe."( Tegumental changes in adult Schistosoma mansoni harboured in mice treated with praziquantel enantiomers.
Binggui, S; Chollet, J; Shuhua, X; Tanner, M, 2000
)
0.53
" Unit doses of selamectin (providing a minimum dosage of 6mgkg(-1)) were administered topically to the skin in a single spot at monthly intervals."( Efficacy and safety of selamectin against gastrointestinal nematodes in cats presented as veterinary patients.
Benchaoui, HA; Boy, MG; Clemence, RG; Jernigan, AD; Rowan, TG; Six, RH; Smith, DG; Sture, GH; Thomas, CA; Watson, P, 2000
)
0.31
" The patient was treated with praziquantel for 3 days at a daily dosage of 75 mg/kg."( [A case of paragonimiasis westermani with a high level of interleukin 5 in bronchoalveolar lavage fluid].
Hiratsuka, T; Ihiboshi, H; Katoh, S; Matsukura, S; Matsumoto, K; Matsumoto, N; Mukae, H; Tokojima, M; Yanagi, S, 2000
)
0.6
" Recently, a novel and brief dosage scheme of praziquantel has been described."( [Pharmacoeconomic analysis of the short scheme praziquantel in the treatment of neurocysticercosis].
Castañeda-Hernández, G; Mateos-García, E; Medina-Santillán, R; Reyes-García, G; Sotelo, J,
)
0.65
"Effects of PTX on the content change of hepatic TGF-beta1, type I and type III collagen in schistosomiasis japonica mice with liver fibrosis were related to the dosage of PTX, high dose PTX treated group could significantly reduce the content of TGF-beta1 (0."( Effects of pentoxifylline on the hepatic content of TGF-beta1 and collagen in Schistosomiasis japonica mice with liver fibrosis.
Cai, SQ; Luo, DD; Xiong, LJ; Zen, LL; Zhu, JF, 2003
)
0.32
"To determine the pharmacokinetics of praziquantel following single and multiple oral dosing in loggerhead sea turtles."( Plasma concentrations of praziquantel after oral administration of single and multiple doses in loggerhead sea turtles (Caretta caretta).
Harman, GR; Jacobson, ER; Laille, EJ; Maxwell, LK, 2003
)
0.9
" The patients were treated with praziquantel for 3 days at a daily dosage of 75 mg/kg and their symptoms were relieved, but one case needed additional treatment with praziquantel for 3 days at a daily dosage of 50 mg/kg because of sustained pleural effusion and a persistently high antibody titer."( [Paragonimiasis westermani caused by ingestion of Chinese freshwater crabs].
Fujikawa, T; Fujiwara, H; Kamimori, T; Miki, Y; Nakamura-Uchiyama, F; Tochino, Y; Yumine, K, 2003
)
0.6
"Mares were randomly allocated into treatment (n = 20) and control (20) groups and administered a placebo or 3 times the therapeutic dosage of ivermectin (0."( Evaluation of the safety of ivermectin-praziquantel administered orally to pregnant mares.
Alves-Branco, F; Mercier, P; Sapper, Mde F; White, CR, 2003
)
0.59
" These effects were more pronounced with dosing regimens launched before the time of oviposition."( Activity of 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine against Schistosomiasis mansoni in mice.
Botros, S; Hammam, O; Holý, A; William, S; Zídek, Z, 2003
)
0.32
"Experiments have established the high efficacy of combinations of the micronized dosage form of trichlorophen, with albendazole or medamine in treating trichocephaliasis (its causative agent being Trichocephalus muris) in DBA/2st mice and that of trichlorophen in combination with azinox or fenasal in outbred albino mice with hymenolepiasis (its causative agent being Hymenolepis nana)."( [Efficacy of the Russian anthelmintic agent trichlorophen].
Astaf'ev, BA; Fedianina, LV; Gitsu, GA; Lebedeva, MN,
)
0.13
" Bithionol is given orally at a dosage of 30-50 mg/kg but on alternate days from 10 to 15 doses."( [Fascioliasis: diagnosis, epidemiology and treatment].
Carrada-Bravo, T,
)
0.13
"4) the pole estimated an acceptable dosage (30-60 mg/kg), a performance statistically similar to that observed in African populations."( The WHO dose pole for the administration of praziquantel is also accurate in non-African populations.
Al-Awaidy, S; Allen, H; Assis, AM; Engels, D; Fenwick, A; Iwata, F; Kabatereine, NB; Montresor, A; Muth, S; Odermatt, P; Raja'a, YA; Savioli, L; Zulkifli, A, 2005
)
0.59
" This can be used as a starting point to investigate alternative administration routes or dosage forms and to examine the mechanism of intestinal absorption of PRZ."( Improvement of antischistosomal activity of praziquantel by incorporation into phosphatidylcholine-containing liposomes.
Costa, PI; Gremião, MP; Mourão, SC; Salgado, HR, 2005
)
0.59
" The recommended dosage of PZQ is a single 40 mg/kg oral dose, and each of these patients continued to pass viable Schistosoma mansoni eggs despite three successive doses at or above this level."( Current status of sensitivity to praziquantel in a focus of potential drug resistance in Egypt.
Amer, N; Bennett, JL; Botros, S; Day, TA; El-Ghannam, M; Sayed, H, 2005
)
0.61
" After drainage of pleural effusion, the patient was treated with praziquantel for three days at a daily dosage of 75 mg/kg, but without effect."( [A case of chronic pleuritis by Paragonimus Westermani infection resistant to standard chemotherapy and cured by three additional cycles of chemotherapy].
Fujikawa, T; Fujiwara, H; Kamimori, T; Mikawa, T; Miki, Y; Nakamura, F; Nisida, K; Sumitani, M; Tochino, Y, 2005
)
0.57
" In reptiles the dosage had to be increased, since the thick outer layer of the epidermis hinders the penetration of the compounds."( Effects of a combinations of emodepside and praziquantel on parasites of reptiles and rodents.
Frese, M; Harder, A; Krieger, K; Mehlhorn, H; Mevissen, I; Schmahl, G, 2005
)
0.59
"The therapeutic effect of a subcurative dosage of praziquantel (PZQ) on Schistosoma mansoni infected mice and resistance to challenged worm infection after treatment were assessed and compared with conventional treatment using a curative dosage of PZQ."( Therapeutic effect of subcurative dose praziquantel on Schistosoma mansoni infected mice and resistance to challenge infection after treatment.
Chaiworaporn, R; Janecharut, T; Kitikoon, V; Maneerat, Y; Matsuda, H; Ramasoota, P; Rojekittikhun, W, 2005
)
0.85
" To evaluate an oral PZQ dosing strategy, the pharmacokinetics of a dissolved and in feed oral PZQ preparation (40 mg kg(-1) body weight) were compared with an intravenous bolus in kingfish plasma and skin using HPLC."( Bioavailability and pharmacokinetics of a praziquantel bolus in kingfish Seriola lalandi.
Tingle, MD; Tubbs, LA, 2006
)
0.6
" Selected compounds were screened for in vitro schistosomicidal activity against Schistosoma mansoni at three different dosage levels (10, 50 and 100 microg/mL)."( Synthesis and in vitro evaluation of new benzothiazole derivatives as schistosomicidal agents.
Mahran, MA; Ramzy, F; Sembel, AM; William, S, 2007
)
0.34
"Investigations into the metabolism of drugs used in aquatic animal therapy are useful for understanding the mechanisms of xenobiotic transformation systems and can aid the development of dosing regimens."( Metabolism of praziquantel in kingfish Seriola lalandi.
Mathieson, T; Tingle, M; Tubbs, L, 2008
)
0.71
" Dogs were treated at the recommended dosage for three or five consecutive days, and a control group remained untreated."( Efficacy of Drontal Flavour Plus (50 mg praziquantel, 144 mg pyrantel embonate, 150 mg febantel per tablet) against Giardia sp in naturally infected dogs.
Dado, D; Espinosa, C; Mateo, M; Miró, G; Montoya, A, 2008
)
0.61
" PZQ given as a dosage of 60 mg/kg (1 day, 3 x 20 mg/kg doses at 4-5 hour intervals) may be as effective as a dosage of 120 mg/kg (6 days, 20 mg/kg for each day split into 3 doses at 4-5 hour intervals)."( A randomized, double-blind, placebo-controlled trial of safety and efficacy of combined praziquantel and artemether treatment for acute schistosomiasis japonica in China.
Balen, J; Ellis, M; Gray, DJ; He, YK; Hou, XY; Li, YS; Luo, XS; McManus, DP; Williams, GM, 2008
)
0.57
" Whilst administration of tribendimidine at smaller but multiple doses given within 2-3 days at the same total dosage resulted in a slightly higher worm reduction (77."( [Effect of tribendimidine, artesunate, artemether and praziquantel, administered intragastrically at single, multiple or combined doses, to rats infected with Clonorchis sinensis].
Keiser, J; Liu, XY; Qiang, HQ; Tanner, M; Utzinger, J; Xiao, SH; Xue, J; Zhang, YN, 2008
)
0.59
" Data from previous experiments were included, and negative binomial regression analyses were carried out to determine dose-response relationships and to study the effect of drug combination."( Combination chemotherapy against Clonorchis sinensis: experiments with artemether, artesunate, OZ78, praziquantel, and tribendimidine in a rat model.
Keiser, J; Smith, TA; Utzinger, J; Xiao, SH, 2009
)
0.57
" The solubility/dose ratios values of PZQ-cyclodextrin complexes calculated considering the low (150 mg) and the high dose (600 mg) of PZQ, used in practice, indicate that PZQ complexation with CDs may result in drug dosage forms that would behave as a BCS-Class I depending on the administered dose."( Effect of cyclodextrin complexation on the aqueous solubility and solubility/dose ratio of praziquantel.
Archontaki, H; Macheras, P; Maragos, S; Valsami, G, 2009
)
0.57
" sinensis, dosed orally with single agents or combination treatments and flukes recovered at 3 or 5 days post-treatment."( Effect of artemether, artesunate, OZ78, praziquantel, and tribendimidine alone or in combination chemotherapy on the tegument of Clonorchis sinensis.
Keiser, J; Vargas, M, 2010
)
0.63
" Application of this simple tool has enabled pragmatic tablet dosing using patient height as a proxy for bodyweight, allowing control programmes to expand into resource-poor settings."( An inclusive dose pole for treatment of schistosomiasis in infants and preschool children with praziquantel.
Betson, M; Day, M; Kabatereine, NB; Sousa-Figueiredo, JC; Stothard, JR, 2010
)
0.58
" The implementation of this assay to the screening of a highly diverse academic chemical library of 14,300 molecules yielded, after secondary assays and generation of dose-response curves, the identification of two natural product inhibitors, cyanidin and delphinidin."( Identification by high-throughput screening of inhibitors of Schistosoma mansoni NAD(+) catabolizing enzyme.
Haiech, J; Hibert, M; Kellenberger, E; Kuhn, I; Lobstein, A; Muller-Steffner, H; Rognan, D; Said-Hassane, F; Schuber, F; Villa, P, 2010
)
0.36
" Although monthly dog dosing achieved the highest efficiency, it required a high frequency and reliability, which were not feasible or sustainable."( An agent-based model for control strategies of Echinococcus granulosus.
Huang, L; Huang, Y; Qiu, D; Wang, Q; Xiao, N; Yi, D; Yu, W, 2011
)
0.37
" The aim of this study was to evaluate alterations in glycolysis, the tricarboxylic acid cycle and glucose concentrations caused by low dosage treatments of the hosts with albendazole and praziquantel."( Taenia crassiceps: host treatment alters glycolisis and tricarboxilic acid cycle in cysticerci.
Bezerra, JC; Costa, TL; de Souza Lino, R; Fraga, CM; Vinaud, MC, 2012
)
0.57
" No dosage significantly (p>0."( Susceptibility of a Brazilian wild rodent isolate of Schistosoma mansoni to praziquantel in mice.
Barros, Lde A; Costa-Silva, M; Garcia, JS; Machado-Silva, JR; Maldonado-Júnior, A; Neves, RH; Rodrigues-Silva, R, 2012
)
0.61
" Treatments were performed at the minimum therapeutic dosage 5 days after the experimental infection."( Treatment of third-stage larvae of Toxocara cati with milbemycin oxime plus praziquantel tablets and emodepside plus praziquantel spot-on formulation in experimentally infected cats.
Böhm, C; Schaper, R; Schnieder, T; Wolken, S, 2012
)
0.61
" Adverse events were monitored within 4h after dosing by the survey team and 24h after treatment using a questionnaire."( Efficacy and safety of two closely spaced doses of praziquantel against Schistosoma haematobium and S. mansoni and re-infection patterns in school-aged children in Niger.
Barkiré, N; Djibo, A; Fenwick, A; Garba, A; Gouvras, AN; Labbo, R; Lamine, MS; Sebangou, H; Sofo, B; Utzinger, J; Webster, JP, 2013
)
0.64
" All 8 animals were treated under anaesthesia by oral gavage with PZQ at 60 mg/kg dosing that was well tolerated."( Intestinal schistosomiasis in chimpanzees on Ngamba Island, Uganda: observations on liver fibrosis, schistosome genetic diversity and praziquantel treatment.
Adriko, M; Ajarova, L; Arinaitwe, M; Betson, M; Kabatereine, NB; Mopya, S; Mugisha, L; Rukundo, J; Standley, CJ; Stothard, JR, 2013
)
0.59
"Further research will help find the optimal dosing regimen of both these drugs in children."( Drugs for treating Schistosoma mansoni infection.
Danso-Appiah, A; Donegan, S; Olliaro, PL; Sinclair, D; Utzinger, J, 2013
)
0.39
" japonicum, the subsequent effect of an IC50 dosage of praziquantel was exacerbated, reducing motility from 47% to 27% in female worms and from 61% to 23% in males."( Transcriptional responses of in vivo praziquantel exposure in schistosomes identifies a functional role for calcium signalling pathway member CamKII.
Brindley, PJ; Gobert, GN; Hu, W; McManus, DP; Smout, MJ; You, H, 2013
)
0.91
" At the beginning of the study, the animals were weighed, randomly allocated to one of the treatment groups (n=21 each) or the control group (n=11) and dosed orally using a praziquantel-containing paste (250 mg/ml) at a dose of either 25 mg (group 1) or 50 mg (group 2) per kg of body weight."( Efficacy and safety of oral praziquantel against Dicrocoelium dendriticum in llamas.
Dadak, AM; Franz, S; Joachim, A; Wieser, C, 2013
)
0.88
"Praziquantel remains the drug of choice for schistosomiasis, but it has the low bioavailability and single dosage form."( [Progress of research on preparation and application of praziquantel].
Liu, YF; Ma, Z; Ning, A; Wu, DZ; Zhu, WF, 2013
)
2.08
"Schistosomiasis is known to occur in preschool-aged children, but achieving accurate dosing of praziquantel in its current form is challenging."( Practical dosing of praziquantel for schistosomiasis in preschool-aged children.
Chitsulo, L; Hayes, DJ; Montresor, A; Olliaro, PL; Vaillant, M, 2013
)
0.93
"We examined several dosing schemes to dose accurately (40-60 mg/kg) children aged 3-72 months (weight range 4-25 kg, based on available weight-for-age growth references from sub-Saharan Africa and Brazil, n = 106,230)."( Practical dosing of praziquantel for schistosomiasis in preschool-aged children.
Chitsulo, L; Hayes, DJ; Montresor, A; Olliaro, PL; Vaillant, M, 2013
)
0.71
"Adequate dosing can be achieved with formulations that can be split into four 150 mg quarters for children weighing 5 kg or more, and with tablets than can be split into two 300 mg halves for children weighing 10 kg or more."( Practical dosing of praziquantel for schistosomiasis in preschool-aged children.
Chitsulo, L; Hayes, DJ; Montresor, A; Olliaro, PL; Vaillant, M, 2013
)
0.71
"Formulations that can be divided into four parts (to give 150 mg increments) are preferred for children weighing less than 11 kg; the same dosing can be applied with 600 mf praziquantel formulations that can be divided into four quarters or two halves from 11 kg body weight."( Practical dosing of praziquantel for schistosomiasis in preschool-aged children.
Chitsulo, L; Hayes, DJ; Montresor, A; Olliaro, PL; Vaillant, M, 2013
)
0.91
" Proper dosage adjustment of praziquantel by bodyweight can be difficult to achieve if accurate weighing scales are unavailable."( Validating the WHO dose pole in the Philippines for school-based mass drug administration of praziquantel for morbidity control of schistosomiasis.
Belizario, VY; Chua, PL; Erfe, JM; Naig, JR, 2013
)
0.9
" A dosing interval for the prevention of clinical disease in dogs exposed to natural infections has not been established."( Efficacy of Milbemax (milbemycin oxime + praziquantel) in the treatment of dogs experimentally infected with Crenosoma vulpis.
Bourque, A; Conboy, G; Miller, L; Schenker, R; Seewald, W, 2013
)
0.66
" From day 42 sheep were orally dosed for 3 consecutive days with the same treatments in the same groups (Phase 2)."( In vivo effect of selected medicinal plants against gastrointestinal nematodes of sheep.
Ahmed, M; Laing, MD; Nsahlai, IV, 2014
)
0.4
" However, use of weighing scales to calculate praziquantel dosing in rural areas can be challenging."( Dosing of praziquantel by height in sub-Saharan African adults.
Brigham, T; Chasekwa, B; Humphrey, JH; Mbuya, MN; Palha De Sousa, CA; Prendergast, AJ; Tielsch, JM, 2014
)
1.06
" The maximum concentrations were reached 24h after dosing in the majority of the animals (six of eight cats)."( Pharmacokinetics and metabolism of eprinomectin in cats when administered in a novel topical combination of fipronil, (S)-methoprene, eprinomectin and praziquantel.
Kellermann, M; Knaus, M; Kvaternick, V; Rehbein, S; Rosentel, J, 2014
)
0.6
" In 2010 the Chinese National Echinococcosis Control Programme was implemented in Xinjiang, and includes regular dosing of domestic dogs with praziquantel."( Independent evaluation of a canine Echinococcosis Control Programme in Hobukesar County, Xinjiang, China.
Chu, X; Craig, PS; Duan, X; Feng, X; Mastin, A; Qi, X; Tao, J; van Kesteren, F; Vuitton, DA; Wen, H; Zhu, J, 2015
)
0.62
"These findings indicate that water environment affects the tissue distribution and elimination of PZQ in grass carps, the elimination in brackish water grass carps is more rapid than that in fresh water grass carps and tissue concentrations of brackish water grass carps are lower than that in freshwater grass carps after orally administrating the same dosage at the same water temperature."( Comparison of praziquantel pharmacokinetics and tissue distribution in fresh and brackish water cultured grass carp (ctenopharyngodon idellus) after oral administration of single bolus.
Hu, K; Xie, X; Yang, X; Zhao, Y, 2015
)
0.78
"Praziquantel (PZQ), an anthelmintic drug used in developing countries for the treatment of schistosome infections, was processed using the fluid bed wet granulation technology to prepare fast dispersible granules, as an appropriate and flexible dosage form for pre-school-aged children."( Development of flexible and dispersible oral formulations containing praziquantel for potential schistosomiasis treatment of pre-school age children.
Albertini, B; Dolci, LS; Passerini, N; Trastullo, R, 2015
)
2.09
" Since many people are aware that dosing with praziquantel (PZQ) is a successful treatment for an episode of the infection, there is a risk that, to avoid the long term consequences, they will engage in a cycle of infection, dosing and reinfection."( Reinfection by Opisthorchis Viverrini after Treatment with Praziquantel.
Bradshaw, P; Promthet, S; Saengsawang, P, 2016
)
0.94
" Our results indicated rapid absorption, rapid elimination, and low bioavailability of PZQ in rice field eels at the tested dosing conditions."( Pharmacokinetics and residue depletion of praziquantel in rice field eels Monopterus albus.
Ai, X; Dong, J; Xu, N; Yang, Y, 2016
)
0.7
" Praziquantel, dosed at 40 milligrams per kilogram bodyweight, is the drug of choice."( The Accuracy of Praziquantel Dose Poles for Mass Treatment of Schistosomiasis in School Girls in KwaZulu-Natal, South Africa.
Aurlund, CG; Baan, M; Gagai, S; Galappaththi-Arachchige, HN; Kjetland, EF; Taylor, M; van Lieshout, L; Vennervald, BJ, 2016
)
1.69
" In the current work, the therapeutic efficacy of different limonin dosing protocols was evaluated in experimentally infected mice harboring Schistosoma mansoni (Egyptian strain) juvenile or adult stages."( Dose-response relationship in Schistosoma mansoni juvenile and adult stages following limonin treatment in experimentally infected mice.
Abdallah, KF; Abou-Ouf, EA; Aly, NS; El-Kholy, AA; Eraky, MA; Hamdan, DI; Hammam, OA; Kishik, SM; Moharam, AF; Rashed, GA, 2016
)
0.43
" muris infection at a single oral dosing of 100 mg/kg, despite being significantly (27."( Compounds Derived from the Bhutanese Daisy, Ajania nubigena, Demonstrate Dual Anthelmintic Activity against Schistosoma mansoni and Trichuris muris.
Becker, L; Giacomin, PR; Loukas, A; Pearson, MS; Pickering, D; Smout, MJ; Sotillo, J; Wangchuk, P, 2016
)
0.43
" Monte Carlo simulations were performed to identify better, future dosing regimens."( Population Pharmacokinetics and Pharmacodynamics of Praziquantel in Ugandan Children with Intestinal Schistosomiasis: Higher Dosages Are Required for Maximal Efficacy.
Atuhaire, A; Bustinduy, AL; Corstjens, PL; de Sousa-Figueiredo, JC; Hope, WW; Kabatereine, NB; Roberts, SA; Scott, JT; Stanton, MC; Stothard, JR; Van Dam, GJ; Ward, S; Waterhouse, D, 2016
)
0.68
" However, there is no specific study on its dosage regimen for feline opisthorchiasis."( Efficacious and safe dose of praziquantel for the successful treatment of feline reservoir hosts with opisthorchiasis.
Mallory, FF; Sereerak, P; Sripa, B; Tangkawattana, P; Tangkawattana, S; Upontain, S, 2017
)
0.75
"These findings suggest that in order to reverse moderate to severe liver fibrosis due to schistosomiasis and improve clinical outcomes, a higher clinical dosage of praziquantel (i."( Biennial versus annual treatment for schistosomiasis and its impact on liver morbidity.
Guevarra, JR; Harn, DA; Inobaya, MT; Lam, AK; Li, Y; McManus, DP; Ng, SK; Olveda, DU; Olveda, RM; Ross, AG; Vinluan, ML, 2017
)
0.65
"\ Methods: The present study was mainly designed to re-evaluate the prevalence of schistosomiasis after many years of mass drug administration with praziquantel 600 mg allowing analysis of the pertinence of World Health Organisation guidelines in terms of dosing frequency, particularly in the Senegal River Basin."( Assessment of schistosomiasis prevalence among children 5 to 14 years old after several years of mass drug administration in the Senegal River basin
Abdellahi, M; Ndir, O; Niang, S, 2016
)
0.63
" Praziquantel, administered at a single 40 mg/kg dose in preventive chemotherapy programs and 3 × 25 mg/kg for individual treatment, is the drug of choice, yet information on the nature of the dose-response relationship is lacking."( Efficacy and Safety of Praziquantel Against Light Infections of Opisthorchis viverrini: A Randomized Parallel Single-Blind Dose-Ranging Trial.
Andrews, JR; Bogoch, II; Hattendorf, J; Keiser, J; Meister, I; Odermatt, P; Phongluxa, K; Sayasone, S; Senggnam, K; Vonghachack, Y; Xayavong, S, 2017
)
1.68
" Dose-response curves were predicted using Emax models."( Efficacy and Safety of Praziquantel Against Light Infections of Opisthorchis viverrini: A Randomized Parallel Single-Blind Dose-Ranging Trial.
Andrews, JR; Bogoch, II; Hattendorf, J; Keiser, J; Meister, I; Odermatt, P; Phongluxa, K; Sayasone, S; Senggnam, K; Vonghachack, Y; Xayavong, S, 2017
)
0.77
" In 2012, an echinococcosis control scheme was started that included dosing owned dogs in the Alay Valley, Kyrgyzstan with praziquantel."( Evaluation of the impact of 2 years of a dosing intervention on canine echinococcosis in the Alay Valley, Kyrgyzstan.
Craig, PS; Mastin, A; Mytynova, B; Torgerson, PR; VAN Kesteren, F, 2017
)
0.66
" The primary objective was to estimate the nature of the dose-response relation in terms of cure rate using the Kato Katz technique."( Efficacy and safety of praziquantel in preschool-aged and school-aged children infected with Schistosoma mansoni: a randomised controlled, parallel-group, dose-ranging, phase 2 trial.
Coulibaly, JT; Hattendorf, J; Keiser, J; Kovač, J; Panic, G; Silué, KD, 2017
)
0.77
"Praziquantel shows a flat dose-response and overall lower efficacy in PSAC compared with in SAC."( Efficacy and safety of praziquantel in preschool-aged and school-aged children infected with Schistosoma mansoni: a randomised controlled, parallel-group, dose-ranging, phase 2 trial.
Coulibaly, JT; Hattendorf, J; Keiser, J; Kovač, J; Panic, G; Silué, KD, 2017
)
2.21
" In view of oral solid dosage forms, various taste masking techniques can be applied encapsulating the active pharmaceutical ingredient (API) to prevent the interaction with the taste buds."( Multiparticulate system combining taste masking and immediate release properties for the aversive compound praziquantel.
Breitkreutz, J; Münster, M; Schmidt, C; Schoch, C, 2017
)
0.67
"Raised dosing of PZQ (>40 mg/kg) is being explored in young children."( Paediatric and maternal schistosomiasis: shifting the paradigms.
Bustinduy, AL; Friedman, JF; Stothard, JR, 2017
)
0.46
" Dose-response studies with racemic PZQ with or without addition of an irreversible pan-cytochrome P450 (CYP) inhibitor, 1-aminobenzotriazole (ABT), were performed."( Evaluation of the pharmacokinetic-pharmacodynamic relationship of praziquantel in the Schistosoma mansoni mouse model.
Abla, N; Haas, H; Keiser, J; Reimers, N; Spangenberg, T; Vargas, M, 2017
)
0.69
" Sample information was recorded and encompassed trade name, active ingredient name, manufacturer's name and full address, labeled medicine strength, dosage form, number of units per container, dosage statement, batch/lot number, manufacturing and expiry dates, storage information and presence of leaflets/package insert."( Quality of anthelminthic medicines available in Jimma Ethiopia.
Belew, S; D'Hondt, M; De Spiegeleer, B; Duchateau, L; Kosgei, A; Suleman, S; Wynendaele, E, 2018
)
0.48
" The nature of the dose-response relationship in terms of cure rate (CR) was the primary objective."( Efficacy and safety of ascending doses of praziquantel against Schistosoma haematobium infection in preschool-aged and school-aged children: a single-blind randomised controlled trial.
Barda, B; Coulibaly, JT; Hattendorf, J; Keiser, J; Kovač, J; N'Gbesso, YK; Panic, G; Yapi, RB, 2018
)
0.75
" The treatment protocols were performed at 14 day-intervals between each dosage of PZQ."( Experimental avian philophthalmosis: Evaluation of diagnosis and treatment of chickens infected with Philophthalmus gralli (Trematoda: Philophthalmidae).
Assis, JCA; Martins, NRS; Pinto, HA, 2018
)
0.48
" Dogs have the potential to maintain the transmission of both species of Echinococcus within local Xiji communities, and the current praziquantel dosing of dogs appears to be ineffective or poorly implemented in this area."( Estimating the prevalence of Echinococcus in domestic dogs in highly endemic for echinococcosis.
Barnes, TS; Cadavid-Restrepo, AM; Clements, AA; Fu, BQ; Gray, DJ; Jia, WZ; Li, L; Liu, CN; Lou, ZZ; McManus, DP; Williams, GM; Xu, YY; Yan, HB; Yang, YR, 2018
)
0.68
"A pioneering strategy developed by the World Health Organization (WHO) for the control of schistosomiasis was the concept of a height-based dose pole to determine praziquantel (PZQ) dosing in large-scale treatment campaigns."( Accuracy of the WHO praziquantel dose pole for large-scale community treatment of urogenital schistosomiasis in northern Mozambique: Is it time for an update?
Aurelio, HO; Campbell, CH; Dhanani, N; Fenwick, A; Ferro, J; Gazzinelli-Guimaraes, PH; King, CH; Nala, R; Phillips, AE, 2018
)
1
"The present study aimed to test the accuracy of the dose pole in determining PZQ dosage by comparing the number of tablets determined by the dose pole with the number of tablets determined according to total body weight."( Accuracy of the WHO praziquantel dose pole for large-scale community treatment of urogenital schistosomiasis in northern Mozambique: Is it time for an update?
Aurelio, HO; Campbell, CH; Dhanani, N; Fenwick, A; Ferro, J; Gazzinelli-Guimaraes, PH; King, CH; Nala, R; Phillips, AE, 2018
)
0.8
" Susceptibility of worms in vivo was first assessed during passage 5 when mice infected with PZQ-selected schistosomes were dosed with a lethal dose of 3 × 300 mg/kg PZQ resulting in only a 10% reduction in worm number compared to control treatment."( Transcriptomic analysis of reduced sensitivity to praziquantel in Schistosoma mansoni.
Bu, L; Cunningham, C; Cupit, PM; Sanchez, MC, 2019
)
0.77
" mansoni-infected mice treated with a fixed dosage of roflumilast and a variable dosage of PZQ resulted in a higher reduction in worm burden, reduced hepatic egg counts, absence of immature eggs and a marked increase in dead eggs, compared to PZQ alone."( The phosphodiesterase-4 inhibitor roflumilast impacts Schistosoma mansoni ovipositing in vitro but displays only modest antischistosomal activity in vivo.
Botros, SS; de Koning, HP; El-Lakkany, NM; Hammam, OA; Sabra, AN; Seif El-Din, SH; William, S, 2020
)
0.56
"Praziquantel (PZQ), a broad spectrum anthelmintic drug, cannot be found in acceptable dosage forms for elderly patients, paediatric patients, and for veterinary use."( First steps in the formulation of praziquantel nanosuspensions for pharmaceutical applications.
Arias, JL; Badillo-García, ML; Cerutti, SE; Delgado, ÁV; Fernández-Álvarez, F; Martínez, NA; Raba, J, 2020
)
2.28
" Those dose-response relationship was statistically significant based on chi-square test for trend (p-value <0."( Association between the Number of Repeated Praziquantel Treatments and Kidney Parenchymal Change in Northeast Thailand.
Chamadol, N; Kelly, M; Khuntikeo, N; Prathumkam, P; Thinkhamrop, B; Thinkhamrop, K; Thuanman, J, 2022
)
0.98
" Age, underweight, and double dosing were associated with increase in ADE incidence, while gender and food intake were not associated with increase in ADE incidence."( Adverse drug effects among students following mass de-worming exercise involving administration of Praziquantel and Albendazole in KEEA Municipality, Ghana.
Akrasi, W; Boye, A; Brah, AS; Essuman, MA; Osei, V, 2022
)
0.94
"Chewable gels present significant advantages over conventional dosage forms, despite their development is not comprehensively assessed."( Nanoparticle-based chewable gels of praziquantel.
Gonzalez Vidal, NL; Gonzalez, MA; Ramírez-Rigo, MV, 2023
)
1.19
" Treatment with praziquantel at a higher dosage may be required."( Case report: Infection with Dicrocoelium dendriticum in a Japanese Chin dog.
Gori, F; Oehm, AW; Schnyder, M, 2023
)
1.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
isoquinolinesA class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (56)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thioredoxin reductaseRattus norvegicus (Norway rat)Potency2.38710.100020.879379.4328AID588453; AID588456
SMAD family member 2Homo sapiens (human)Potency21.41940.173734.304761.8120AID1346859; AID1346924
PPM1D proteinHomo sapiens (human)Potency14.74030.00529.466132.9993AID1347411
SMAD family member 3Homo sapiens (human)Potency21.41940.173734.304761.8120AID1346859; AID1346924
AR proteinHomo sapiens (human)Potency24.54420.000221.22318,912.5098AID743036
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency19.73230.011212.4002100.0000AID1030
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency68.58960.000657.913322,387.1992AID1259377
regulator of G-protein signaling 4Homo sapiens (human)Potency5.31820.531815.435837.6858AID504845
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency17.67300.01237.983543.2770AID1346984; AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency33.39350.001310.157742.8575AID1259252; AID1259253
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency25.72610.003041.611522,387.1992AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency34.85930.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency44.46620.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency25.66210.005428.02631,258.9301AID1346982; AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency36.26280.000229.305416,493.5996AID743069; AID743075; AID743079
cytochrome P450 2D6Homo sapiens (human)Potency34.67130.00108.379861.1304AID1645840
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency30.38760.001019.414170.9645AID743094; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency24.48760.023723.228263.5986AID743222
arylsulfatase AHomo sapiens (human)Potency19.01151.069113.955137.9330AID720538
aryl hydrocarbon receptorHomo sapiens (human)Potency12.19720.000723.06741,258.9301AID743122
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency14.12540.10009.191631.6228AID1346983
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.00320.540617.639296.1227AID2364; AID2528
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency0.12590.316212.443531.6228AID902
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency61.00630.000323.4451159.6830AID743065
mitogen-activated protein kinase 1Homo sapiens (human)Potency25.11890.039816.784239.8107AID995
survival motor neuron protein isoform dHomo sapiens (human)Potency1.41250.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency19.95260.031610.279239.8107AID884; AID885
M-phase phosphoprotein 8Homo sapiens (human)Potency89.12510.177824.735279.4328AID488949
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency39.81070.00419.962528.1838AID2675
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency28.37090.00106.000935.4813AID943; AID944
lamin isoform A-delta10Homo sapiens (human)Potency35.48130.891312.067628.1838AID1487
neuropeptide S receptor isoform AHomo sapiens (human)Potency6.30960.015812.3113615.5000AID1461
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Interferon betaHomo sapiens (human)Potency14.74030.00339.158239.8107AID1347411
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency19.95261.000012.224831.6228AID885
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency37.93300.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpRattus norvegicus (Norway rat)IC50 (µMol)153.30000.40002.75008.6000AID1209456
Bile salt export pumpHomo sapiens (human)IC50 (µMol)74.72330.11007.190310.0000AID1209455; AID1449628; AID1473738
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
karyopherin alpha 2 (RAG cohort 1, importin alpha 1), isoform CRA_bHomo sapiens (human)EC50 (µMol)500.00000.918141.9368121.5000AID435026
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (71)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (28)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (279)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID644990Antischistosomal activity against adult Schistosoma japonicum assessed as worm survival at 80 uM after 24 hrs relative to control2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Praziquantel derivatives exhibit activity against both juvenile and adult Schistosoma japonicum.
AID1453196Fraction absorbed in po dosed dog2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1412378Antischistosomal activity against Schistosoma japonicum infected in mouse at 50 mg/kg/day, po treated for 5 days measured after day 5 post last dose by ELISA2018MedChemComm, Feb-01, Volume: 9, Issue:2
Design, synthesis and bioactivities of phenithionate analogues or derivatives for anti-schistosomiasis.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1752683Antischistosomal activity against Schistosoma japonicum infected in ICR mouse assessed as total worm reduction at 250 mg/kg, po administered as single dose relative to control2020RSC medicinal chemistry, Apr-01, Volume: 11, Issue:4
Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?
AID1878024Antischistosomal activity against Schistosoma mansoni Liberian adult worms assessed as reduction in worm viability measured after 72 hrs by microscopy2022Bioorganic & medicinal chemistry letters, 03-01, Volume: 59Antischistosomal tetrahydro-γ-carboline sulfonamides.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1453192Drug level in human plasma after 1 to 2 hrs2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine.
AID1453193Half life in human2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID763660Antischistosomal activity against Schistosoma mansoni assessed as mortality at 50 ug/ml after 24 hrs by microscopic analysis2013European journal of medicinal chemistry, Aug, Volume: 66Nonclassical antifolates, part 4. 5-(2-aminothiazol-4-yl)-4-phenyl-4H-1,2,4-triazole-3-thiols as a new class of DHFR inhibitors: synthesis, biological evaluation and molecular modeling study.
AID299627Antischistosomal activity against Schistosoma mansoni assessed as 100% killing of schistosomes2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Praziquantel derivatives I: Modification of the aromatic ring.
AID1686673Intrinsic clearance in human liver microsome in presence of NADPH-regenerating system incubated over 60 mins by LC-MS analysis2016Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23
Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).
AID1686672Kinetic solubility of compound at pH 6.5 phosphate buffer by nephelometry2016Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23
Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).
AID1683378Selectivity index, ratio of CC50 for cytotoxicity against human HaCaT cells to LC50 for antischistosomal activity against Schistosoma mansoni BH
AID1671490Concentration required to kill 50% of 21 day old worms 5 days after drug treatment.2021PLoS neglected tropical diseases, 07, Volume: 15, Issue:7
The discovery of a novel series of compounds with single-dose efficacy against juvenile and adult Schistosoma species.
AID645148Antischistosomal activity against juvenile Schistosoma japonicum assessed as worm survival at 100 uM after 48 hrs relative to control2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Praziquantel derivatives exhibit activity against both juvenile and adult Schistosoma japonicum.
AID1453195Fraction absorbed in po dosed rat2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine.
AID704018Antischistosomal activity against Schistosoma mansoni NTS incubated for 72 hrs2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Identification of antischistosomal leads by evaluating bridged 1,2,4,5-tetraoxanes, alphaperoxides, and tricyclic monoperoxides.
AID563685Antischistosomal activity against Schistosoma mansoni isolated from infected Syrian golden hamsters assessed as worm mortality at 5 uM treated for overnight followed by drug washout measured on day 52009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Antischistosomal activity of hexadecyloxypropyl cyclic 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine and other alkoxyalkyl esters of acyclic nucleoside phosphonates assessed by schistosome worm killing in vitro.
AID1898603Antischistosomal activity against adult stage of Schistosoma mansoni assessed as inhibition of oviposition at 0.0095 to 10 uM measured after 72 hrs2021European journal of medicinal chemistry, Dec-15, Volume: 226Anti-schistosomal activities of quinoxaline-containing compounds: From hit identification to lead optimisation.
AID1412376Antischistosomal activity against Schistosoma japonicum infected in mouse at 50 mg/kg/day, po treated for 5 days measured after day 4 post last dose by ELISA2018MedChemComm, Feb-01, Volume: 9, Issue:2
Design, synthesis and bioactivities of phenithionate analogues or derivatives for anti-schistosomiasis.
AID1281539Antischistosomal activity against adult stage of Schistosoma japonicum infected in ICR mouse assessed as reduction of parasite burden at 400 mg/kg, po administered as single dose measured after 14 days2016Bioorganic & medicinal chemistry letters, Mar-01, Volume: 26, Issue:5
Antischistosomal activity of N,N'-arylurea analogs against Schistosoma japonicum.
AID1222793Dissociation constant, pKa of the compound2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Which metabolites circulate?
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1671496Concentration required to kill 50% MRC-5 cells as detected by Alamar blue staining2021PLoS neglected tropical diseases, 07, Volume: 15, Issue:7
The discovery of a novel series of compounds with single-dose efficacy against juvenile and adult Schistosoma species.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1453194Fraction absorbed in po dosed human2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1784198Antischistosomal activity against Schistosoma mansoni schistosomula at 20 uM incubated for 48 hrs by Alamar Blue assay2021European journal of medicinal chemistry, Dec-05, Volume: 225Synthesis, structure-activity relationships, cocrystallization and cellular characterization of novel smHDAC8 inhibitors for the treatment of schistosomiasis.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1784199Cytotoxicity against human HEK293 assessed as reduction in cell viability at 50 uM measured for 24 hrs by Alamar Blue assay2021European journal of medicinal chemistry, Dec-05, Volume: 225Synthesis, structure-activity relationships, cocrystallization and cellular characterization of novel smHDAC8 inhibitors for the treatment of schistosomiasis.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1209455Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID645122Antischistosomal activity against adult Schistosoma japonicum assessed as worm survival at 100 uM after 48 hrs relative to control2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Praziquantel derivatives exhibit activity against both juvenile and adult Schistosoma japonicum.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1671487Concentration required to kill 50% of 84 day old worms 5 days after drug treatment.2021PLoS neglected tropical diseases, 07, Volume: 15, Issue:7
The discovery of a novel series of compounds with single-dose efficacy against juvenile and adult Schistosoma species.
AID299629Antischistosomal activity against Schistosoma mansoni assessed as complete spastic paralysis2007Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15
Praziquantel derivatives I: Modification of the aromatic ring.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID475952Antischistosomal activity in juvenile Schistosoma mansoni infected in mouse assessed as total worm reduction at 400 mg/kg, po after 28 days2010Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
Praziquantel analogs with activity against juvenile Schistosoma mansoni.
AID1412372Antischistosomal activity against Schistosoma japonicum infected in mouse at 50 mg/kg/day, po treated for 5 days measured after day 2 post last dose by ELISA2018MedChemComm, Feb-01, Volume: 9, Issue:2
Design, synthesis and bioactivities of phenithionate analogues or derivatives for anti-schistosomiasis.
AID1898595Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay2021European journal of medicinal chemistry, Dec-15, Volume: 226Anti-schistosomal activities of quinoxaline-containing compounds: From hit identification to lead optimisation.
AID475955Antischistosomal activity in adult Schistosoma mansoni infected in mouse assessed as female worm reduction at 400 mg/kg, po after 28 days2010Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
Praziquantel analogs with activity against juvenile Schistosoma mansoni.
AID1412382Antischistosomal activity against Schistosoma japonicum infected in mouse at 50 mg/kg/day, po treated for 5 days measured after day 7 post last dose by ELISA2018MedChemComm, Feb-01, Volume: 9, Issue:2
Design, synthesis and bioactivities of phenithionate analogues or derivatives for anti-schistosomiasis.
AID644991Antischistosomal activity against adult Schistosoma japonicum assessed as worm survival at 100 uM after 24 hrs relative to control2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Praziquantel derivatives exhibit activity against both juvenile and adult Schistosoma japonicum.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1209456Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID563684Antischistosomal activity against Schistosoma mansoni isolated from infected Syrian golden hamsters assessed as worm mortality at 12.5 uM treated for overnight followed by drug washout measured on day 5 relative to control2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Antischistosomal activity of hexadecyloxypropyl cyclic 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine and other alkoxyalkyl esters of acyclic nucleoside phosphonates assessed by schistosome worm killing in vitro.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1627142Antischistosomal activity against adult male Schistosoma mansoni BH assessed as inhibition of parasite motility after 72 hrs by HCS microscopic analysis2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
Discovery of New Anti-Schistosomal Hits by Integration of QSAR-Based Virtual Screening and High Content Screening.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1671488Concentration required to kill 50% of 42 day old worms 5 days after drug treatment.2021PLoS neglected tropical diseases, 07, Volume: 15, Issue:7
The discovery of a novel series of compounds with single-dose efficacy against juvenile and adult Schistosoma species.
AID1412363Antischistosomal activity against Schistosoma japonicum imago derived from infected mouse assessed as reduction in imago viability after 72 hrs2018MedChemComm, Feb-01, Volume: 9, Issue:2
Design, synthesis and bioactivities of phenithionate analogues or derivatives for anti-schistosomiasis.
AID1453198Tmax in human2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine.
AID645125Antischistosomal activity against adult Schistosoma japonicum assessed as worm survival at 50 uM after 72 hrs relative to control2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Praziquantel derivatives exhibit activity against both juvenile and adult Schistosoma japonicum.
AID1412387Acute toxicity in po dosed mouse infected with Schistosoma japonicum treated for 5 days2018MedChemComm, Feb-01, Volume: 9, Issue:2
Design, synthesis and bioactivities of phenithionate analogues or derivatives for anti-schistosomiasis.
AID1898617Selectivity index, ratio of CC50 for human HepG2 cells measured after 72 hrs to EC50 for antischistosomal activity against Schistosoma mansoni Puerto-Rican schistosomula measured after 72 hrs2021European journal of medicinal chemistry, Dec-15, Volume: 226Anti-schistosomal activities of quinoxaline-containing compounds: From hit identification to lead optimisation.
AID755556Antiparasitic activity against Schistosoma japonicum assessed as worm survival at 50 uM incubated for 16 hrs measured after 48 hrs2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Development of a novel class of pyrrolo-[1,2,5]benzothiadiazepine derivatives as potential anti-schistosomal agents.
AID645155Antischistosomal activity against juvenile Schistosoma japonicum assessed as worm survival at 100 uM after 72 hrs relative to control2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Praziquantel derivatives exhibit activity against both juvenile and adult Schistosoma japonicum.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1627143Antischistosomal activity against adult female Schistosoma mansoni BH assessed as inhibition of parasite motility up to 72 hrs by HCS microscopic analysis2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
Discovery of New Anti-Schistosomal Hits by Integration of QSAR-Based Virtual Screening and High Content Screening.
AID1453211Antiparasitic activity against Schistosoma mansoni in patient assessed as cure rate by measuring reduction in eggs in stool at 60 mg/kg/day for 3 consecutive days measured up to day 180 post dose relative to control2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1686676Antischistosomal activity against Schistosoma mansoni infected in NMRI mouse assessed as reduction in total worm burden at 100 mg/kg, po administered as single dose starting on day 49 post-infection and measured at 28 days post treatment relative to contr2016Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23
Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).
AID1532038Antischistosomal activity against adult stage of Schistosoma mansoni cercariae after 72 hrs by microscopic analysis2018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
SAR of a new antischistosomal urea carboxylic acid.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1412371Antischistosomal activity against Schistosoma japonicum infected in mouse at 25 mg/kg/day, po treated for 5 days measured after day 2 post last dose by ELISA2018MedChemComm, Feb-01, Volume: 9, Issue:2
Design, synthesis and bioactivities of phenithionate analogues or derivatives for anti-schistosomiasis.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1453204Protein binding in plasma (unknown origin) relative to control2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine.
AID1453190Apparent permeability in human Caco2 cells2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine.
AID1453205Drug excretion in human urine up to 4 days2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine.
AID1898619Antischistosomal activity against adult stage of Schistosoma mansoni assessed as inhibition of oviposition at 0.0024 to 10 uM measured after 72 hrs2021European journal of medicinal chemistry, Dec-15, Volume: 226Anti-schistosomal activities of quinoxaline-containing compounds: From hit identification to lead optimisation.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1474016Ratio of drug concentration at steady state in human at 20 to 25 mg/kg, po TID after 8 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1686674Intrinsic clearance in mouse liver microsome in presence of NADPH-regenerating system incubated over 60 mins by LC-MS analysis2016Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23
Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).
AID1453197Fraction absorbed in po dosed monkey2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine.
AID1474015Drug concentration at steady state in human at 20 to 25 mg/kg, po TID after 8 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1671489Concentration required to kill 50% of 42 day old worms 5 days after drug treatment.2021PLoS neglected tropical diseases, 07, Volume: 15, Issue:7
The discovery of a novel series of compounds with single-dose efficacy against juvenile and adult Schistosoma species.
AID1412380Antischistosomal activity against Schistosoma japonicum infected in mouse at 50 mg/kg/day, po treated for 5 days measured after day 6 post last dose by ELISA2018MedChemComm, Feb-01, Volume: 9, Issue:2
Design, synthesis and bioactivities of phenithionate analogues or derivatives for anti-schistosomiasis.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1412386Antischistosomal activity against Schistosoma japonicum infected in mouse at 50 mg/kg/day, po treated for 5 days measured after day 9 post last dose by ELISA2018MedChemComm, Feb-01, Volume: 9, Issue:2
Design, synthesis and bioactivities of phenithionate analogues or derivatives for anti-schistosomiasis.
AID755555Antiparasitic activity against Schistosoma japonicum assessed as worm survival at 50 uM incubated for 16 hrs measured after 72 hrs2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Development of a novel class of pyrrolo-[1,2,5]benzothiadiazepine derivatives as potential anti-schistosomal agents.
AID212406Cestocidal activity against Taenia pisiformis in a group of 4 dogs when administered orally at 5 mg/kg, in gelatin capsule1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Synthesis and anthelmintic activity of a series of pyrazino[2,1-a][2]benzazepine derivatives.
AID1412370Antischistosomal activity against Schistosoma japonicum infected in mouse at 50 mg/kg/day, po treated for 5 days measured after day 1 post last dose by ELISA2018MedChemComm, Feb-01, Volume: 9, Issue:2
Design, synthesis and bioactivities of phenithionate analogues or derivatives for anti-schistosomiasis.
AID562282Antiparasitic activity against Schistosoma mansoni assessed as parasite death at 5 ug/ml2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activities of trioxaquines against Schistosoma mansoni.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1209457Unbound Cmax in human plasma2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID1898586Antischistosomal activity against Schistosoma mansoni Puerto-Rican schistosomula assessed as phenotypic changes measured after 72 hrs2021European journal of medicinal chemistry, Dec-15, Volume: 226Anti-schistosomal activities of quinoxaline-containing compounds: From hit identification to lead optimisation.
AID322084Antimicrobial activity against Schistosoma mansoni assessed as worm vitality at 1 uM after 4 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Bis-acridines as lead antiparasitic agents: structure-activity analysis of a discrete compound library in vitro.
AID1453202Antiparasitic activity against Schistosoma in intestinal schistosomiasis patient assessed as cure rate at 40 mg/kg2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine.
AID563683Antischistosomal activity against Schistosoma mansoni isolated from infected Syrian golden hamsters assessed as worm mortality at 25 uM treated for overnight followed by drug washout measured on day 5 relative to control2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Antischistosomal activity of hexadecyloxypropyl cyclic 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine and other alkoxyalkyl esters of acyclic nucleoside phosphonates assessed by schistosome worm killing in vitro.
AID562275Antiparasitic activity against Schistosoma mansoni larva assessed as reduction of body contractility and movement at 50 ug/ml2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activities of trioxaquines against Schistosoma mansoni.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID645121Antischistosomal activity against adult Schistosoma japonicum assessed as worm survival at 80 uM after 48 hrs relative to control2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Praziquantel derivatives exhibit activity against both juvenile and adult Schistosoma japonicum.
AID562274Antiparasitic activity against Schistosoma mansoni assessed as parasite death at 10 ug/ml2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activities of trioxaquines against Schistosoma mansoni.
AID1183304Inhibition of Schistosoma mansoni recombinant thioredoxin glutathione reductase assessed as 5-thio-2nitrobezoic acid formation after 3 mins2014European journal of medicinal chemistry, Sep-12, Volume: 84New praziquantel derivatives containing NO-donor furoxans and related furazans as active agents against Schistosoma mansoni.
AID644984Antischistosomal activity against adult Schistosoma japonicum assessed as worm survival at 50 uM after 24 hrs relative to control2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Praziquantel derivatives exhibit activity against both juvenile and adult Schistosoma japonicum.
AID475950Antischistosomal activity against adult Schistosoma mansoni assessed as motility reduction at 10 ug/ml after 120 hrs2010Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
Praziquantel analogs with activity against juvenile Schistosoma mansoni.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1671495Percentage of worms remaining following treatment of female CD1 mice infected with S. mansoni worms (21 day old - juvenile or 42 day old - adult) with compound by oral gavage. Worms were recovered by portal perfusion with citrate saline 8-14 days post tre2021PLoS neglected tropical diseases, 07, Volume: 15, Issue:7
The discovery of a novel series of compounds with single-dose efficacy against juvenile and adult Schistosoma species.
AID1683377Cytotoxicity against human HaCaT cells assessed as reduction in cell viability after 48 hrs by MTT assay
AID645156Antischistosomal activity against adult Schistosoma japonicum infected in mouse assessed as total worm reduction at 200 mg/kg, po administered 21 days after infection relative to control2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Praziquantel derivatives exhibit activity against both juvenile and adult Schistosoma japonicum.
AID475951Antischistosomal activity against adult Schistosoma mansoni assessed as morphological changes at 10 ug/ml after 120 hrs2010Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
Praziquantel analogs with activity against juvenile Schistosoma mansoni.
AID563680Antischistosomal activity against Schistosoma mansoni isolated from infected Syrian golden hamsters assessed as worm mortality at 100 uM treated for overnight followed by drug washout measured on day 5 relative to control2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Antischistosomal activity of hexadecyloxypropyl cyclic 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine and other alkoxyalkyl esters of acyclic nucleoside phosphonates assessed by schistosome worm killing in vitro.
AID475953Antischistosomal activity in juvenile Schistosoma mansoni infected in mouse assessed as female worm reduction at 400 mg/kg, po after 28 days2010Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
Praziquantel analogs with activity against juvenile Schistosoma mansoni.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1752685Schistosomicidal-activity against adult Schistosoma japonicum at 10 uM incubated for 72 hrs by inverted microscopic method relative to control2020RSC medicinal chemistry, Apr-01, Volume: 11, Issue:4
Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1412375Antischistosomal activity against Schistosoma japonicum infected in mouse at 25 mg/kg/day, po treated for 5 days measured after day 4 post last dose by ELISA2018MedChemComm, Feb-01, Volume: 9, Issue:2
Design, synthesis and bioactivities of phenithionate analogues or derivatives for anti-schistosomiasis.
AID1686670Protein binding in immobilized human serum albumin by HPLC analysis2016Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23
Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1878023Antischistosomal activity against Schistosoma mansoni Liberian adult worms assessed as reduction in worm viability at 3.3 uM measured after 72 hrs by microscopy relative to control2022Bioorganic & medicinal chemistry letters, 03-01, Volume: 59Antischistosomal tetrahydro-γ-carboline sulfonamides.
AID1474014AUC in human at 20 to 25 mg/kg, po TID after 8 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1183308Antiparasitic activity against Schistosoma mansoni infected in female Swiss-Webster mouse assessed as worm killing at 10 uM after 48 hrs by stereomicroscopy2014European journal of medicinal chemistry, Sep-12, Volume: 84New praziquantel derivatives containing NO-donor furoxans and related furazans as active agents against Schistosoma mansoni.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1627151Inhibition of papaya papain using Z-FR-AMC fluorogenic peptide substrate preincubated for 5 mins followed by substrate addition2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
Discovery of New Anti-Schistosomal Hits by Integration of QSAR-Based Virtual Screening and High Content Screening.
AID475954Antischistosomal activity in adult Schistosoma mansoni infected in mouse assessed as total worm reduction at 400 mg/kg, po after 28 days2010Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
Praziquantel analogs with activity against juvenile Schistosoma mansoni.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1453213Antiparasitic activity against Schistosoma mansoni in patient assessed as reduction in eggs per gram of rectal mucosa at 60 mg/kg/day for 3 consecutive days measured up to day 180 post dose relative to control2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine.
AID562280Antiparasitic activity against Schistosoma mansoni adult worm assessed as reduction of body contractility and movement at 5 ug/ml2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activities of trioxaquines against Schistosoma mansoni.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID322086Antimicrobial activity against Schistosoma mansoni assessed as worm vitality at 6 uM after 4 hrs2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Bis-acridines as lead antiparasitic agents: structure-activity analysis of a discrete compound library in vitro.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1183305Antiparasitic activity against Schistosoma mansoni cercariae infected in female Swiss-Webster mouse assessed as worm contraction at 50 uM after 24 to 48 hrs by stereomicroscopy2014European journal of medicinal chemistry, Sep-12, Volume: 84New praziquantel derivatives containing NO-donor furoxans and related furazans as active agents against Schistosoma mansoni.
AID1412383Antischistosomal activity against Schistosoma japonicum infected in mouse at 25 mg/kg/day, po treated for 5 days measured after day 8 post last dose by ELISA2018MedChemComm, Feb-01, Volume: 9, Issue:2
Design, synthesis and bioactivities of phenithionate analogues or derivatives for anti-schistosomiasis.
AID645132Antischistosomal activity against adult Schistosoma japonicum assessed as worm survival at 100 uM after 72 hrs relative to control2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Praziquantel derivatives exhibit activity against both juvenile and adult Schistosoma japonicum.
AID212403Minimum inhibitory concentration to prevent all movement of cysts and evaginated scoleces of in vitro Taenia crassiceps screen after 48 h1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
Synthesis and anthelmintic activity of a series of pyrazino[2,1-a][2]benzazepine derivatives.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID639983Antischistosomal activity against Schistosoma mansoni assessed as worm survival incubated for overnight followed by drug washout measured on day 72012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Synthesis of new praziquantel analogues: potential candidates for the treatment of schistosomiasis.
AID1453191Cmax in human after 1 to 2 hrs2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine.
AID704019Antischistosomal activity against adult Schistosoma mansoni schistosomes incubated for 72 hrs2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Identification of antischistosomal leads by evaluating bridged 1,2,4,5-tetraoxanes, alphaperoxides, and tricyclic monoperoxides.
AID475958Antischistosomal activity against adult Schistosoma mansoni2010Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
Praziquantel analogs with activity against juvenile Schistosoma mansoni.
AID1412369Antischistosomal activity against Schistosoma japonicum infected in mouse at 25 mg/kg/day, po treated for 5 days measured after day 1 post last dose by ELISA2018MedChemComm, Feb-01, Volume: 9, Issue:2
Design, synthesis and bioactivities of phenithionate analogues or derivatives for anti-schistosomiasis.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID755554Antiparasitic activity against Schistosoma japonicum adult worm infected in ICR mouse assessed as worm reduction at 200 mg/kg, po administered for 3 days measured after 21 days2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Development of a novel class of pyrrolo-[1,2,5]benzothiadiazepine derivatives as potential anti-schistosomal agents.
AID1683380Selectivity index, ratio of CC50 for cytotoxicity against human SH-SY5Y cells to LC50 for antischistosomal activity against Schistosoma mansoni BH
AID1412381Antischistosomal activity against Schistosoma japonicum infected in mouse at 25 mg/kg/day, po treated for 5 days measured after day 7 post last dose by ELISA2018MedChemComm, Feb-01, Volume: 9, Issue:2
Design, synthesis and bioactivities of phenithionate analogues or derivatives for anti-schistosomiasis.
AID1532040Antischistosomal activity against Schistosoma mansoni cercariae infected in NMRI mouse assessed as worm burden reduction at 100 mg/kg, po administered as single dose on day 49 of post infection and measured on day 21 of post treatment relative to control2018Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24
SAR of a new antischistosomal urea carboxylic acid.
AID645115Antischistosomal activity against adult Schistosoma japonicum assessed as worm survival at 50 uM after 48 hrs relative to control2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Praziquantel derivatives exhibit activity against both juvenile and adult Schistosoma japonicum.
AID1296354Antiparasitic activity against schistosomula stage of Schistosoma mansoni assessed as parasite viability at 20 uM after 48 hrs by Alamar Blue assay relative to control2016Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6
Structure-Based Design and Synthesis of Novel Inhibitors Targeting HDAC8 from Schistosoma mansoni for the Treatment of Schistosomiasis.
AID1412373Antischistosomal activity against Schistosoma japonicum infected in mouse at 25 mg/kg/day, po treated for 5 days measured after day 3 post last dose by ELISA2018MedChemComm, Feb-01, Volume: 9, Issue:2
Design, synthesis and bioactivities of phenithionate analogues or derivatives for anti-schistosomiasis.
AID1142193Anthelmintic activity against sexually mature Schistosoma mansoni PR-1 adult worm assessed as parasite death by measuring worm contractility at 1 uM incubated for overnight measured after 7 days drug wash-out period by stereomicroscopic analysis2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Design and synthesis of molecular probes for the determination of the target of the anthelmintic drug praziquantel.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1671491Dose administered in treatment of female CD1 mice infected with S. mansoni worms (21 day old - juvenile or 42 day old - adult) with compound by oral gavage. Worms were recovered by portal perfusion with citrate saline 8-14 days post treatment and counted.2021PLoS neglected tropical diseases, 07, Volume: 15, Issue:7
The discovery of a novel series of compounds with single-dose efficacy against juvenile and adult Schistosoma species.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID537630Inhibition of Schistosoma mansoni recombinant NAD+ glycohydrolase expressed in Pichia pastoris at up to 100 uM by continuous fluorometric method2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Identification by high-throughput screening of inhibitors of Schistosoma mansoni NAD(+) catabolizing enzyme.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1412385Antischistosomal activity against Schistosoma japonicum infected in mouse at 25 mg/kg/day, po treated for 5 days measured after day 9 post last dose by ELISA2018MedChemComm, Feb-01, Volume: 9, Issue:2
Design, synthesis and bioactivities of phenithionate analogues or derivatives for anti-schistosomiasis.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID645141Antischistosomal activity against juvenile Schistosoma japonicum assessed as worm survival at 100 uM after 24 hrs relative to control2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Praziquantel derivatives exhibit activity against both juvenile and adult Schistosoma japonicum.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1627146Cytotoxicity against human WSS1 cells assessed as reduction in cell viability after 48 hrs by resazurin assay2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
Discovery of New Anti-Schistosomal Hits by Integration of QSAR-Based Virtual Screening and High Content Screening.
AID755557Antiparasitic activity against Schistosoma japonicum assessed as worm survival at 50 uM incubated for 16 hrs measured after 24 hrs2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Development of a novel class of pyrrolo-[1,2,5]benzothiadiazepine derivatives as potential anti-schistosomal agents.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID704022Selectivity index, ratio of IC50 for rat L6 cells to IC50 for adult Schistosoma mansoni schistosomes2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Identification of antischistosomal leads by evaluating bridged 1,2,4,5-tetraoxanes, alphaperoxides, and tricyclic monoperoxides.
AID1187809Antischistosomal activity against adult Schistosoma japonicum infected in ICR Kunming mouse assessed as worm reduction at 200 mg/kg, po for 5 days beginning on day 14 after infection (Rvb = 0%)2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Development of chiral praziquantel analogues as potential drug candidates with activity to juvenile Schistosoma japonicum.
AID1453189In vivo antiparasitic activity against Schistosoma mansoni assessed as reduction in egg count in urine at 40 to 60 mg/kg relative to control2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine.
AID1142196Anthelmintic activity against sexually mature Schistosoma mansoni PR-1 adult worm assessed as parasite death incubated for overnight measured after 7 days drug wash-out period by stereomicroscopic analysis2014Bioorganic & medicinal chemistry letters, Jun-01, Volume: 24, Issue:11
Design and synthesis of molecular probes for the determination of the target of the anthelmintic drug praziquantel.
AID1412374Antischistosomal activity against Schistosoma japonicum infected in mouse at 50 mg/kg/day, po treated for 5 days measured after day 3 post last dose by ELISA2018MedChemComm, Feb-01, Volume: 9, Issue:2
Design, synthesis and bioactivities of phenithionate analogues or derivatives for anti-schistosomiasis.
AID1683370Antischistosomal activity against Schistosoma mansoni BH cercariae infected in mouse assessed as reduction in worm burden at 400 mg/kg, po administered as single dose starting on day 49 post-infection and measured after 14 days post treatment relative to
AID1683376Antischistosomal activity against Schistosoma mansoni BH assessed as reduction in parasitic viability after 72 hrs by inverted microscopic method
AID1453188In vivo antiparasitic activity against Schistosoma mansoni assessed as cure rate at 40 to 60 mg/kg relative to control2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID563682Antischistosomal activity against Schistosoma mansoni isolated from infected Syrian golden hamsters assessed as worm mortality at 50 uM treated for overnight followed by drug washout measured on day 5 relative to control2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Antischistosomal activity of hexadecyloxypropyl cyclic 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine and other alkoxyalkyl esters of acyclic nucleoside phosphonates assessed by schistosome worm killing in vitro.
AID1683379Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability after 48 hrs by MTT assay
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1412362Antischistosomal activity against Schistosoma japonicum larva derived from infected mouse assessed as reduction in larva viability after 72 hrs2018MedChemComm, Feb-01, Volume: 9, Issue:2
Design, synthesis and bioactivities of phenithionate analogues or derivatives for anti-schistosomiasis.
AID704021Cytotoxicity against rat L6 cells incubated for 690 hrs by Alamar blue assay2012Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20
Identification of antischistosomal leads by evaluating bridged 1,2,4,5-tetraoxanes, alphaperoxides, and tricyclic monoperoxides.
AID1296353Antiparasitic activity against schistosomula stage of Schistosoma mansoni assessed as parasite viability at 10 uM after 48 hrs by Alamar Blue assay relative to control2016Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6
Structure-Based Design and Synthesis of Novel Inhibitors Targeting HDAC8 from Schistosoma mansoni for the Treatment of Schistosomiasis.
AID1898585Antischistosomal activity against Schistosoma mansoni Puerto-Rican schistosomula assessed as inhibition of parasite motility measured after 72 hrs2021European journal of medicinal chemistry, Dec-15, Volume: 226Anti-schistosomal activities of quinoxaline-containing compounds: From hit identification to lead optimisation.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1686669Octanol/water partition coefficient, logD of the compound at pH 7.4 by HPLC analysis2016Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23
Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).
AID1671492Number of days since CD1 mice infected with S. mansoni cercariae2021PLoS neglected tropical diseases, 07, Volume: 15, Issue:7
The discovery of a novel series of compounds with single-dose efficacy against juvenile and adult Schistosoma species.
AID1453206Protein binding in plasma (unknown origin)2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1898594Antischistosomal activity against adult stage of Schistosoma mansoni assessed as inhibition of parasite motility measured after 72 hrs2021European journal of medicinal chemistry, Dec-15, Volume: 226Anti-schistosomal activities of quinoxaline-containing compounds: From hit identification to lead optimisation.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID563686Antischistosomal activity against Schistosoma mansoni isolated from infected Syrian golden hamsters assessed as worm mortality treated for overnight followed by drug washout measured on day 52009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Antischistosomal activity of hexadecyloxypropyl cyclic 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine and other alkoxyalkyl esters of acyclic nucleoside phosphonates assessed by schistosome worm killing in vitro.
AID1412384Antischistosomal activity against Schistosoma japonicum infected in mouse at 50 mg/kg/day, po treated for 5 days measured after day 8 post last dose by ELISA2018MedChemComm, Feb-01, Volume: 9, Issue:2
Design, synthesis and bioactivities of phenithionate analogues or derivatives for anti-schistosomiasis.
AID1183307Antiparasitic activity against Schistosoma mansoni infected in female Swiss-Webster mouse assessed as worm killing at 50 uM after 48 hrs by stereomicroscopy2014European journal of medicinal chemistry, Sep-12, Volume: 84New praziquantel derivatives containing NO-donor furoxans and related furazans as active agents against Schistosoma mansoni.
AID1453201Solubility of the compound2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1686671Kinetic solubility of the compound in 0.01 M HCl at pH 2 by nephelometry2016Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23
Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID562273Antiparasitic activity against Schistosoma mansoni larva assessed as reduction of body contractility and movement at 5 ug/ml2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activities of trioxaquines against Schistosoma mansoni.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1898618Selectivity index, ratio of CC50 for human HepG2 cells measured after 72 hrs to EC50 for antischistosomal activity against adult stage of Schistosoma mansoni measured after 72 hrs2021European journal of medicinal chemistry, Dec-15, Volume: 226Anti-schistosomal activities of quinoxaline-containing compounds: From hit identification to lead optimisation.
AID562281Antiparasitic activity against Schistosoma mansoni adult worm assessed as reduction of body contractility and movement at 50 ug/ml2009Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11
In vitro activities of trioxaquines against Schistosoma mansoni.
AID1686675Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay2016Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23
Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).
AID1453199Binding affinity to albumin (unknown origin)2017Bioorganic & medicinal chemistry, 07-01, Volume: 25, Issue:13
Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine.
AID1784197Antischistosomal activity against Schistosoma mansoni schistosomula at 10 uM incubated for 48 hrs by Alamar Blue assay2021European journal of medicinal chemistry, Dec-05, Volume: 225Synthesis, structure-activity relationships, cocrystallization and cellular characterization of novel smHDAC8 inhibitors for the treatment of schistosomiasis.
AID1686683Antischistosomal activity against juvenile Schistosoma mansoni cercariae infected in mouse assessed as effective dose causing reduction in worm burden2016Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23
Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).
AID645157Antischistosomal activity against juvenile Schistosoma japonicum infected in mouse assessed as total worm reduction at 200 mg/kg, po administered 14 days after infection relative to control2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Praziquantel derivatives exhibit activity against both juvenile and adult Schistosoma japonicum.
AID1183306Antiparasitic activity against Schistosoma mansoni cercariae infected in female Swiss-Webster mouse assessed as worm contraction at 10 uM after 24 to 48 hrs by stereomicroscopy2014European journal of medicinal chemistry, Sep-12, Volume: 84New praziquantel derivatives containing NO-donor furoxans and related furazans as active agents against Schistosoma mansoni.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1627132Antischistosomal activity against Schistosoma mansoni BH schistosomula assessed as inhibition of parasite motility after 48 hrs by HCS microscopic analysis2016Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15
Discovery of New Anti-Schistosomal Hits by Integration of QSAR-Based Virtual Screening and High Content Screening.
AID1898588Antischistosomal activity against adult stage of Schistosoma mansoni assessed as cessation of worm motility at 0.0095 to 10 uM measured after 72 hrs2021European journal of medicinal chemistry, Dec-15, Volume: 226Anti-schistosomal activities of quinoxaline-containing compounds: From hit identification to lead optimisation.
AID1412379Antischistosomal activity against Schistosoma japonicum infected in mouse at 25 mg/kg/day, po treated for 5 days measured after day 6 post last dose by ELISA2018MedChemComm, Feb-01, Volume: 9, Issue:2
Design, synthesis and bioactivities of phenithionate analogues or derivatives for anti-schistosomiasis.
AID1898596Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2021European journal of medicinal chemistry, Dec-15, Volume: 226Anti-schistosomal activities of quinoxaline-containing compounds: From hit identification to lead optimisation.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID563681Antischistosomal activity against Schistosoma mansoni isolated from infected Syrian golden hamsters assessed as worm mortality at 75 uM treated for overnight followed by drug washout measured on day 5 relative to control2009Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12
Antischistosomal activity of hexadecyloxypropyl cyclic 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine and other alkoxyalkyl esters of acyclic nucleoside phosphonates assessed by schistosome worm killing in vitro.
AID1412377Antischistosomal activity against Schistosoma japonicum infected in mouse at 25 mg/kg/day, po treated for 5 days measured after day 5 post last dose by ELISA2018MedChemComm, Feb-01, Volume: 9, Issue:2
Design, synthesis and bioactivities of phenithionate analogues or derivatives for anti-schistosomiasis.
AID645131Antischistosomal activity against adult Schistosoma japonicum assessed as worm survival at 80 uM after 72 hrs relative to control2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Praziquantel derivatives exhibit activity against both juvenile and adult Schistosoma japonicum.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4,197)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990783 (18.66)18.7374
1990's775 (18.47)18.2507
2000's837 (19.94)29.6817
2010's1329 (31.67)24.3611
2020's473 (11.27)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 61.65

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index61.65 (24.57)
Research Supply Index8.53 (2.92)
Research Growth Index4.72 (4.65)
Search Engine Demand Index172.07 (26.88)
Search Engine Supply Index3.13 (0.95)

This Compound (61.65)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials423 (9.15%)5.53%
Reviews426 (9.21%)6.00%
Case Studies880 (19.03%)4.05%
Observational2 (0.04%)0.25%
Other2,894 (62.57%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (46)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Study on the Role of Antioxidant Micronutrients on the Reversal of Schistosomal Peri-portal Fibrosis of the Liver. [NCT01260012]414 participants (Anticipated)Interventional2010-01-31Recruiting
Praziquantel Pharmacokinetics in Pregnancy and During Lactation [NCT01288872]Phase 147 participants (Actual)Interventional2012-01-31Completed
A Proof-of-concept Trial to Evaluate Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children [NCT03893097]Phase 3726 participants (Actual)Interventional2019-10-14Completed
Prevention of HIV and Improved Diagnosis of Adolescent Genital Disease in Bilharzia Endemic KwaZulu-Natal, South Africa [NCT01154907]6,500 participants (Anticipated)Observational2010-04-30Recruiting
A Phase I, Open-label, Randomized, Three-period, Crossover, Partial Replicated, Reference-scaled, Single Center Trial to Assess the Bioequivalence of a Single Oral Dose of 1200 mg of the New Cisticid 600 mg Tablet Formulation Versus Comparator Biltricide [NCT03437447]Phase 160 participants (Actual)Interventional2018-06-18Completed
Open-label, Dose-finding, 2-parts, Efficacy Phase II Study With Three Formulations (Racemate Raziquantel Commercial Oral Tablets, New Oral Disintegrating Tablets of Racemate Praziquantel and L-praziquantel) in Schistosomiasis (S. Mansoni) Infected Childre [NCT02806232]Phase 2444 participants (Actual)Interventional2016-06-12Completed
Impact of Parasitic Infections on Intestinal Epithelial Barrier and Immune Activation Among Persons Living With HIV in Lilongwe, Malawi [NCT05323396]100 participants (Anticipated)Interventional2022-05-02Active, not recruiting
Phase II PK/PD Driven Dose Finding Trial of Praziquantel in Children Under Four [NCT03640377]Phase 2600 participants (Anticipated)Interventional2021-02-01Recruiting
An Open Label, Phase III Efficacy and Safety Study of L-PZQ ODT in Schistosoma Infected Children 3 Months to 6 Years of Age, Including a 2:1 Randomized, Controlled Cohort of Schistosoma Mansoni Infected Children 4 to 6 Years of Age Treated With L PZQ ODT [NCT03845140]Phase 3311 participants (Actual)Interventional2019-09-02Completed
Efficacy of Chinese-made Versus WHO-PQ Praziquantel for Treatment of Schistosoma Haematobium in Zanzibar: a Randomized Controlled Trial [NCT03133832]Phase 3120 participants (Anticipated)Interventional2017-04-10Recruiting
Prospective, Observational Study to Assess the Performance of CAA Measurement as a Diagnostic Tool for the Detection of Schistosoma Haematobium Infections in Pregnant Women and Their Newborn and Child in Lambaréné, Gabon [NCT03779347]Phase 3100 participants (Anticipated)Interventional2019-05-01Recruiting
Effect of Schistosomiasis Mansoni and Its Treatment on HIV Susceptibility and Female Genital Immunology [NCT02878564]Phase 434 participants (Actual)Interventional2016-03-31Completed
Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST): An Open Label, Randomized Controlled Trial of Single vs. Multiple Treatments of Praziquantel in Intestinal African Schistosomiasis in Côte d'Ivoire [NCT02868385]Phase 3167 participants (Actual)Interventional2018-10-01Completed
Effects of Arachidonic Acid Supplementation on Schistosomiasis Mansoni Infection in Egyptian School Children [NCT02144389]335 participants (Actual)Interventional2013-01-31Completed
A Phase I, Open-label, Randomized, Four-period, Crossover, Fully Replicated, Reference-scaled, Single Center Study to Assess the Bioequivalence of a Single Oral Dose of 1200 mg of the Coated Cesol Tablet Formulation Versus Comparator Biltricide® in Health [NCT04314037]Phase 136 participants (Actual)Interventional2020-06-17Completed
Parasitologic Impact of Different Mass Drug Administration Strategies Against Schistosoma Mansoni in Endemic Areas of Mwanza Region, Tanzania, Where Prevalence is 25% or Above [NCT02162875]37,500 participants (Anticipated)Interventional2011-03-31Completed
Study of Reproductive Health in Rural Madagascar With Emphasis on Urogenital Schistosomiasis and Sexually Transmitted Infections [NCT00713999]680 participants (Actual)Interventional2001-08-31Completed
Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study [NCT04115072]Phase 2/Phase 3116 participants (Actual)Interventional2019-09-03Completed
Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in Subjects With Schistosomiasis: A Pilot Study [NCT02734186]Phase 40 participants (Actual)Interventional2016-04-06Withdrawn
Gaps in Helminth Control: Safety and Efficacy of Drug Combinations Against Triple Infections [NCT01050517]250 participants (Anticipated)Interventional2007-10-31Completed
Open-label, Randomized Clinical Trial in Kenya to Determine the Effectiveness of Artesunate + Sulfamethoxypyrazine/Pyrimethamine Vs. Praziquantel in the Treatment of S. Mansoni in Children [NCT01054651]Phase 3212 participants (Actual)Interventional2009-10-31Completed
Gaps in Helminth Control: Safety and Efficacy of Drug Combinations. Praziquantel Study [NCT01050374]650 participants (Anticipated)Interventional2007-10-31Completed
Intestinal Schistosomiasis in Children Aged 1-5 Years,Morbidity Assessment and the Effect of Praziquantel on Morbidity; Along Lake Victoria Shorelines. [NCT01901484]Phase 2800 participants (Anticipated)Interventional2012-12-31Completed
The Effect of One Versus Two Praziquantel Treatments on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria in Uganda [NCT00215267]540 participants (Anticipated)Interventional2005-09-30Completed
Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Highly Endemic Areas of Northeastern Brazil [NCT00403611]Phase 4196 participants (Actual)Interventional2006-03-31Completed
Can Anthelminthic Treatment Delay the Progression of HIV? Randomised Open-label Trial Testing Presumptive Anthelminthic Treatment on Progression of HIV in ART-naïve HIV-positive Patients in a Rural African Setting With Presumed High Prevalence of Helminth [NCT00817713]295 participants (Actual)Interventional2009-01-31Terminated(stopped due to Terminated prematurely due to recruitment difficulties. Expansion to more study sites not planned.)
Assessing the Effect of Neglected Tropical Diseases on Plasmodium Falciparum Transmission in an Area of Co-endemicity [NCT02769013]380 participants (Actual)Observational2016-04-30Completed
Prevalence of Potential Schistosome Hybrids and Their Invasive Capacity Under Praziquantel Pressure in Northern Senegal [NCT04635553]250 participants (Anticipated)Observational2020-08-11Recruiting
Randomized Double Blind Clinical Trial in Mali, Comparing the Effectiveness of Artesunate + Sulfamethoxypyrazine/Pyrimethamine Versus Praziquantel in the Treatment of S. Haematobium in Children [NCT00510159]Phase 2/Phase 3800 participants (Actual)Interventional2007-08-31Completed
Empiric Therapy of Helminth Co-infection to Reduce HIV-1 Disease Progression [NCT00507221]948 participants (Actual)Interventional2008-02-29Completed
The Influence of Transmission Season on Outcome of Schistosoma Haematobium Infection Treatment Among School Children in Urban and Peri-Urban Areas of Maputo and Matola, Mozambique [NCT00231322]520 participants Interventional2004-03-31Completed
A Phase I, Open-label, Randomized, Four-period, Crossover, Single Center Trial to Assess the Relative Bioavailability of a Single Oral Dose of the New 150 mg Oral Dispersible Tablet (ODT) Formulation of Praziquantel (PZQ), MSC1028703A, at Different Dose L [NCT02325713]Phase 132 participants (Actual)Interventional2015-01-31Completed
The Effect of Schistosome and Soil-transmitted Helminth Infections on Malaria,Infection, Morbidity and Antibody Response Among School and Pre-school Children in Mwanza, Tanzania [NCT00347113]620 participants (Anticipated)Interventional2006-07-31Completed
Safety and Efficacy of Mirazid for Schistosomiasis Treatment as Compared to Praziquantel: An Open-label Randomized Non-placebo-Controlled Study [NCT01529710]Phase 3200 participants (Actual)Interventional2011-12-31Completed
Epidemiology of Human Immunodeficiency Virus (HIV-1) and Schistosoma Mansoni Co-infections and Its Impact on Anthelminthic Treatment Outcome Among HIV-1 Infected Individuals in Fishing Communities in Mwanza Region, Northwestern Tanzania. [NCT01541631]2,000 participants (Anticipated)Interventional2012-05-31Not yet recruiting
S. Japonicum and Pregnancy Outcomes: A Randomized, Double Blind, Placebo Controlled Trial (RCT) [NCT00486863]Phase 2370 participants (Actual)Interventional2007-08-31Completed
Taenia Solium Elimination Versus Control: What is the Best Way Forward for Sub-Saharan Africa? [NCT02612896]2,900 participants (Actual)Interventional2016-03-31Completed
Phase1,Randomized,Open-Label,Parallel-Group,Relative Bioavailability Study to Investigate PK,Including Food Effect,Safety and Tolerability of Single Doses of New Immediate Release Tablet Formulations of Emodepside (BAY 44-4400),Compared to Oral Solution,i [NCT03383523]Phase 177 participants (Actual)Interventional2017-10-26Completed
Efficacy and Safety of Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine Regimens Delivered Through Intermittent Preventive Treatment in Schoolchildren of Democratic Republic of Congo: A Randomised Control Trial [NCT01722539]Phase 3616 participants (Actual)Interventional2012-11-30Completed
Schistosoma Haematobium Infections Among Schoolchildren in Central Sudan One Year After Treatment With Praziquantel [NCT01558336]Phase 3520 participants (Actual)Interventional2008-08-31Completed
The Impact of Intermittent Preventive Malaria Treatment With Artemisinin Combination Therapy (ACT) on Hemoglobin, Malaria, Schistosomiasis, and School Attention Among Primary Schoolchildren in the Kassena-Nankana Districts, Ghana [NCT01459146]Phase 4345 participants (Anticipated)Interventional2010-12-31Recruiting
Feasibility and Effectiveness of Delivering Mass Drug Administration for Helminths Through the Seasonal Malaria Chemoprevention (SMC) Platform in a West African Paediatric Population [NCT05354258]600 participants (Anticipated)Interventional2022-06-16Active, not recruiting
A Phase I, Open-Label, Randomized, Single Dose, Five Period, Crossover, Single Center Trial To Assess The Relative Bioavailability Of The 150 mg ODT Formulation Of L PZQ (MSC2499550A) Versus The Current 500 mg PZQ Commercial Racemate Tablet Formulation In [NCT02271984]Phase 136 participants (Actual)Interventional2014-10-31Completed
Clinical Evaluation of Ujiplus®, a Porridge Snack With Deworming Properties for Activity Against Schistosoma Mansoni [NCT04679831]Phase 2/Phase 3400 participants (Actual)Interventional2021-05-06Completed
Antiparasitic Therapy for Neurocysticercosis: Phase II/III Study on Safety and Efficacy of Combined Treatment With Praziquantel and Albendazole [NCT00441285]Phase 2/Phase 3156 participants (Actual)Interventional2010-01-31Completed
A Randomized Trial of Combined Albendazole Plus Praziquantel for Subarachnoid Cysticercosis of the Sylvian Fissure or the Basal Cisterns [NCT02947581]Phase 3107 participants (Actual)Interventional2016-11-14Terminated(stopped due to Albendazole and albendazole placebo are not available in our local suppliers or in the international market. Consequently, it is no possible to re-initiate the enrollment to complete the original sample size.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00441285 (7) [back to overview]PK Substudy - Area Under the Curve of Praziquantel by Antiepileptic Drug in Treatment Days 10 and 11
NCT00441285 (7) [back to overview]PK Substudy - Area Under the Curve of Albendazole in Treatment in Day 1
NCT00441285 (7) [back to overview]PK Substudy - Area Under the Curve of Albendazole in Treatment Days 10 and 11
NCT00441285 (7) [back to overview]Phase III Trial - Proportion of Patients Without Remaining Live Cysts
NCT00441285 (7) [back to overview]PK Substudy - Safety of Combined Albendazole Plus Praziquantel Therapy
NCT00441285 (7) [back to overview]PK Substudy - Maximum Concentration of Albendazole
NCT00441285 (7) [back to overview]PK Substudy - Area Under the Curve of Praziquantel by Antiepileptic Drug in Treatment Day 1
NCT00486863 (17) [back to overview]Number of Participants Reporting Abnormalities in Clinical Chemistry Assessments Within 24 Hours of Dosing
NCT00486863 (17) [back to overview]Newborn Median Serum Transferrin Receptor:Ferritin Ratio
NCT00486863 (17) [back to overview]4-hydroxy Praziquantel Pharmacokinetic Concentrations
NCT00486863 (17) [back to overview]Number of Subjects With Reduction in S. Japonicum Egg Counts From Screening to 22 Weeks Gestation of Greater Than 90 Percent
NCT00486863 (17) [back to overview]Number of Participants Whose Pregnancy Resulted in a Live Birth
NCT00486863 (17) [back to overview]Number of Participants Whose Infant Was Born With Congenital Anomalies
NCT00486863 (17) [back to overview]Number of Participants Reporting Serious Adverse Events Within 24 Hours of Dosing
NCT00486863 (17) [back to overview]Number of Participants Experiencing Fetal Loss by Abortion
NCT00486863 (17) [back to overview]Median Maternal Hepcidin at 32 Weeks Gestation
NCT00486863 (17) [back to overview]Median Change in Maternal Transferrin Receptor:Ferritin Ratio From 14 to 32 Weeks Gestation
NCT00486863 (17) [back to overview]Mean Newborn Birth Weight
NCT00486863 (17) [back to overview]Mean Change in Maternal Weight From 14 to 32 Weeks Gestation
NCT00486863 (17) [back to overview]Mean Change in Maternal Thigh Skinfold Thickness From 14 to 32 Weeks Gestation
NCT00486863 (17) [back to overview]Mean Change in Maternal Hemoglobin From 14 to 32 Weeks Gestation
NCT00486863 (17) [back to overview]Number of Participants With Pre-eclampsia
NCT00486863 (17) [back to overview]Number of Participants Reporting Abnormalities in Hematology Assessments Within 24 Hours of Dosing
NCT00486863 (17) [back to overview]Praziquantel Pharmacokinetic Concentrations
NCT02271984 (14) [back to overview]Palatability Score
NCT02271984 (14) [back to overview]Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs, TEAEs Leading to Death and TEAEs Leading to Discontinuation
NCT02271984 (14) [back to overview]Number of Subjects With Clinical Significant Laboratory Abnormalities, Electrocardiogram (ECG), Physical Examination and Vital Signs Reported as Treatment Emergent Adverse Events
NCT02271984 (14) [back to overview]Time to Reach the Maximum Plasma Concentration (Tmax) of L-Praziquantel (L-PZQ)
NCT02271984 (14) [back to overview]Time Prior to the First Measurable (Non-zero) Concentration (Tlag) of L-Praziquantel (L-PZQ)
NCT02271984 (14) [back to overview]Maximum Observed Concentration in Plasma (Cmax) of L-Praziquantel (L-PZQ) After Dose Adjustment
NCT02271984 (14) [back to overview]Extrapolated Area Under the Concentration Time Curve (AUC) From Time Tlast to Infinity Given as Percentage From AUC0-inf (AUCextra) of L-Praziquantel (L-PZQ)
NCT02271984 (14) [back to overview]Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of L-Praziquantel (L-PZQ) After Dose Adjustment
NCT02271984 (14) [back to overview]Relative Bioavailability (Frel) of L-Praziquantel (L-PZQ)
NCT02271984 (14) [back to overview]Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUC0-inf) Adj of L-Praziquantel (L-PZQ) After Dose Adjustment
NCT02271984 (14) [back to overview]Apparent Volume of Distribution During the Terminal Phase (Vz/f) of L-Praziquantel (L-PZQ)
NCT02271984 (14) [back to overview]Apparent Total Body Clearance of Drug From Plasma (CL/f) of L-Praziquantel (L-PZQ)
NCT02271984 (14) [back to overview]Apparent Terminal Half-life (T1/2) of L-Praziquantel (L-PZQ)
NCT02271984 (14) [back to overview]Apparent Terminal Elimination Rate Constant (Lambda Z) of L-Praziquantel (L-PZQ)
NCT02325713 (15) [back to overview]Apparent Terminal Half-life (t1/2) of L-PZQ, D-PZQ, and Racemate PZQ
NCT02325713 (15) [back to overview]Apparent Total Body Clearance of Drug From Plasma (CL/f) of L-PZQ, D-PZQ, and Racemate PZQ
NCT02325713 (15) [back to overview]Apparent Volume of Distribution During the Terminal Phase (Vz/f) of L-PZQ, D-PZQ, and Racemate PZQ
NCT02325713 (15) [back to overview]Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to Infinity (AUC0-inf) Adjusted for the Actual Administered Dose (AUC0-inf, Adj) of D-PZQ and Racemate PZQ
NCT02325713 (15) [back to overview]AUC From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) Adjusted for the Actual Administered Dose (AUC0-t, Adj) of L-PZQ, D-PZQ, and Racemate PZQ
NCT02325713 (15) [back to overview]Extrapolated Area Under the Plasma Concentration Curve From Time Tlast to Infinity (AUCextra) of L-PZQ, D-PZQ, and Racemate PZQ
NCT02325713 (15) [back to overview]Maximum Observed Concentration in Plasma (Cmax) Adjusted for the Actual Administered Dose (Cmax, Adj) of L-PZQ, D-PZQ and Racemate PZQ
NCT02325713 (15) [back to overview]Number of Subjects With Treatment-emergent Adverse (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation
NCT02325713 (15) [back to overview]Palatability Assessment Based on Visual Analog Scale (VAS) Score
NCT02325713 (15) [back to overview]Relative Bioavailability (Frel) of L-PZQ, D-PZQ, and Racemate PZQ
NCT02325713 (15) [back to overview]Number of Subjects With Clinically Significant Change From Baseline in Vital Signs, Physical Examinations, Electrocardiogram (ECG) and Laboratory Parameters
NCT02325713 (15) [back to overview]Time to Reach Maximum Plasma Concentration (Tmax) of L-PZQ, D-PZQ, and Racemate PZQ
NCT02325713 (15) [back to overview]Time Prior to the First Measurable (Non-zero) Concentration (Tlag) of L-PZQ, D-PZQ, and Racemate PZQ
NCT02325713 (15) [back to overview]Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUC0-inf) Adjusted for the Actual Administered Dose (AUC0-inf, Adj) of L-Praziquantel (L-PZQ)
NCT02325713 (15) [back to overview]Apparent Terminal Elimination Rate Constant (λz) of L-PZQ, D-PZQ, and Racemate PZQ
NCT02806232 (3) [back to overview]Egg Reduction Rate (Percent)
NCT02806232 (3) [back to overview]Number of Participants With Clinical Cure Determined by Kato-Katz Method
NCT02806232 (3) [back to overview]Number of Participants With Clinical Cure Determined by Point-of-Care Circulating Cathodic Antigen (POC-CCA) Test
NCT03383523 (8) [back to overview]Safety and Tolerability as Measured by Number of Participants With Clinical Laboratory Tests Findings
NCT03383523 (8) [back to overview]PK (AUC0-7d) of Two New Tablet Formulations of Emodepside in Comparison to the Liquid Formulation (LSF) Oral Solution.
NCT03383523 (8) [back to overview]PK (Cmax) of Two New Tablet Formulations of Emodepside in Comparison to the Liquid Formulation (LSF) Oral Solution.
NCT03383523 (8) [back to overview]Safety and Tolerability as Measured by Number of Participants With Vital Signs Findings
NCT03383523 (8) [back to overview]Safety and Tolerability as Measured by Number of Participants With Treatment-related Adverse Events
NCT03383523 (8) [back to overview]Safety and Tolerability as Measured by Number of Participants With 12-lead ECG Findings
NCT03383523 (8) [back to overview]Safety and Tolerability as Measured by Number of Participants With Neurological Examination Findings
NCT03383523 (8) [back to overview]Safety and Tolerability as Measured by Number of Participants With Physical Examination Findings
NCT03437447 (16) [back to overview]Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)
NCT03437447 (16) [back to overview]Terminal Elimination Half-Life (t1/2) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)
NCT03437447 (16) [back to overview]Apparent Volume of Distribution During Terminal Phase (Vd/f) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)
NCT03437447 (16) [back to overview]Number of Participants With Clinically Significant Abnormalities in Vital Signs
NCT03437447 (16) [back to overview]Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters
NCT03437447 (16) [back to overview]Number of Participants With Clinically Significant Abnormalities in 12-lead Electrocardiogram (ECG) Findings
NCT03437447 (16) [back to overview]Maximum Observed Plasma Concentration (Cmax) of Racemate PZQ (Rac-PZQ)
NCT03437447 (16) [back to overview]Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Racemate PZQ (Rac-PZQ)
NCT03437447 (16) [back to overview]Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of L-Praziquantel (L-PZQ)
NCT03437447 (16) [back to overview]Maximum Observed Plasma Concentration (Cmax) of L-Praziquantel (L-PZQ)
NCT03437447 (16) [back to overview]Apparent Clearance (CL/f) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)
NCT03437447 (16) [back to overview]Time to Reach Maximum Plasma Concentration (Tmax) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)
NCT03437447 (16) [back to overview]Time Prior to the First Measurable (Non-zero) Concentration (Tlag) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)
NCT03437447 (16) [back to overview]Terminal Elimination Rate Constant (Lambda Z) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)
NCT03437447 (16) [back to overview]Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs
NCT03437447 (16) [back to overview]Extrapolated Area Under the Plasma Concentration Curve From Time Tlast to Infinity (AUCextra) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)
NCT04314037 (16) [back to overview]Terminal Elimination Half-Life (T1/2) of Racemic-Praziquantel (Rac-PZQ), R-(-)-PZQ and S-(+)-PZQ
NCT04314037 (16) [back to overview]Number of Participants With Treatment Emergent Adverse Events (TEAEs) by Severity According to Qualitative Toxicity Scale
NCT04314037 (16) [back to overview]Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Related TEAEs
NCT04314037 (16) [back to overview]Maximum Observed Plasma Concentration (Cmax) of Praziquantel (PZQ) Enantiomers: R-(-)-PZQ and S-(+) PZQ
NCT04314037 (16) [back to overview]Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Praziquantel (PZQ) Enantiomers: R-(-)-PZQ and S-(+)-PZQ
NCT04314037 (16) [back to overview]Apparent Volume of Distribution During Terminal Phase (Vz/f) of Racemic-Praziquantel (Rac-PZQ), R-(-)-PZQ and S-(+)-PZQ
NCT04314037 (16) [back to overview]Time to Reach Maximum Plasma Concentration (Tmax) of Racemic-Praziquantel (Rac-PZQ), R-(-)-PZQ and S-(+)-PZQ
NCT04314037 (16) [back to overview]Apparent Clearance (CL/f) of Racemic-Praziquantel (Rac-PZQ), R-(-)-PZQ and S-(+)-PZQ
NCT04314037 (16) [back to overview]Number of Participants With Clinically Significant Changes From Baseline in 12-Lead Electrocardiogram (ECG) Findings
NCT04314037 (16) [back to overview]Number of Participants With Clinically Relevant Changes From Baseline in Vital Signs
NCT04314037 (16) [back to overview]Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Racemic-Praziquantel (Rac-PZQ), R-(-)-PZQ and S-(+)-PZQ
NCT04314037 (16) [back to overview]Maximum Observed Plasma Concentration (Cmax) of Racemic-Praziquantel (Rac-PZQ)
NCT04314037 (16) [back to overview]Number of Participants With Clinically Relevant Changes From Baseline in Laboratory Parameters
NCT04314037 (16) [back to overview]Time Prior to the First Measurable (Non-zero) Concentration (Tlag) of Racemic-Praziquantel (Rac-PZQ), R-(-)-PZQ and S-(+)-PZQ
NCT04314037 (16) [back to overview]Terminal Rate Constant (Lambda z) of Racemic-Praziquantel (Rac-PZQ), R-(-)-PZQ and S-(+)-PZQ
NCT04314037 (16) [back to overview]Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Racemic-Praziquantel (Rac-PZQ)

PK Substudy - Area Under the Curve of Praziquantel by Antiepileptic Drug in Treatment Days 10 and 11

- To evaluate the kinetic disposition of Praziquantel by antiepileptic drug after the last praziquantel dose, we calculated the Area Under the Curve of Praziquantel with Carbamazepine or Phenytoin (NCT00441285)
Timeframe: 0.5, 1, 1.5, 2, 3, 4, 8, 10, 12, 24 and 36 hours post dose on treatment days 10-11

Interventionng*h/ml (Mean)
Carbamazepine240.2
Phenytoin550.1

[back to top]

PK Substudy - Area Under the Curve of Albendazole in Treatment in Day 1

- To evaluate kinetic disposition of Albendazole we calculated the Area under the curve of the active metabolite of Albendazole (Albendazole Sulphoxide) with Praziquantel or Placebo (of Praziquantel). (NCT00441285)
Timeframe: 0, 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 12 hours post dose on Treatment day 1

Interventionng*h/mL (Mean)
Albendazole + Praziquantel1412.2
Albendazole + Placebo1111

[back to top]

PK Substudy - Area Under the Curve of Albendazole in Treatment Days 10 and 11

- To evaluate kinetic disposition of Albendazole we calculated the Area under the curve of the active metabolite of Albendazole (Albendazole Sulphoxide) with Praziquantel or Placebo (of Praziquantel). (NCT00441285)
Timeframe: 0.5, 1, 1.5, 2, 3, 4, 8, 10, 12, 24 and 36 hours post dose on Treatment days 10-11

Interventionng*h/ml (Mean)
Albendazole + Praziquantel4925.3
Albendazole + Placebo2969.6

[back to top]

Phase III Trial - Proportion of Patients Without Remaining Live Cysts

Proportion of patients whose 6 month MR does not show viable parasites anymore (NCT00441285)
Timeframe: Day 180

Interventionparticipants (Number)
Phase III Trial - ABZ+PZQ25
Phase III Trial - Increased ABZ19
Phase III Trial - Standard ABZ15

[back to top]

PK Substudy - Safety of Combined Albendazole Plus Praziquantel Therapy

- Describe if some Serious Adverse Event was associated to combined Albendazole plus Praziquantel therapy. (NCT00441285)
Timeframe: 90 days post tx

InterventionEvents (Number)
Albendazole + Praziquantel0
Albendazole + Placebo0

[back to top]

PK Substudy - Maximum Concentration of Albendazole

Highest serum level of Albendazole measured from all level assessments in the curve. (NCT00441285)
Timeframe: Treatment day 1 and Treatment days 10-11

Interventionng/mL (Mean)
Albendazole + Praziquantel1293.9
Albendazole + Placebo2232.8

[back to top]

PK Substudy - Area Under the Curve of Praziquantel by Antiepileptic Drug in Treatment Day 1

- To evaluate the kinetic disposition of Praziquantel by antiepileptic drug after the last praziquantel dose, we calculated the Area Under the Curve of Praziquantel with Carbamazepine or Phenytoin (NCT00441285)
Timeframe: 0, 0.5, 1, 1.5, 2, 3, 4, 8, 10 and 12 hours post dose in treatment day 1

Interventionng*h / mL (Mean)
Carbamazepine (n=8)Phenytoin (n=8)
Albendazole + Praziquantel548.3923.7

[back to top]

Number of Participants Reporting Abnormalities in Clinical Chemistry Assessments Within 24 Hours of Dosing

Toxicity to maternal kidney and liver was assessed by laboratory parameters collected just before and 24 hours after dosing. Specifically, blood was drawn just before the dose at 12-16 weeks gestation to determine baseline blood urea nitrogen (BUN), creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and bilirubin. Blood was then drawn 24 hours after the second part of the split dose and before discharge from the hospital to assess any changes in these parameters. Any values that were 1.1 times the upper limit of normal or greater for the parameter were considered abnormal. (NCT00486863)
Timeframe: Just before and 24 hours after dosing

,
Interventionparticipants (Number)
Blood Urea Nitrogen (BUN) AbnormalCreatinine AbnormalAspartate Aminotransferase (AST) AbnormalAlanine Aminotransferase (ALT) AbnormalBilirubin Abnormal
Placebo Control at 12-16 Weeks Gestation12723813127
Praziquantel at 12-16 Weeks Gestation13739910137

[back to top]

Newborn Median Serum Transferrin Receptor:Ferritin Ratio

To assess total body iron, the serum transferrin receptor:ferritin ratio was assessed in the infant. At delivery, a heel stick blood sample and a cord blood sample were collected for assessment of total body iron by determination of the transferrin receptor:ferritin ratio. (NCT00486863)
Timeframe: 0-6 days after delivery.

,
Interventionratio (Median)
Cord BloodHeel Stick
Placebo Control at 12-16 Weeks Gestation1.760.00
Praziquantel at 12-16 Weeks Gestation1.330.00

[back to top]

4-hydroxy Praziquantel Pharmacokinetic Concentrations

Since pregnancy is associated with increased cytochrome P450 activity and physiologic changes in the gastrointestinal tract that tend to reduce drug absorption, praziquantel pharmacokinetics may be affected by pregnancy. Thus, the metabolite-to-parent drug ratio may serve as a differential marker to help determine if variability in drug exposure following oral administration during pregnancy is due to altered metabolism or drug absorption. Samples that were collected from subjects who were randomized to receive praziquantel were analyzed for praziquantel and 4-hydroxy praziquantel concentrations. Assays were performed using high performance liquid chromatography-electrospray mass spectrometry in the University of California at San Diego Pediatric Clinical Pharmacology Laboratory. Descriptive statistics were obtained for concentrations at each of the four sparse sampling timepoints. (NCT00486863)
Timeframe: 4.5 and 8 hours after the first praziquantel dose (subjects assigned to an even study number) or 6 and 10 hours after the first praziquantel dose (subjects assigned to an odd study number).

Interventionng/ml (Median)
4.5 Hours, n=506 Hours, n=498 Hours, n=5010 Hours, n=49
Praziquantel at 12-16 Weeks Gestation4020.14590.85373.74304.1

[back to top]

Number of Subjects With Reduction in S. Japonicum Egg Counts From Screening to 22 Weeks Gestation of Greater Than 90 Percent

Parasitologic response to treatment was evaluated by counting S. japonicum eggs per gram of stool at screening and again at 22 weeks gestation. Success of treatment was pre-specified as greater than 90 percent reduction in egg count from screening to 22 weeks gestation. (NCT00486863)
Timeframe: Screening and 22 weeks gestation

Interventionparticipants (Number)
Placebo Control at 12-16 Weeks Gestation92
Praziquantel at 12-16 Weeks Gestation157

[back to top]

Number of Participants Whose Pregnancy Resulted in a Live Birth

Each participant was followed until delivery to record if the outcome of the pregnancy was a live birth. Live births were defined as the complete expulsion or extraction from its mother of a product of conception, irrespective of the duration of the pregnancy, which, after such separation, breathes or shows any other evidence of life such as heartbeat, umbilical cord pulsation, or definite movement of voluntary muscles, whether the umbilical cord had been cut or the placenta was attached. (NCT00486863)
Timeframe: At delivery

Interventionparticipants (Number)
Placebo Control at 12-16 Weeks Gestation181
Praziquantel at 12-16 Weeks Gestation181

[back to top]

Number of Participants Whose Infant Was Born With Congenital Anomalies

The newborn was examined by the midwife at delivery and within 2-6 days of delivery to assess the presence of congenital anomalies and well-being. The newborn was also examined by study pediatrician at 28 days of life. (NCT00486863)
Timeframe: At delivery, within 2-6 days of delivery, and at 28 days

Interventionparticipants (Number)
Placebo Control at 12-16 Weeks Gestation1
Praziquantel at 12-16 Weeks Gestation1

[back to top]

Number of Participants Reporting Serious Adverse Events Within 24 Hours of Dosing

Participants were observed in hospital for 24 hours after dosing for serious adverse events. Serious adverse events included any untoward medical occurrence that resulted in death; was life threatening; was a persistent/significant disability/incapacity; required in-patient hospitalization or prolongation thereof (for reasons other than the 24-hour observation period); resulted in a congenital anomaly/birth defect; or may have jeopardized the participant, or required intervention to prevent one of these outcomes. (NCT00486863)
Timeframe: Within 24 hours of dosing

Interventionparticipants (Number)
Placebo Control at 12-16 Weeks Gestation0
Praziquantel at 12-16 Weeks Gestation0

[back to top]

Number of Participants Experiencing Fetal Loss by Abortion

Abortion was defined by the protocol as bleeding followed by fetal loss as supported by ultrasound before 20 weeks gestation. Abortion was an important safety outcome measure due to the fact that abortion would occur closer to the time of dosing than miscarriage or stillbirth. Participants were observed in hospital for 24 hours after dosing and asked to return for any bleeding at any time. (NCT00486863)
Timeframe: After dosing and before 20 weeks gestation

Interventionparticipants (Number)
Placebo Control at 12-16 Weeks Gestation0
Praziquantel at 12-16 Weeks Gestation0

[back to top]

Median Maternal Hepcidin at 32 Weeks Gestation

Anemia of inflammation was assessed via maternal urine hepcidin levels. In response to inflammation, elevated serum levels of hepcidin is synthesized. Hepcidin causes sequestration of iron from bio-available forms to storage forms such as ferritin and decreases intestinal absorption of iron. Hepcidin was measured in participants' urine at 32 weeks gestation. (NCT00486863)
Timeframe: 32 weeks gestation

Interventionnanograms/milliliter (Median)
Placebo Control at 12-16 Weeks Gestation2.58
Praziquantel at 12-16 Weeks Gestation3.38

[back to top]

Median Change in Maternal Transferrin Receptor:Ferritin Ratio From 14 to 32 Weeks Gestation

To assess total body iron, one needs to assess the storage compartment, which will contain sequestered iron, and the functional compartment, which represents bioavailable iron. Body iron status is defined by the two laboratory measurements that reflect these compartments, ferritin and serum transferrin receptor. The serum transferrin receptor:ferritin ratio has been shown in quantitative phlebotomy studies to provide an accurate assessment of total body iron over the entire range of status. At 14 and 32 weeks gestation, a blood sample was collected for assessment of total body iron by determination of the transferrin receptor:ferritin ratio. Each participant's change in ratio was calculated, and the median and interquartile range were determined for each group. (NCT00486863)
Timeframe: 14 weeks and 32 weeks gestation

Interventionratio (Median)
Placebo Control at 12-16 Weeks Gestation0.0
Praziquantel at 12-16 Weeks Gestation0.0

[back to top]

Mean Newborn Birth Weight

Birth weight was collected for live infants at the time of delivery by a trained midwife, or within 24 hours of delivery for participants who chose to deliver at home with a helot, a birth attendant without formal training. (NCT00486863)
Timeframe: Within 24 hours of delivery.

Interventionkilograms (Mean)
Placebo Control at 12-16 Weeks Gestation2.85
Praziquantel at 12-16 Weeks Gestation2.85

[back to top]

Mean Change in Maternal Weight From 14 to 32 Weeks Gestation

Maternal weight gain was assessed by measuring participants' weight in kilograms. The weight increase from 14 to 32 weeks was determined for each participant, and the mean and standard deviation calculated. (NCT00486863)
Timeframe: 14 and 32 weeks gestation

Interventionkilograms (Mean)
Placebo Control at 12-16 Weeks Gestation0.33
Praziquantel at 12-16 Weeks Gestation0.32

[back to top]

Mean Change in Maternal Thigh Skinfold Thickness From 14 to 32 Weeks Gestation

Maternal fat stores were measured by thigh skinfold thickness obtained using a Holtain skinfold caliper. The thickness increase from 14 to 32 weeks was determined for each participant, and the mean and standard deviation calculated. (NCT00486863)
Timeframe: 14 and 32 weeks gestation

Interventionmillimeters (Mean)
Placebo Control at 12-16 Weeks Gestation0.08
Praziquantel at 12-16 Weeks Gestation0.08

[back to top]

Mean Change in Maternal Hemoglobin From 14 to 32 Weeks Gestation

Hemoglobin concentration in a venous blood sample collected at 14 and 32 weeks gestation was measured using a multi-analyte analyzer. Each participant's change in hemoglobin concentration between the two timepoints was determined, and the mean and standard deviation for each group calculated. (NCT00486863)
Timeframe: 14 weeks and 32 weeks gestation

Interventiongrams/deciliter (Mean)
Placebo Control at 12-16 Weeks Gestation-0.42
Praziquantel at 12-16 Weeks Gestation-0.44

[back to top]

Number of Participants With Pre-eclampsia

Participants were assessed for the presence of pre-eclampsia at both the 22 and 32 week visits. Pre-eclampsia was defined by the presence of proteinurea (2+ protein on urine dipstick) and a single diastolic blood pressure reading of 100 millimiters of mercury (mm Hg) or above OR more than one reading, four hours apart, of 90 mm Hg or above. (NCT00486863)
Timeframe: 22 weeks and 32 weeks

Interventionparticipants (Number)
Placebo Control at 12-16 Weeks Gestation0
Praziquantel at 12-16 Weeks Gestation0

[back to top]

Number of Participants Reporting Abnormalities in Hematology Assessments Within 24 Hours of Dosing

Toxicity to maternal bone marrow, kidney, and liver was assessed by laboratory parameters collected just before and 24 hours after dosing. Specifically, blood was drawn just before the dose at 12-16 weeks gestation to determine baseline complete blood count, including white blood count (WBC), platelets, and hemoglobin. Blood was then drawn 24 hours after the second part of the split dose and before discharge from the hospital to assess any changes in these parameters. White blood count was abnormal at or above 10,800 or at or below 3500 cells/square millimeter (sq mm), platelets were abnormal at or below 140,000 cells/sq mm, and hemoglobin was abnormal at or below 10.9 grams/deciliter (g/dL). (NCT00486863)
Timeframe: Just before and 24 hours after dosing

,
Interventionparticipants (Number)
White Blood Cell AbnormalPlatelets AbnormalHemoglobin Abnormal
Placebo Control at 12-16 Weeks Gestation69354
Praziquantel at 12-16 Weeks Gestation60056

[back to top]

Praziquantel Pharmacokinetic Concentrations

Two plasma samples were collected during the overnight hospitalization from approximately 200 subjects that remained at the time of study modification to incorporate PK studies. Subjects had samples collected based on one of two sample collection strategies: 4.5 and 8 hr after the first praziquantel dose or 6 and 10 hr after the first praziquantel dose. Subjects randomized to an even study number were assigned to the 4.5 and 8 hour schedule. Subjects randomized to an odd study number were assigned to the 6 and 10 hour schedule. Samples only from subjects randomized to receive praziquantel were analyzed for praziquantel. Samples drawn from subjects randomized to the control group were not analyzed. Praziquantel concentrations (ng/ml) were assayed using high performance liquid chromatography-electrospray mass spectrometry in the University of California at San Diego Pediatric Clinical Pharmacology Laboratory. (NCT00486863)
Timeframe: 4.5 and 8 hours after the first praziquantel dose (subjects assigned to an even study number) or 6 and 10 hours after the first praziquantel dose (subjects assigned to an odd study number).

Interventionng/mL (Median)
4.5 Hours, n=506 Hours, n=498 Hours, n=5010 Hours, n=49
Praziquantel at 12-16 Weeks Gestation814.7945.2687.8422.2

[back to top]

Palatability Score

"Each administration was assessed at 0 minutes on Day 1 for flavor, smell, sweetness, overall liking of the medicine and at 2-5 minutes on Day 1 for taste in mouth and acceptability to swallow using a modified 100 millimeter (mm), visual analog scale (VAS) incorporating a facial hedonic scale, where lower score (0) indicates not acceptable/not liked at all and higher score (100) indicates very acceptable/liked very much." (NCT02271984)
Timeframe: 0 min for flavor, smell, sweetness, overall liking; 2-5 minutes post dose for taste in mouth and acceptability on Day 1

,,,,,
Interventionmillimeter (mm) (Mean)
Flavor: Day 1: 0 minSmell: Day 1: 0 minSweetness: Day 1: 0 minOverall liking of Medicine: Day 1: 0 minTaste in Mouth: Day 1:2-5 minutes after medicationAcceptable to swallow:Day1:2-5min after medication
Treatment A67.563.174.867.850.980.7
Treatment B45.856.430.547.039.559.2
Treatment C172.264.872.269.768.982.5
Treatment C268.861.973.068.047.168.7
Treatment D65.964.668.063.347.770.0
Treatment E32.946.940.853.229.538.1

[back to top]

Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs, TEAEs Leading to Death and TEAEs Leading to Discontinuation

An Adverse Event (AE) was defined as any new untoward medical occurrences/worsening of pre-existing medical condition without regard to possibility of causal relationship. A Serious Adverse Event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAEs were adverse events that occurred between the first dose of study drug and up to 3-10 days after the last dose that were absent before treatment or that worsened relative to pretreatment state. Subjects who discontinued and who died due to TEAEs were also reported. (NCT02271984)
Timeframe: From the first dose of study drug administration up to 3-10 days after the last dose of the study drug (up to a maximum of 7 weeks)

,,,,,
InterventionSubjects (Number)
TEAEsSerious TEAEsTEAEs leading to discontinuationTEAEs leading to death
Treatment A8000
Treatment B17000
Treatment C14000
Treatment C24000
Treatment D5000
Treatment E1000

[back to top]

Number of Subjects With Clinical Significant Laboratory Abnormalities, Electrocardiogram (ECG), Physical Examination and Vital Signs Reported as Treatment Emergent Adverse Events

Any clinically significant changes in laboratory evaluations ECGs,physical examination (body weight) and vital signs (temperature, blood pressure, pulse rate) were recorded as treatment emergent adverse events. Following parameters were analyzed for laboratory examination: hematology (haemoglobin, hematocrit, red blood cell count, mean cell hemoglobin [MCH], MCH concentration, mean cell volume, white cell count, platelets, neutrophils, lymphocytes, monocytes, eosinophils, Basophils); serum chemistry (sodium, potassium, calcium, inorganic phosphate, creatinine, total protein, albumin, urea, uric acid, aspartate aminotransferase [AST], alanine aminotransferase [ALT] gamma glutamyl transpeptidase, total bilirubin, alkaline phosphatase, glucose, triglycerides cholesterol); urinalysis (protein, glucose, ketones, pH, blood, leukocytes, nitrite); The 12-lead ECGs were recorded after the subjects had rested for at least 5 minutes in supine position. (NCT02271984)
Timeframe: From the first dose of study drug administration up to 3-10 days after the last dose of the study drug (up to a maximum of 7 weeks)

,,,,,
InterventionSubjects (Number)
Laboratory abnormalitiesECG abnormalitiesVital signs abnormalitiesPhysical signs abnormalities
Treatment A0000
Treatment B0000
Treatment C10000
Treatment C20000
Treatment D0000
Treatment E0000

[back to top]

Time to Reach the Maximum Plasma Concentration (Tmax) of L-Praziquantel (L-PZQ)

(NCT02271984)
Timeframe: Pre-dose, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 8.0, 12.0, 16 and 24 hours post-dose

Interventionhour (Median)
Treatment A2.500
Treatment B2.500
Treatment C12.250
Treatment C23.000
Treatment D2.000
Treatment E4.000

[back to top]

Time Prior to the First Measurable (Non-zero) Concentration (Tlag) of L-Praziquantel (L-PZQ)

Time prior to the first measurable (non-zero) concentration (tlag) of drug L-PZQ (NCT02271984)
Timeframe: Pre-dose, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 8.0, 12.0, 16 and 24 hours post-dose

Interventionhour (Median)
Treatment A0.0
Treatment B0.0
Treatment C10.0
Treatment C20.0
Treatment D0.0
Treatment E0.0

[back to top]

Maximum Observed Concentration in Plasma (Cmax) of L-Praziquantel (L-PZQ) After Dose Adjustment

(NCT02271984)
Timeframe: Pre-dose, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 8.0, 12.0, 16 and 24 hours post-dose

Interventionnanogram per milliliter (ng/mL) (Geometric Mean)
Treatment A378.83
Treatment B727.27
Treatment C189.93
Treatment C21051.76
Treatment D131.06
Treatment E471.18

[back to top]

Extrapolated Area Under the Concentration Time Curve (AUC) From Time Tlast to Infinity Given as Percentage From AUC0-inf (AUCextra) of L-Praziquantel (L-PZQ)

Extrapolated AUC from time tlast to infinity given as percentage from AUC0-inf. AUCextra =(last predicted concentration [Clast pred] divided by terminal elimination rate constant [lambda z]) divided by AUC0-inf., where Clast pred is the last predicted concentration. (NCT02271984)
Timeframe: Pre-dose, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 8.0, 12.0, 16 and 24 hours post-dose

InterventionPercent extrapolated (Geometric Mean)
Treatment A3.40
Treatment B2.20
Treatment C16.62
Treatment C21.80
Treatment D5.81
Treatment E3.15

[back to top]

Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of L-Praziquantel (L-PZQ) After Dose Adjustment

The AUC (0-t) was defined as the area under the plasma concentration versus time curve from time zero to time of last quantifiable concentration at or above the lower limit of quantification (AUC0-t) of L-PZQ. (NCT02271984)
Timeframe: Pre-dose, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 8.0, 12.0, 16 and 24 hours post-dose

Interventionhour*nanogram per milliliter (h*ng/mL) (Geometric Mean)
Treatment A791.0
Treatment B2010.7
Treatment C1186.2
Treatment C22273.5
Treatment D464.7
Treatment E918.0

[back to top]

Relative Bioavailability (Frel) of L-Praziquantel (L-PZQ)

Relative bioavailability (Frel) was calculated for L-PZQ only (treatment A versus treatment B) using the formula: Frel = (AUC0-inf (test or Treatment A)/AUC0-inf (reference or treatment B)) multiplied by 100. (NCT02271984)
Timeframe: Pre-dose, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 8.0, 12.0, 16 and 24 hours post-dose

InterventionPercentage bioavailability (Geometric Mean)
Treatment A and B40.075

[back to top]

Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUC0-inf) Adj of L-Praziquantel (L-PZQ) After Dose Adjustment

The AUC(0-inf) was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. (NCT02271984)
Timeframe: Pre-dose, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 8.0, 12.0, 16 and 24 hours post-dose

Interventionhour*nanogram per milliliter (h*ng/mL) (Geometric Mean)
Treatment A825.2
Treatment B2066.0
Treatment C1216.7
Treatment C22324.9
Treatment D506.2
Treatment E954.5

[back to top]

Apparent Volume of Distribution During the Terminal Phase (Vz/f) of L-Praziquantel (L-PZQ)

The Vz/f was defined as the theoretical volume in which the total amount of L-PZQ required to uniformly distribute to produce the desired plasma concentration of L-PZQ. Apparent volume of distribution after oral dose (Vz/F) was influenced by the fraction absorbed. The Vz/f was calculated by dividing the dose with area under the concentration time curve from time zero to infinity multiplied with terminal elimination rate constant (lambda z) (Vz/f=Dose/( AUC0-inf* lambda z). (NCT02271984)
Timeframe: Pre-dose, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 8.0, 12.0, 16 and 24 hours post-dose

InterventionLiter (Geometric Mean)
Treatment A6671
Treatment B3685
Treatment C17155
Treatment C24478
Treatment D11170
Treatment E5452

[back to top]

Apparent Total Body Clearance of Drug From Plasma (CL/f) of L-Praziquantel (L-PZQ)

The CL/f of L-PZQ was a measure of the rate at which it was metabolized or eliminated by normal biological processes. Clearance obtained after oral dose was influenced by the fraction of the dose absorbed. The CL/F of L-PZQ from plasma was calculated using the formula: Dose divided by area under the concentration time curve from time zero to infinity (AUC0-inf). (NCT02271984)
Timeframe: Pre-dose, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 8.0, 12.0, 16 and 24 hours post-dose

InterventionLiter per hour (Geometric Mean)
Treatment A1665
Treatment B667.3
Treatment C13091
Treatment C2923.5
Treatment D2729
Treatment E1440

[back to top]

Apparent Terminal Half-life (T1/2) of L-Praziquantel (L-PZQ)

The apparent terminal half-life was calculated by dividing natural log 2 with lambda z (ln2/lambda Z); where lambda Z is the terminal rate constant. (NCT02271984)
Timeframe: Pre-dose, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 8.0, 12.0, 16 and 24 hours post-dose

Interventionhour (Median)
Treatment A2.984
Treatment B3.788
Treatment C11.059
Treatment C23.296
Treatment D2.801
Treatment E2.711

[back to top]

Apparent Terminal Elimination Rate Constant (Lambda Z) of L-Praziquantel (L-PZQ)

The lambda z was calculated as the negative of the slope of the log-linear regression of the natural logarithm concentration-time curve during the terminal phase. (NCT02271984)
Timeframe: Pre-dose, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 8.0, 12.0, 16 and 24 hours post-dose

Interventionper hour (1/hour) (Geometric Mean)
Treatment A0.250
Treatment B0.181
Treatment C10.432
Treatment C20.206
Treatment D0.244
Treatment E0.264

[back to top]

Apparent Terminal Half-life (t1/2) of L-PZQ, D-PZQ, and Racemate PZQ

Apparent terminal half-life was defined as the time required for the plasma concentration of drug to decrease 50 percent in the final stage of its elimination. (NCT02325713)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 16 and 24 hours post-dose on Day 1 of each treatment

,,,,,
Interventionhours (Geometric Mean)
L-PZQ (n= 30,30,14,15,14,14)D-PZQ (n= 30,30,15,15,14,15)racemate PZQ (n= 30,30,15,15,14,15)
Treatment A: 40 mg/kg Test ODT-PZQ After Meal3.3054.5774.462
Treatment B: 40 mg/kg Cysticide Tablet After Meal3.8304.6184.408
Treatment C1: 20 mg/kg Test ODT-PZQ After Meal1.9163.9623.775
Treatment C2: 60 mg/kg Test ODT-PZQ After Meal4.2024.3464.316
Treatment D1: 40 mg/kg Test ODT-PZQ Without Meal4.1685.2814.889
Treatment D2: 40 mg/kg Cysticide Crushed Tablets After Meal3.0724.3474.204

[back to top]

Apparent Total Body Clearance of Drug From Plasma (CL/f) of L-PZQ, D-PZQ, and Racemate PZQ

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. (NCT02325713)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 16 and 24 hours post-dose on Day 1 of each treatment

,,,,,
InterventionLiter/hour (Geometric Mean)
L-PZQ (n= 30,30,14,15,14,14)D-PZQ (n= 30,30,15,15,14,15)racemate PZQ (n= 30,30,15,15,14,15)
Treatment A: 40 mg/kg Test ODT-PZQ After Meal716.8187.2293.3
Treatment B: 40 mg/kg Cysticide Tablet After Meal691.3170.7271.0
Treatment C1: 20 mg/kg Test ODT-PZQ After Meal2028.4316.7548.7
Treatment C2: 60 mg/kg Test ODT-PZQ After Meal438.5145.5217.1
Treatment D1: 40 mg/kg Test ODT-PZQ Without Meal1466.9271.6455.6
Treatment D2: 40 mg/kg Cysticide Crushed Tablets After Meal971.1227.6366.1

[back to top]

Apparent Volume of Distribution During the Terminal Phase (Vz/f) of L-PZQ, D-PZQ, and Racemate PZQ

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz/f after oral dose was influenced by the fraction absorbed. (NCT02325713)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 16 and 24 hours post-dose on Day 1 of each treatment

,,,,,
InterventionLiters (Geometric Mean)
L-PZQ (n= 30,30,14,15,14,14)D-PZQ (n= 30,30,15,15,14,15)racemate PZQ (n= 30,30,15,15,14,15)
Treatment A: 40 mg/kg Test ODT-PZQ After Meal3417.61236.01887.7
Treatment B: 40 mg/kg Cysticide Tablet After Meal3820.41137.41723.7
Treatment C1: 20 mg/kg Test ODT-PZQ After Meal5605.61810.12987.7
Treatment C2: 60 mg/kg Test ODT-PZQ After Meal2658.4912.11352.0
Treatment D1: 40 mg/kg Test ODT-PZQ Without Meal8820.42069.23213.2
Treatment D2: 40 mg/kg Cysticide Crushed Tablets After Meal4304.41427.22220.2

[back to top]

Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero to Infinity (AUC0-inf) Adjusted for the Actual Administered Dose (AUC0-inf, Adj) of D-PZQ and Racemate PZQ

AUC0-inf is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time. AUC0-inf, adj was defined as the AUC0-inf adjusted for the actual administered dose of D-PZQ and Racemate PZQ. (NCT02325713)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 16 and 24 hours post-dose on Day 1 of each treatment

,,,,,
Interventionh*ng/mL (Geometric Mean)
D-PZQracemate PZQ
Treatment A: 40 mg/kg Test ODT-PZQ After Meal7542.39627.2
Treatment B: 40 mg/kg Cysticide Tablet After Meal8292.710446.9
Treatment C1: 20 mg/kg Test ODT-PZQ After Meal2226.02569.5
Treatment C2: 60 mg/kg Test ODT-PZQ After Meal14685.819679.5
Treatment D1: 40 mg/kg Test ODT-PZQ Without Meal4996.05956.0
Treatment D2: 40 mg/kg Cysticide Crushed Tablets After Meal6508.98091.8

[back to top]

AUC From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) Adjusted for the Actual Administered Dose (AUC0-t, Adj) of L-PZQ, D-PZQ, and Racemate PZQ

(NCT02325713)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 16 and 24 hours post-dose on Day 1 of each treatment

,,,,,
Interventionh*ng/mL (Geometric Mean)
L-PZQD-PZQracemate PZQ
Treatment A: 40 mg/kg Test ODT-PZQ After Meal1928.07405.99476.3
Treatment B: 40 mg/kg Cysticide Tablet After Meal1994.08131.410266.0
Treatment C1: 20 mg/kg Test ODT-PZQ After Meal300.52169.22515.2
Treatment C2: 60 mg/kg Test ODT-PZQ After Meal4770.114367.219262.2
Treatment D1: 40 mg/kg Test ODT-PZQ Without Meal863.74740.65694.0
Treatment D2: 40 mg/kg Cysticide Crushed Tablets After Meal1342.66365.57929.9

[back to top]

Extrapolated Area Under the Plasma Concentration Curve From Time Tlast to Infinity (AUCextra) of L-PZQ, D-PZQ, and Racemate PZQ

AUCextra was reported in terms of percentage of AUC0-inf. (NCT02325713)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 16 and 24 hours post-dose on Day 1 of each treatment

,,,,,
Interventionpercentage of AUC0-inf (Geometric Mean)
L-PZQ (n= 30,30,14,15,14,14)D-PZQ (n= 30,30,15,15,14,15)racemate PZQ (n= 30,30,15,15,14,15)
Treatment A: 40 mg/kg Test ODT-PZQ After Meal1.861.301.10
Treatment B: 40 mg/kg Cysticide Tablet After Meal2.231.481.24
Treatment C1: 20 mg/kg Test ODT-PZQ After Meal5.252.261.85
Treatment C2: 60 mg/kg Test ODT-PZQ After Meal1.601.511.38
Treatment D1: 40 mg/kg Test ODT-PZQ Without Meal5.523.693.05
Treatment D2: 40 mg/kg Cysticide Crushed Tablets After Meal2.301.601.38

[back to top]

Maximum Observed Concentration in Plasma (Cmax) Adjusted for the Actual Administered Dose (Cmax, Adj) of L-PZQ, D-PZQ and Racemate PZQ

(NCT02325713)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 16 and 24 hours post-dose on Day 1 of each treatment

,,,,,
Interventionng/mL (Geometric Mean)
L-PZQD-PZQRacemate PZQ
Treatment A: 40 mg/kg Test ODT-PZQ After Meal881.323303250
Treatment B: 40 mg/kg Cysticide Tablet After Meal762.621792974
Treatment C1: 20 mg/kg Test ODT-PZQ After Meal154.6786.3949.9
Treatment C2: 60 mg/kg Test ODT-PZQ After Meal154832344780
Treatment D1: 40 mg/kg Test ODT-PZQ Without Meal189.3838.51042
Treatment D2: 40 mg/kg Cysticide Crushed Tablets After Meal446.315562040

[back to top]

Number of Subjects With Treatment-emergent Adverse (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation

An adverse event (AE) was defined as any untoward medical occurrence in a subject which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. The term TEAE is defined as AEs starting or worsening after the first intake of the stud drug. (NCT02325713)
Timeframe: Baseline up to end of treatment (up to Day 32)

,,,,,
Interventionsubjects (Number)
TEAEsSerious TEAEsTEAE leading to Discontinuation
Treatment A: 40 mg/kg Test ODT-PZQ After Meal500
Treatment B: 40 mg/kg Cysticide Tablet After Meal400
Treatment C1: 20 mg/kg Test ODT-PZQ After Meal100
Treatment C2: 60 mg/kg Test ODT-PZQ After Meal600
Treatment D1: 40 mg/kg Test ODT-PZQ Without Meal000
Treatment D2: 40 mg/kg Cysticide Crushed Tablets After Meal300

[back to top]

Palatability Assessment Based on Visual Analog Scale (VAS) Score

"Palatability was assessed in terms of Flavor, Smell, Sweetness, Overall liking of the medicine, Taste and Acceptability to swallow, each parameter assessed on a 0 to 100 millimeter (mm) visual analog scale (VAS), where 0 indicates Did not like and 100 indicates very much liked. Flavor, Smell, Sweetness and Overall liking of the medicine were evaluated immediately after taking the medication (Day 1, 0 Hour) and Taste and Acceptability to swallow were assessed 2-5 minutes post administration of medication." (NCT02325713)
Timeframe: Immediately and 2-5 minutes (min) after dosing on Day 1 of each treatment

,,,,,
Interventionmillimiter (mm) (Mean)
Day 1, 0 Hour: FlavourDay 1, 0 Hour: SmellDay 1, 0 Hour: SweetnessDay 1, 0 Hour: Overall likingDay 1, 2-5 Min After Medicine: Taste in MouthDay1,2-5 Min After Medicine:Acceptable to Swallow
Treatment A: 40 mg/kg Test ODT-PZQ After Meal43.460.747.346.839.768.2
Treatment B: 40 mg/kg Cysticide Tablet After Meal44.661.541.251.344.962.5
Treatment C1: 20 mg/kg Test ODT-PZQ After Meal50.347.551.450.244.755.7
Treatment C2: 60 mg/kg Test ODT-PZQ After Meal46.151.150.740.735.039.9
Treatment D1: 40 mg/kg Test ODT-PZQ Without Meal55.951.761.648.846.761.1
Treatment D2: 40 mg/kg Cysticide Crushed Tablets After Meal20.129.412.913.714.423.1

[back to top]

Relative Bioavailability (Frel) of L-PZQ, D-PZQ, and Racemate PZQ

Frel was calculated for Treatment A versus Treatment B only. It was calculated by using AUC0-∞, with treatment A as the Test and treatment B as the Reference. Frel = AUC0-inf (test) / AUC0-inf (reference). (NCT02325713)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 16 and 24 hours post-dose on Day 1 of each treatment

Interventionpercent bioavailability (Geometric Mean)
L-PZQD-PZQracemate PZQ
PZQ 40 mg/kg (Treatment A and Treatment B)96.17590.95192.2

[back to top]

Number of Subjects With Clinically Significant Change From Baseline in Vital Signs, Physical Examinations, Electrocardiogram (ECG) and Laboratory Parameters

Vital signs included oral body temperature, blood pressure and pulse rate. Body weight was recorded for physical examinations. The 12-lead ECGs were recorded after the subjects have rested for at least 5 minutes in supine position. The parameters heart rate (HR), RR, PR, QRS, QT and QTcB calculated by the Bazett formula. Laboratory investigation including chemistry, hematology and urinalysis. (NCT02325713)
Timeframe: Baseline up to end of treatment (up to Day 32)

Interventionsubjects (Number)
Treatment A: 40 mg/kg Test ODT-PZQ After Meal0
Treatment B: 40 mg/kg Cysticide Tablet After Meal0
Treatment C1: 20 mg/kg Test ODT-PZQ After Meal0
Treatment C2: 60 mg/kg Test ODT-PZQ After Meal0
Treatment D1: 40 mg/kg Test ODT-PZQ Without Meal0
Treatment D2: 40 mg/kg Cysticide Crushed Tablets After Meal0

[back to top]

Time to Reach Maximum Plasma Concentration (Tmax) of L-PZQ, D-PZQ, and Racemate PZQ

(NCT02325713)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 16 and 24 hours post-dose on Day 1 of each treatment

,,,,,
Interventionhours (Median)
L-PZQD-PZQracemate PZQ
Treatment A: 40 mg/kg Test ODT-PZQ After Meal3.0003.0003.000
Treatment B: 40 mg/kg Cysticide Tablet After Meal1.5002.0001.750
Treatment C1: 20 mg/kg Test ODT-PZQ After Meal4.0003.5003.500
Treatment C2: 60 mg/kg Test ODT-PZQ After Meal3.0004.0003.500
Treatment D1: 40 mg/kg Test ODT-PZQ Without Meal4.2504.5004.500
Treatment D2: 40 mg/kg Cysticide Crushed Tablets After Meal2.5003.5002.500

[back to top]

Time Prior to the First Measurable (Non-zero) Concentration (Tlag) of L-PZQ, D-PZQ, and Racemate PZQ

(NCT02325713)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 16 and 24 hours post-dose on Day 1 of each treatment

,,,,,
Interventionhours (Median)
L-PZQD-PZQracemate PZQ
Treatment A: 40 mg/kg Test ODT-PZQ After Meal0.0000.0000.000
Treatment B: 40 mg/kg Cysticide Tablet After Meal0.0000.0000.000
Treatment C1: 20 mg/kg Test ODT-PZQ After Meal0.0000.0000.000
Treatment C2: 60 mg/kg Test ODT-PZQ After Meal0.0000.0000.000
Treatment D1: 40 mg/kg Test ODT-PZQ Without Meal0.0000.0000.000
Treatment D2: 40 mg/kg Cysticide Crushed Tablets After Meal0.0000.0000.000

[back to top]

Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUC0-inf) Adjusted for the Actual Administered Dose (AUC0-inf, Adj) of L-Praziquantel (L-PZQ)

AUC0-inf is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time. AUC0-inf, adj was defined as the AUC0-inf adjusted for the actual administered dose of L-PZQ. (NCT02325713)
Timeframe: Pre-dose,0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 16 and 24 hours post-dose on Day 1 of each treatment

InterventionHour*nanograms per milliliter (h*ng/mL) (Geometric Mean)
Treatment A: 40 mg/kg Test ODT-PZQ After Meal1969.6
Treatment B: 40 mg/kg Cysticide Tablet After Meal2047.9
Treatment C1: 20 mg/kg Test ODT-PZQ After Meal345.4
Treatment C2: 60 mg/kg Test ODT-PZQ After Meal4871.3
Treatment D1: 40 mg/kg Test ODT-PZQ Without Meal924.9
Treatment D2: 40 mg/kg Cysticide Crushed Tablets After Meal1537.7

[back to top]

Apparent Terminal Elimination Rate Constant (λz) of L-PZQ, D-PZQ, and Racemate PZQ

λz was determined from the terminal slope of the log-transformed plasma concentration curve using linear regression method. (NCT02325713)
Timeframe: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8, 12, 16 and 24 hours post-dose on Day 1 of each treatment

,,,,,
Intervention1/h (Geometric Mean)
L-PZQ (n= 30,30,14,15,14,14)D-PZQ (n= 30,30,15,15,14,15)racemate PZQ (n= 30,30,15,15,14,15)
Treatment A: 40 mg/kg Test ODT-PZQ After Meal0.2100.1510.155
Treatment B: 40 mg/kg Cysticide Tablet After Meal0.1810.1500.157
Treatment C1: 20 mg/kg Test ODT-PZQ After Meal0.3620.1750.184
Treatment C2: 60 mg/kg Test ODT-PZQ After Meal0.1650.1590.161
Treatment D1: 40 mg/kg Test ODT-PZQ Without Meal0.1660.1310.142
Treatment D2: 40 mg/kg Cysticide Crushed Tablets After Meal0.2260.1590.165

[back to top]

Egg Reduction Rate (Percent)

Percent reduction in egg count was calculated as geometric mean egg count at post-treatment minus geometric mean egg count at baseline (before treatment) divided by geometric mean egg count at baseline. (NCT02806232)
Timeframe: Baseline, 14-21 days post treatment

Interventionpercent reduction in egg count (Geometric Mean)
Part 1, Cohort 1: Biltricide (Racemate Praziquantel) 20 mg/kg94.6
Part 1, Cohort 2: Biltricide (Racemate Praziquantel) 40 mg/kg83.3
Part 1, Cohort 3: Racemate Praziquantel 40 mg/kg88.6
Part 1, Cohort 4: Racemate Praziquantel 60 mg/kg88.6
Part 1, Cohort 5: Levo Praziquantel 30 mg/kg88.3
Part 1, Cohort 6: Levo Praziquantel 45 mg/kg92.3
Part 1, Cohort 7: Levo Praziquantel 60 mg/kg94.1
Part 2, Cohort 8: Levo Praziquantel 50 mg/kg97.7
Part 2, Cohort 9: Levo Praziquantel 50 mg/kg100.0

[back to top]

Number of Participants With Clinical Cure Determined by Kato-Katz Method

Clinical cure was defined as zero egg counts at 14-21 days post treatment as determined by the Kato-Katz method. Number of participants with clinical cure were reported. (NCT02806232)
Timeframe: 14-21 days post treatment

InterventionParticipants (Count of Participants)
Part 1, Cohort 1: Biltricide (Racemate Praziquantel) 20 mg/kg51
Part 1, Cohort 2: Biltricide (Racemate Praziquantel) 40 mg/kg43
Part 1, Cohort 3: Racemate Praziquantel 40 mg/kg47
Part 1, Cohort 4: Racemate Praziquantel 60 mg/kg46
Part 1, Cohort 5: Levo Praziquantel 30 mg/kg44
Part 1, Cohort 6: Levo Praziquantel 45 mg/kg49
Part 1, Cohort 7: Levo Praziquantel 60 mg/kg52
Part 2, Cohort 8: Levo Praziquantel 50 mg/kg14
Part 2, Cohort 9: Levo Praziquantel 50 mg/kg4

[back to top]

Number of Participants With Clinical Cure Determined by Point-of-Care Circulating Cathodic Antigen (POC-CCA) Test

Clinical Cure defined as no parasite eggs in the stools as assessed by the commercially available POC-CCA assay for S. mansoni. Number of participants with clinical cure were reported. (NCT02806232)
Timeframe: Day 2, Day 8 and 14-21 days post treatment

,,,,,,,,
InterventionParticipants (Count of Participants)
Day 2Day 814-21 days post treatment
Part 1, Cohort 1: Biltricide (Racemate Praziquantel) 20 mg/kg82833
Part 1, Cohort 2: Biltricide (Racemate Praziquantel) 40 mg/kg31621
Part 1, Cohort 3: Racemate Praziquantel 40 mg/kg31924
Part 1, Cohort 4: Racemate Praziquantel 60 mg/kg81832
Part 1, Cohort 5: Levo Praziquantel 30 mg/kg41624
Part 1, Cohort 6: Levo Praziquantel 45 mg/kg62835
Part 1, Cohort 7: Levo Praziquantel 60 mg/kg113842
Part 2, Cohort 8: Levo Praziquantel 50 mg/kg5810
Part 2, Cohort 9: Levo Praziquantel 50 mg/kg000

[back to top]

Safety and Tolerability as Measured by Number of Participants With Clinical Laboratory Tests Findings

number of participants with relevant abnormal laboratory tests results (NCT03383523)
Timeframe: 7 days

,,,,,,
Interventionparticipants (Number)
number of subject with abnormal lab valuesnumber subject with clinically significant finding
Part 1a - Treatment A00
Part 1a - Treatment B00
Part 1a - Treatment C00
Part 1b - Treatment D00
Part 1b - Treatment E00
Part 2 - Treatment F00
Part 2 - Treatment G00

[back to top]

PK (AUC0-7d) of Two New Tablet Formulations of Emodepside in Comparison to the Liquid Formulation (LSF) Oral Solution.

Means AUC from zero to 7 days (AUC0-7d) = means area under the plasma concentration-time curve from time zero (pre-dose) to 7 days. To create the curve, the following PK Timepoints have been collected: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3,4,6,8,12,36,48,72,120 and 168h post dose (NCT03383523)
Timeframe: means from zero to 7 days

Interventionh.ng/ml (Geometric Mean)
Part 1a - Treatment A1215
Part 1a - Treatment B852
Part 1a - Treatment C931
Part 1b - Treatment D674
Part 1b - Treatment E733
Part 2 - Treatment F1609
Part 2 - Treatment G1943

[back to top]

PK (Cmax) of Two New Tablet Formulations of Emodepside in Comparison to the Liquid Formulation (LSF) Oral Solution.

Cmax means maximum observed plasma concentration. To create the PK curve, the following PK timepoints have been collected: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3,4,6,8,12,36,48,72,120 and 168h post dose (NCT03383523)
Timeframe: 7 days

Interventionng/ml (Geometric Mean)
Part 1a - Treatment A88.5
Part 1a - Treatment B41.9
Part 1a - Treatment C54.2
Part 1b - Treatment D27.1
Part 1b - Treatment E36.2
Part 2 - Treatment F71.7
Part 2 - Treatment G135

[back to top]

Safety and Tolerability as Measured by Number of Participants With Vital Signs Findings

number of participants with vital signs (VS) findings. The vital signs ranges are the following Supine Systolic BP : 85-160mm HG, Supine Diastolic BP: 40-90mm HG, Supine HR: 35-100 beats/min. Details are described in the protocol section 8.11.2 (NCT03383523)
Timeframe: 7 days

,,,,,,
Interventionparticipants (Number)
number of subject with VS findingsnumber subject with clinically significant finding
Part 1a - Treatment A00
Part 1a - Treatment B10
Part 1a - Treatment C20
Part 1b - Treatment D20
Part 1b - Treatment E30
Part 2 - Treatment F00
Part 2 - Treatment G00

[back to top] [back to top]

Safety and Tolerability as Measured by Number of Participants With 12-lead ECG Findings

number of participants with 12-lead ECG findings. The ECG reference ranges used are the following: ventricular rate: 45-100beats/min, PR interval:120-220msec, QRS:<120msec, QTc:<430msec (NCT03383523)
Timeframe: 7 days

,,,,,,
Interventionparticipants (Number)
number of subject with abnormal ECG findingsnumber subject with clinically significant finding
Part 1a - Treatment A00
Part 1a - Treatment B00
Part 1a - Treatment C00
Part 1b - Treatment D00
Part 1b - Treatment E00
Part 2 - Treatment F00
Part 2 - Treatment G00

[back to top]

Safety and Tolerability as Measured by Number of Participants With Neurological Examination Findings

Number of participants with abnormal neurological examination (NE) findings (NCT03383523)
Timeframe: 7 days

,,,,,,
Interventionparticipants (Number)
number of subject with abnormal NE findingsnumber subject with clinically significant finding
Part 1a - Treatment A00
Part 1a - Treatment B00
Part 1a - Treatment C00
Part 1b - Treatment D00
Part 1b - Treatment E00
Part 2 - Treatment F00
Part 2 - Treatment G00

[back to top]

Safety and Tolerability as Measured by Number of Participants With Physical Examination Findings

number of participants with abnormal physical examination (PE) findings. Standard examination done on head, ears, eyes, nose, thyroid, lymph node, back, neck, lungs, skin, abdomen, chest. The details are listed in protocol section 8.11.3 (NCT03383523)
Timeframe: 7 days

,,,,,,
Interventionparticipants (Number)
number of subject with abnormal PE findingsnumber subject with clinically significant finding
Part 1a - Treatment A00
Part 1a - Treatment B00
Part 1a - Treatment C10
Part 1b - Treatment D00
Part 1b - Treatment E10
Part 2 - Treatment F00
Part 2 - Treatment G00

[back to top]

Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)

AUC0-inf is defined as the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf). (NCT03437447)
Timeframe: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose

,,
Interventionh*ng/ml (Mean)
L-PZQRac-PZQ
Biltricide First Administration584.232509.42
Biltricide Second Administration497.892189.25
Cisticid468.522130.19

[back to top]

Terminal Elimination Half-Life (t1/2) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)

Elimination Half Life (t1/2) was defined as the time required for the concentration or amount of drug in the body to be reduced by one-half. (NCT03437447)
Timeframe: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose

,,
Interventionhours (Mean)
L-PZQRac-PZQ
Biltricide First Administration2.592.54
Biltricide Second Administration2.322.18
Cisticid1.872.19

[back to top]

Apparent Volume of Distribution During Terminal Phase (Vd/f) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vd/f after oral dose was influenced by the fraction absorbed. (NCT03437447)
Timeframe: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose

,,
InterventionMilliliter (Mean)
L-PZQRac-PZQ
Biltricide First Administration1660474.33385223.26
Biltricide Second Administration1800582.47431494.33
Cisticid1540237.10430368.23

[back to top]

Number of Participants With Clinically Significant Abnormalities in Vital Signs

Number of participants with clinically significant abnormalities in vital signs were reported. Vital signs included body temperature, systolic / diastolic blood pressure, and pulse rate. (NCT03437447)
Timeframe: Baseline up to Day 29

InterventionParticipants (Count of Participants)
Cisticid0
Biltricide First Administration0
Biltricide Second Administration0

[back to top]

Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters

Number of participants with clinically significant abnormalities in laboratory parameters were reported. Laboratory investigation included hematology, biochemistry, urinalysis and coagulation. (NCT03437447)
Timeframe: Baseline up to Day 29

InterventionParticipants (Count of Participants)
Cisticid0
Biltricide First Administration0
Biltricide Second Administration0

[back to top]

Number of Participants With Clinically Significant Abnormalities in 12-lead Electrocardiogram (ECG) Findings

Number of participants with clinically significant abnormalities in 12-lead electrocardiogram (ECG) were reported. The 12-lead ECGs were recorded after the participants have rested for at least 5 minutes in supine position. (NCT03437447)
Timeframe: Baseline up to Day 29

InterventionParticipants (Count of Participants)
Cisticid0
Biltricide First Administration0
Biltricide Second Administration0

[back to top]

Maximum Observed Plasma Concentration (Cmax) of Racemate PZQ (Rac-PZQ)

The maximum observed plasma concentration of rac-Praziquantel (rac-PZQ). (NCT03437447)
Timeframe: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose

Interventionng/mL (Mean)
Cisticid1209.15
Biltricide First Administration1530.23
Biltricide Second Administration1356.18

[back to top]

Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Racemate PZQ (Rac-PZQ)

Area under the drug plasma concentration-time curve from time zero to the time last measurable concentration. (NCT03437447)
Timeframe: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose

Interventionh*ng/ml (Mean)
Cisticid2071.35
Biltricide First Administration2421.73
Biltricide Second Administration2131.01

[back to top]

Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of L-Praziquantel (L-PZQ)

Area under the plasma concentration-time curve from 0 to the time of the last quantifiable concentration. (NCT03437447)
Timeframe: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose

InterventionHour*nanogram per milliliter (h*ng/ml) (Mean)
Cisticid441.53
Biltricide First Administration547.41
Biltricide Second Administration460.25

[back to top]

Maximum Observed Plasma Concentration (Cmax) of L-Praziquantel (L-PZQ)

The maximum observed plasma concentration of L-Praziquantel (L-PZQ). (NCT03437447)
Timeframe: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose

Interventionng/mL (Mean)
Cisticid310.87
Biltricide First Administration426.42
Biltricide Second Administration363.20

[back to top]

Apparent Clearance (CL/f) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. (NCT03437447)
Timeframe: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose

,,
InterventionMilliliter per hour (Mean)
L-PZQRac-PZQ
Biltricide First Administration585260.42128110.14
Biltricide Second Administration673193.51155851.99
Cisticid749261.50147268.6

[back to top]

Time to Reach Maximum Plasma Concentration (Tmax) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)

Time of the maximum drug concentration. (NCT03437447)
Timeframe: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose

,,
Interventionhours (Median)
L-PZQRac-PZQ
Biltricide First Administration22
Biltricide Second Administration2.52.5
Cisticid2.52.5

[back to top]

Time Prior to the First Measurable (Non-zero) Concentration (Tlag) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)

Time prior to the first measurable (non-zero) concentration; calculated as last time point at which the concentration is less than (<) Lower Limit of Quantification (LLOQ) before the occurrence of the first quantifiable concentration. (NCT03437447)
Timeframe: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose

,,
Interventionhours (Median)
L-PZQRac-PZQ
Biltricide First Administration10.75
Biltricide Second Administration10.75
Cisticid10.75

[back to top]

Terminal Elimination Rate Constant (Lambda Z) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)

Lambda Z was determined from the terminal slope of the log-transformed plasma concentration curve using linear regression method. (NCT03437447)
Timeframe: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose

,,
InterventionPer hour (Median)
L-PZQRac-PZQ
Biltricide First Administration0.3832670.331359
Biltricide Second Administration0.3708540.370806
Cisticid0.4529270.365639

[back to top]

Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs

An adverse event (AE) was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs included both Serious TEAEs and non-serious TEAEs. (NCT03437447)
Timeframe: Baseline up to Day 29

,,
InterventionParticipants (Count of Participants)
Participants with TEAEsParticipants with Serious TEAEs
Biltricide First Administration50
Biltricide Second Administration60
Cisticid20

[back to top]

Extrapolated Area Under the Plasma Concentration Curve From Time Tlast to Infinity (AUCextra) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)

AUCextra was reported in terms of percentage of AUC0-inf. (NCT03437447)
Timeframe: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose

,,
InterventionPercentage of AUC0-inf (Mean)
L-PZQRac-PZQ
Biltricide First Administration5.492.84
Biltricide Second Administration5.742.57
Cisticid5.362.60

[back to top]

Terminal Elimination Half-Life (T1/2) of Racemic-Praziquantel (Rac-PZQ), R-(-)-PZQ and S-(+)-PZQ

Elimination Half Life (T1/2) was defined as the time required for the concentration or amount of drug in the body to be reduced by one-half. T1/2 was calculated by natural log 2 divided by Lambda z. Lambda z was determined from the terminal slope of the log-transformed plasma concentration curve using linear regression method. (NCT04314037)
Timeframe: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12 hours post-dose in each treatment period

,,,
Interventionhours (Geometric Mean)
rac-PZQR-(-)-PZQS-(+)-PZQ
Biltricide First Administration2.431.352.51
Biltricide Second Administration2.201.242.34
Cesol First Administration2.441.392.62
Cesol Second Administration2.081.352.18

[back to top]

Number of Participants With Treatment Emergent Adverse Events (TEAEs) by Severity According to Qualitative Toxicity Scale

Severity of TEAEs were graded using Qualitative Toxicity Scale, as follows: Mild: Participant is aware of the event or symptom, but the event or symptom is easily tolerated; Moderate: Participant experiences sufficient discomfort to interfere with or reduce his or her usual level of activity; Severe: Significant impairment of functioning: the participant is unable to carry out his or her usual activities. Number of participants with TEAEs by severity were reported. (NCT04314037)
Timeframe: Baseline up to Day 27

,,,
InterventionParticipants (Count of Participants)
Mild TEAEsModerate TEAEsSevere TEAEs
Biltricide First Administration540
Biltricide Second Administration520
Cesol First Administration520
Cesol Second Administration510

[back to top] [back to top]

Maximum Observed Plasma Concentration (Cmax) of Praziquantel (PZQ) Enantiomers: R-(-)-PZQ and S-(+) PZQ

Cmax was obtained directly from the concentration versus time curve. (NCT04314037)
Timeframe: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12 hours post-dose in each treatment period

,,,
Interventionng/mL (Geometric Mean)
R-(-)-PZQS-(+)-PZQ
Biltricide First Administration66.2355
Biltricide Second Administration80.0374
Cesol First Administration67.8349
Cesol Second Administration71.4346

[back to top]

Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Praziquantel (PZQ) Enantiomers: R-(-)-PZQ and S-(+)-PZQ

Area under the plasma concentration versus time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was calculated according to the mixed log-linear trapezoidal rule. (NCT04314037)
Timeframe: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12 hours post-dose in each treatment period

,,,
Interventionh*ng/mL (Geometric Mean)
R-(-)-PZQS-(+)-PZQ
Biltricide First Administration104767
Biltricide Second Administration125824
Cesol First Administration103772
Cesol Second Administration111758

[back to top]

Apparent Volume of Distribution During Terminal Phase (Vz/f) of Racemic-Praziquantel (Rac-PZQ), R-(-)-PZQ and S-(+)-PZQ

Vz/f: the distribution of a study drug between plasma and the rest of the body after oral dosing. For single dose Vz/f = Dose/(AUC0-inf*Lambda Z), where AUC0-inf = (AUC0-t + Clast pred/Lambda Z). Clastpred was the calculated plasma concentration at the last sampling time point at which the measured plasma concentration was at or above the LLQ and Lambda Z = the apparent terminal rate constant determined from the terminal slope of the log-transformed plasma concentration curve. (NCT04314037)
Timeframe: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12 hours post-dose in each treatment period

,,,
Interventionliters (Geometric Mean)
rac-PZQR-(-)-PZQS-(+)-PZQ
Biltricide First Administration4542148065385
Biltricide Second Administration3801119934685
Cesol First Administration4528137615568
Cesol Second Administration3963141004765

[back to top]

Time to Reach Maximum Plasma Concentration (Tmax) of Racemic-Praziquantel (Rac-PZQ), R-(-)-PZQ and S-(+)-PZQ

Tmax was obtained directly from the concentration versus time curve. (NCT04314037)
Timeframe: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12 hours post-dose in each treatment period

,,,
Interventionhours (Median)
rac-PZQR-(-)-PZQS-(+)-PZQ
Biltricide First Administration2.502.502.50
Biltricide Second Administration2.502.502.50
Cesol First Administration2.502.502.50
Cesol Second Administration2.002.002.00

[back to top]

Apparent Clearance (CL/f) of Racemic-Praziquantel (Rac-PZQ), R-(-)-PZQ and S-(+)-PZQ

CL/f was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes. CL/f was calculated as Dose/AUC0-inf, where AUC0-inf was estimated by determining the total area under the curve of the concentration versus time curve extrapolated to infinity. AUC0-inf was calculated as AUC0-t + Clast pred/Lambda Z, where Clast pred was the calculated plasma concentration at the last sampling time point at which the measured plasma concentration was at or above the lower limit of quantification (LLQ) and Lambda Z was the apparent terminal rate constant determined from the terminal slope of the log-transformed plasma concentration curve. (NCT04314037)
Timeframe: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12 hours post-dose in each treatment period

,,,
Interventionliter per hour (Geometric Mean)
rac-PZQR-(-)-PZQS-(+)-PZQ
Biltricide First Administration129676201486
Biltricide Second Administration119967001389
Cesol First Administration128768681475
Cesol Second Administration132372511516

[back to top]

Number of Participants With Clinically Significant Changes From Baseline in 12-Lead Electrocardiogram (ECG) Findings

12-lead ECG recordings included rhythm, heart rate (as measured by RR interval), PR interval, QRS duration and QT interval. The corrected QT interval (QTcF) was calculated using Fridericia's formula. 12-lead ECG recordings were obtained after the participants have rested for at least 10 minutes in semisupine position. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in 12-Lead ECG findings were reported. (NCT04314037)
Timeframe: Baseline up to Day 27

InterventionParticipants (Count of Participants)
Cesol First Administration0
Cesol Second Administration0
Biltricide First Administration0
Biltricide Second Administration0

[back to top]

Number of Participants With Clinically Relevant Changes From Baseline in Vital Signs

Vital signs included body temperature, systolic and diastolic blood pressure and pulse rate. Clinical relevance was determined by the investigator. The number of participants with clinically relevant changes from baseline in vital signs were reported. (NCT04314037)
Timeframe: Baseline up to Day 27

InterventionParticipants (Count of Participants)
Cesol First Administration0
Cesol Second Administration0
Biltricide First Administration0
Biltricide Second Administration0

[back to top]

Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Racemic-Praziquantel (Rac-PZQ), R-(-)-PZQ and S-(+)-PZQ

AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Lambda z, where Clast pred was the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and Lambda z was the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase. (NCT04314037)
Timeframe: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12 hours post-dose in each treatment period

,,,
Interventionh*ng/mL (Geometric Mean)
rac-PZQR-(-)-PZQS-(+)-PZQ
Biltricide First Administration926157808
Biltricide Second Administration1001179864
Cesol First Administration932175813
Cesol Second Administration907166792

[back to top]

Maximum Observed Plasma Concentration (Cmax) of Racemic-Praziquantel (Rac-PZQ)

Cmax was obtained directly from the concentration versus time curve. (NCT04314037)
Timeframe: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12 hours post-dose in each treatment period

Interventionnanogram per milliliter (ng/mL) (Geometric Mean)
Cesol First Administration421
Cesol Second Administration415
Biltricide First Administration425
Biltricide Second Administration459

[back to top]

Number of Participants With Clinically Relevant Changes From Baseline in Laboratory Parameters

Laboratory investigation included hematology, biochemistry and urinalysis. Clinical relevance was determined by the investigator. The number of participants with clinically relevant changes from baseline in laboratory parameters were reported. (NCT04314037)
Timeframe: Baseline up to Day 27

InterventionParticipants (Count of Participants)
Cesol First Administration0
Cesol Second Administration0
Biltricide First Administration0
Biltricide Second Administration0

[back to top]

Time Prior to the First Measurable (Non-zero) Concentration (Tlag) of Racemic-Praziquantel (Rac-PZQ), R-(-)-PZQ and S-(+)-PZQ

Time prior to the first measurable (non-zero) concentration; calculated as last time point at which the concentration is less than (<) Lower Limit of Quantification (LLQ) before the occurrence of the first quantifiable concentration. (NCT04314037)
Timeframe: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12 hours post-dose in each treatment period

,,,
Interventionhours (Median)
rac-PZQR-(-)-PZQS-(+)-PZQ
Biltricide First Administration1.001.001.00
Biltricide Second Administration0.7501.000.750
Cesol First Administration0.7501.000.750
Cesol Second Administration0.5001.000.500

[back to top]

Terminal Rate Constant (Lambda z) of Racemic-Praziquantel (Rac-PZQ), R-(-)-PZQ and S-(+)-PZQ

Lambda z was determined from the terminal slope of the log-transformed plasma concentration curve using linear regression method. (NCT04314037)
Timeframe: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12 hours post-dose in each treatment period

,,,
Intervention1/hour (Geometric Mean)
rac-PZQR-(-)-PZQS-(+)-PZQ
Biltricide First Administration0.2850.5150.276
Biltricide Second Administration0.3150.5590.297
Cesol First Administration0.2840.4990.265
Cesol Second Administration0.3340.5140.318

[back to top]

Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Racemic-Praziquantel (Rac-PZQ)

Area under the plasma concentration versus time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was calculated according to the mixed log-linear trapezoidal rule. (NCT04314037)
Timeframe: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12 hours post-dose in each treatment period

Interventionhours*nanogram per milliliter (h*ng/mL) (Geometric Mean)
Cesol First Administration894
Cesol Second Administration873
Biltricide First Administration886
Biltricide Second Administration964

[back to top]